NCCN Non-Hodgkin’s Lymphomas Panel Members

* Andrew D. Zelenetz, MD, PhD/Chair † Medical Oncology
Memorial Sloan-Kettering Cancer Center

Jeremy S. Abramson, MD † ‡
Massachusetts General Hospital Cancer Center

Ranjana H. Advani, MD †
Stanford Comprehensive Cancer Center

John C. Byrd, MD † ‡
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

Myron S. Czuczman, MD † ‡
Roswell Park Cancer Institute

Lloyd E. Damon, MD ‡
UCSF Helen Diller Family Comprehensive Cancer Center

Luis Fayad, MD † ‡
The University of Texas M. D. Anderson Cancer Center

Andres Forero, MD † ‡
University of Alabama at Birmingham Comprehensive Cancer Center

Martha J. Glenn, MD † ‡
Huntsman Cancer Institute at the University of Utah

Jon P. Gockerman, MD † ‡
Duke Comprehensive Cancer Center

Leo I. Gordon, MD ‡
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Nancy Lee Harris, MD ≠
Massachusetts General Hospital Cancer Center

Richard T. Hoppe, MD §
Stanford Comprehensive Cancer Center

* Steven M. Horwitz, MD † ‡
Memorial Sloan-Kettering Cancer Center

Mark S. Kaminski, MD †
University of Michigan Comprehensive Cancer Center

Adetola Kassim, MD, MS ‡
Vanderbilt-Ingram Cancer Center

* Youn H. Kim, MD ¬
Stanford Comprehensive Cancer Center

Ann S. LaCasce, MD †
Dana-Farber/Brigham and Women’s Cancer Center

Auyporn Nademanee, MD † ‡
City of Hope Comprehensive Cancer Center

Pierluigi Porcu, MD ‡
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

Oliver Press, MD, PhD †
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Leonard Prosnitz, MD §
Duke Comprehensive Cancer Center

Mitchell R. Smith, MD, PhD † ‡
Fox Chase Cancer Center

Lubomir Sokol, MD, PhD † ‡ §
H. Lee Moffitt Cancer Center & Research Institute

Lode Swinnen, MB, ChB ‡
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Julie M. Vose, MD † §
UNMC Eppley Cancer Center at The Nebraska Medical Center

William G. Wierda, MD, PhD ‡
The University of Texas M. D. Anderson Cancer Center

Joachim Yahalom, MD §
Memorial Sloan-Kettering Cancer Center

Furhan Yunus, MD ‡
St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute

NCCN Guidelines Panel Disclosures

† Medical Oncology
‡ Hematology/Hematology and Oncology
§ Radiotherapy/Radiation Oncology
≠ Pathology
 европейское западное
®
Copyright © 2009 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
# Table of Contents

- NCCN Non-Hodgkin’s Lymphoma Panel Members
- Summary of Guidelines Updates
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CSLL-1)
- Follicular Lymphoma (FOLL-1)
- Gastric MALT Lymphoma (MALT-1)
- Nongastric MALT Lymphoma (NGMLT-1)
- Nodal Marginal Zone Lymphoma (NODE-1)
- Splenic Marginal Zone Lymphoma (SPLN-1)
- Mantle Cell Lymphoma (MANT-1)
- Diffuse Large B-Cell Lymphoma (BCEL-1)
- Burkitt’s Lymphoma (BURK-1)
- Lymphoblastic Lymphoma (BLAST-1)
- AIDS-Related B-Cell Lymphoma (AIDS-1)
- Peripheral T-Cell Lymphoma (TCEL-1)
- Mycosis Fungoides/Sezary Syndrome (MFSS-1)
- Primary Cutaneous B-Cell Lymphoma (CUTB-1)
- Primary CNS Lymphoma (See NCCN CNS Guidelines)
- Use of Immunophenotyping in Differential Diagnosis of Mature B-Cell and T/NK-Cell Neoplasms (NHODG-A)
- Tumor Lysis Syndrome (NHODG-B)
- Response Criteria for Non-Hodgkin’s Lymphoma (NHODG-C)
- Rituximab and Viral Reactivation (NHODG-D)

These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2009.
Summary of changes in the 1.2009 version of the Non-Hodgkin's Lymphoma guidelines from the 3.2008 version include:

**New Guidelines**

**CUTB-1**
- Primary Cutaneous B-Cell Lymphoma is a new algorithm.

**NHODG-A**
- "Use of immunophenotyping in differential diagnosis of mature B-cell and T/NK-cell neoplasms" is new to the guidelines and a link to the page was added to each lymphoma subtype.

**NHODG-B**
- "Tumor lysis syndrome" is new to the guidelines and a link to the page was added to the appropriate lymphoma subtype.

**NHODG-D**
- "Rituximab and viral reactivation" is new to the guidelines and a link to the page was added to the appropriate lymphoma subtype.

**Global Changes**

- Diagnosis (essential): a bullet regarding an FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma was added to the appropriate lymphoma subtype.
- Footnote regarding Hepatitis B testing was clarified by adding appropriate testing for a patient with and without risk factors.
- PET or PET/CT scan was clarified as PET-CT scan.
- The diagnostic markers recommendations for each lymphoma subtype were modified as appropriate.
- Workup (essential): "Pregnancy testing in women of childbearing age (if chemotherapy planned)" was added.

**Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma**
- The guideline was extensively revised with a separation of CLL/SLL and Monoclonal B-cell lymphocytosis and CLL treatment was separated based on the presence or absence of a 17p deletion.
- "Supportive Care for Patients with CLL" was added as a new page.

**CSLL-D**
- Suggested treatment regimens were separated based on the presence or absence of a deletion of 17p.
- Follicular Lymphoma

**FOLL-1**
- Footnote ‘b’, was revised by adding "Germin al center (or follicular center) cell phenotype is not equivalent to follicular lymphoma and can occur in DLBCL and Burkitt lymphoma. Morphology is required to establish diagnosis.
- Footnote ‘e’, “In BCL2 negative young patients with localized disease, consider entity of pediatric follicular lymphoma” is new to the page.

**FOLL-3**
- Indication present, additional therapy, “Local RT (palliation of locally symptomatic disease)” and corresponding footnote ‘r’ were added.

**FOLL-4**
- Minimal or no prior chemotherapy treatment was clarified as, “Chemotherapy (anthracycline-based chemotherapy preferred unless contraindicated) (See BCEL-B) + rituximab ± RT”

**FOLL-A**
- Footnote ‘d’ was clarified by adding that the map is “used to determine the number of nodal sites for the FLIPI criteria.”

**FOLL-B 1 of 3**
- First-line therapy, “CHOP followed by radioimmunotherapy” was changed to “chemotherapy followed by radioimmunotherapy” and changed from a category 2B to category 1 recommendation.
- First-line therapy for elderly or infirm was clarified by adding “if none of the above treatments are tolerable”
- Second-line extended and subsequent therapy, “Bendamustine” was changed from a category 2B to a category 2A.
- Second-line extended and subsequent therapy “FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)” was added as a treatment option.

Continued on next page
### Summary of the Guidelines updates (Continued)

**Gastric MALT Lymphoma**
- **MALT-1**
  - Diagnosis (essential): second bullet was modified, “Diagnosis of Gastric MALT lymphoma requires an endoscopic biopsy and an FNA is never adequate.”
  - Diagnosis (essential): “If positive, the PCR or FISH for t(11;18)” was added to “Helicobacter Pylori stain.”
  - Workup, “MUGA scan/echocardiogram” was moved to useful in selected cases.

**MALT-2**
- Staging system was modified to follow the “Lugano Staging System for gastrointestinal lymphoma.”

**MALT-3**
- Algorithm was clarified as 3-month restaging “after antibiotics”.
- H. pylori positive, lymphoma positive, progressive or symptomatic disease, “and second-line antibiotic treatment” was added to RT.

**MALT-4**
- Algorithm was clarified as 3-month restaging “after RT”.

**Nongastric MALT Lymphoma**
- **NGMLT-1**
  - Workup, “MUGA scan/echocardiogram” was moved to useful in selected cases.
  - Footnote 'b' regarding the Nongastic MALT lymphoma algorithm is for non-cutaneous disease and for Cutaneous Marginal Zone B-cell Lymphoma, see CUTB was added.
  - Workup (useful in selected cases): bone marrow biopsy ± aspirate was clarified by adding, “for patients with multifocal disease”.

### Splenic Marginal Zone Lymphoma
- **SPLN-1**
  - Diagnosis (useful under some circumstances): “CLL panel, del (7q31-32), and cryoglobulins” were added.
  - Workup (essential): “SPEP and/or quantitative immunoglobulin levels” was added.

**Mantle Cell Lymphoma**
- **MANT-1**
  - Diagnosis (useful under some circumstances): “CLL panel” was added.
  - Workup, “Endoscopy/colonoscopy” was moved to useful in selected cases and corresponding footnote 'e' was added.

**MANT-2**
- Footnote 'f' referring to the MIPI: Mantle Cell Lymphoma International Prognostic Index is new to the page.

**MANT-A 1 of 3**
- First-line therapy, “Nordic regimen” and “cladribine ± rituximab” were added.
- First-line consolidation, “clinical trial” was added.
- Second-line therapy options added:
  - Lenalidomide
  - PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) ± R
  - Temsirolimus

**MANT-B**
- “MIPI: Mantle Cell Lymphoma International Prognostic Index” is new to the guidelines.

---

**Continued on next page**
**Summary of the Guidelines updates (Continued)**

**Diffuse Large B-Cell Lymphoma**

**BCEL-1**
- Workup (useful in selected cases): the list of sites when lumbar puncture should be performed was modified.
- Footnote 'a', was revised by adding “Germinal center (or follicular center) cell phenotype is not equivalent to follicular lymphoma and can occur in DLBCL and Burkitt lymphoma. Morphology is required to establish diagnosis.”
- Footnote 'c' was modified by adding, “other markers used for subclassification”.

**BCEL-2**
- Stage I, II, nonbulky, adverse risk factors not present, “± RT (category 2B for RT)” was added to RCHOP 6-8 cycles.
- Age-adjusted IPI was removed from stage III, IV.

**BCEL-5**
- Consolidation/Additional therapy, “High dose therapy with allogeneic stem cell rescue in selected cases” and corresponding footnote were added.
- Not candidate for high-dose therapy and no response, “Palliative RT” was added as a treatment option.

**BCEL-B 1 of 3**
- First-line consolidation with the recommendation of high dose therapy with autologous stem cell rescue was clarified for “high risk patients”.
- Second-line therapy, “± rituximab” was added to EPOCH.

**Burkitt's Lymphoma**

**BURK-1**
- Footnote 'a' was modified to describe that the WHO classification may not be able to distinguish between DLBCL and Burkitt’s lymphoma.
- Footnote 'b' describing the preference for this disease to be treated at a center with management expertise due to the complexity and curative nature was added.

**BURK-2**
- Low risk, abdominal mass was clarified as “< 10 cm”.
- For both high and low risk, < complete response, relapsed disease, “Palliative RT” was added as a relapse treatment option.

**BURK-A of 2**
- Dose adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + R (regimen includes intrathecal methotrexate) was added as a treatment option for both low and high risk combination regimens.

**Lymphoblastic Lymphoma**

**BLAST-1**
- Footnote 'a' describing the preference for this disease to be treated at a center with management expertise due to the complexity and curative nature was added.

**BLAST-A 1 of 3**
- Berlin-Frankfurt-Munster (BFM) regimen was described.
- “Cytarabine + high-dose mitoxantrone”, “high-dose cytarabine + rituximab or high-dose methotrexate + rituximab”, and “standard vincristine/prednisone induction” were removed.

**BLAST-A 2 of 3**
- CALGB ALL regimen was described.
- Maintenance chemotherapy recommendation was modified as, “up to 2 y of maintenance based on treatment protocol.”
- Footnote 'b' recommending irradiation of residual masses for T-cell lymphoblastic lymphomas with primary mediastinal presentation is new to the page.

Continued on next page
Summary of the Guidelines updates (Continued)

**AIDS-Related B-cell lymphoma**

**AIDS-2**
- Burkitt’s lymphoma, CHOP alone was removed as a treatment option and “± rituximab” was added as appropriate.
- Lymphoma-associated Castleman’s disease, Primary effusion, and Plasmoblastic lymphoma and their respective treatment options and follow-up were added.
- Primary CNS lymphoma, “best supportive care” was added.

**Peripheral T-Cell Lymphomas**

**ALCL (ALK positive) and ALCL (ALK negative) were added as subtypes to the title.**

**TCEL-1**
- Footnote ‘b’ regarding molecular diagnosis for T-cell receptor rearrangements was added.
- Footnote ‘d’ regarding the role of intrathecal prophylaxis is largely unknown in PTCL was added.

**TCEL-2**
- AILT was combined with PTCL NOS and ALCL.
- Stage II, IV and aalPI high/high-intermediate, “± RT for localized disease” was added to “multiagent chemotherapy 6-8 cycles”.
- Footnote ‘g’ regarding a trial of single agent corticosteroids for select patients is new to the page.

**TCEL-4**
- Not candidate for high-dose therapy and no response, “Palliative RT” was added as a treatment option.

**TCEL-B 1 of 2**
- Second-line therapy for patients who are candidates for high dose therapy, “GemOX (gemcitabine, oxaliplatin)” was added.
- Second-line therapy for patients who are not candidates for high dose therapy, “Radiation therapy” was added.

**Mycosis Fungoides/Sezary Syndrome**

- For CR/PR, “or inadequate response” was added after primary treatment throughout the algorithm.
- Footnote ‘j’ defining refractory disease as, “refractory or intolerant to multiple previous therapies” was added throughout the algorithm.

**MFSS-1**
- Footnote ‘f’, “many skin-directed and systemic therapies are contraindicated or of unknown safety in pregnancy. Refer to individual drug information” was added.

**MFSS-3**
- For refractory disease, “TSEBT if not previously administered” was added as a treatment option.

**MFSS-6**
- Primary treatment of lymph node disease and visceral disease, “± RT for local control” was added.
- “Consider allogeneic transplant, as appropriate” was moved from refractory disease to CR/PR.

**MFSS-A 1 of 3**
- Bortezomib was added as a second-line option of a category B systemic therapy.
- Footnote ‘c’ regarding systemic therapy after TSEBT was added.

**Staging**

**ST-1**
- Staging has been updated with the 2008 WHO Classification of the Mature B-cell, T-cell, and NK-cell neoplasms.
DIAGNOSIS

ESSENTIAL:
- Hematopathology review of all slides with at least one paraffin block representative of the tumor, if the diagnosis was made on a lymph node or bone marrow biopsy. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis. This is particularly true for the diagnosis of CLL/SLL.
- Flow cytometry of blood adequate for diagnosis of CLL/SLL (biopsy not required).

INFORMATIVE FOR PROGNOSTIC DETERMINATION:
- Adequate immunophenotyping to establish diagnosis
  - Recommended panel for paraffin section immunohistochemistry: CD3, CD5, CD10, CD20, CD23, cyclin D1
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10
- Absolute B-cell lymphocyte count

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
WORKUP

ESSENTIAL:
- Physical exam: attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Comprehensive metabolic panel
- Hepatitis B testing if rituximab contemplated
- MUGA scan/echocardiogram
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

USEFUL UNDER CERTAIN CIRCUMSTANCES:
- Quantitative immunoglobulins
- Reticulocyte count and direct Coombs’ test
- Chest/abdominal/pelvic CT should be done prior to initiation of therapy (particularly when peripheral adenopathy is present and symptoms suggest bulky lymph nodes)
- Beta-2-microglobulin
- Uric acid
- Unilateral bone marrow biopsy (± aspirate) at initiation of therapy
- Discussion of fertility issues and sperm banking

Induction Therapy
SLL/Localized
(Ann Arbor Stage I)
(See CSLL-3)

Induction Therapy
CLL or SLL
(Ann Arbor Stage II - IV, Rai Stages 0-IV)
(See CSLL-3)


\[^9\] Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.

\[^h\] If treatment includes regimens containing anthracyclines or anthracenediones.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**CLL/SLL**

**PRESENTATION**

1. **SLL/Localized (Ann Arbor Stage I)**
   - Locoregional RT (if indicated)
   - Observe
   - Evaluate for indications for treatment:
     - Eligible for clinical trial
     - Significant disease-related symptoms: Fatigue, Night sweats, Weight loss, Fever without infection
     - Threatened end-organ function
     - Bulky disease (spleen > 6 cm beneath costal margin, lymph nodes > 10 cm)
     - Lymphocyte doubling time (LDT) ≤ 6 mo
     - Progressive anemia
     - Platelet count < 100,000 cells/mm³

2. **SLL or CLL (Ann Arbor Stages II-IV, Rai Stages 0-IV)**
   - CLL Rai Low (0) and Intermediate (I-II) risk
   - CLL Progressive Rai High (III-IV) Risk
   - Histologic transformation to diffuse large-cell/ Hodgkin lymphoma
     - Manage as aggressive lymphoma (See BCEL-B)
     - Consider allogeneic stem cell transplant (See BCEL-B)

3. **Consider prophylaxis for tumor lysis syndrome (See NHODG-B)**

---

1. See Supportive Care For Patients With CLL (CSLL-C).
2. See Rai and Binet Classification Systems (CSLL-B).
3. Absolute lymphocyte count alone is not an indication for treatment.
4. Given incurability with conventional therapy, consider a clinical trial as first line of treatment.
5. Re-evaluation of FISH is helpful to direct treatment options.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
CLL WITHOUT DELETION OF 17p

**FIRST LINE THERAPY**

- Frail patient, significant co-morbidity (not able to tolerate purine analogs)
  - See Suggested Regimens (CSLL-D)

- Age ≥ 70 y
  - See Suggested Regimens (CSLL-D)

- Age < 70 y or older with good co-morbidity index
  - See Suggested Regimens (CSLL-D)

**RESPONSE TO THERAPY**

- Long response > 3-5 y, repeat FISH, if del (17p) see CSLL-5
  - Retreat with first line therapy until a short response

- Short response < 1-2 y, repeat FISH, if del (17p) see CSLL-5
  - Consider allogeneic stem cell transplant, if fit

- Consider prophylaxis for tumor lysis syndrome (See NHODG-B)

---

\[\text{Note: All recommendations are category 2A unless otherwise indicated.} \]

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

\[\text{See Supportive Care For Patients With CLL (CSLL-C).} \]

\[\text{\textsuperscript{k}Absolute lymphocyte count alone is not an indication for treatment.} \]

\[\text{\textsuperscript{i}Given incurability with conventional therapy, consider a clinical trial as first line of treatment.} \]

\[\text{\textsuperscript{n}If long response, treat with the same first line therapy. If short response, consider alternative first line therapy not used before.} \]
CLL WITH DELETION OF 17p

**FIRST LINE THERAPY**

- Consider prophylaxis for tumor lysis syndrome ([See NHODG-B](#)).

**RESPONSE TO THERAPY**

- **CR/PR**
  - Candidate for transplant
    - Allogeneic stem cell transplant
  - Non-candidate for transplant
    - No response

- **No response**
  - Observe
  - Clinical trial

**CLL with del (17p) with > 20% cells**

- **Clinical trial**
  - See Suggested Regimens ([CSLL-D](#))

- **See Supportive Care For Patients With CLL ([CSLL-C](#))**.

- Absolute lymphocyte count alone is not an indication for treatment.

- 17p deletion is associated with low response rates with all treatments and has no standard treatment; clinical trial is recommended.

- **See Response Criteria: CLL ([CSLL-E](#)) or SLL ([NHODG-C](#)).**

- For patients with non-bulky adenopathy.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### PROGNOSTIC INFORMATION FOR CLL<sup>a</sup>

#### Immunoglobulin Variable Gene Mutation and Surrogates by Flow

<table>
<thead>
<tr>
<th></th>
<th>Outcome Association</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Favorable</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>DNA sequencing V&lt;sub&gt;H&lt;/sub&gt;</td>
<td>&gt; 2% mutation</td>
<td>≤ 2% mutation</td>
</tr>
<tr>
<td>Flow Cytometry CD38 &gt; 30%</td>
<td>Negative</td>
<td>Positive</td>
</tr>
</tbody>
</table>

#### Interphase Cytogenetics (FISH)<sup>b</sup>

<table>
<thead>
<tr>
<th></th>
<th>Unfavorable</th>
<th>Neutral</th>
<th>Favorable</th>
</tr>
</thead>
<tbody>
<tr>
<td>t (11q;v) del(11q) del(17p)</td>
<td></td>
<td>Normal</td>
<td>del(13q) (as a sole abnormality)</td>
</tr>
<tr>
<td>del(13q) (as a sole abnormality)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>This table provides useful prognostic information relative to the time to progression where therapy is required and survival. The presence of del(11q) and/or del (17p) are associated with short progression free survival to chemotherapy and chemoimmunotherapy approaches. Alemtuzumab or high dose steroids have anecdotal response in del(17p) disease.

<sup>b</sup>Formal studies identifying the percentage of abnormal cells identified by FISH are ongoing although populations less than 10% appear to not have the clinical impact as noted in the table.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
# CLL Staging Systems

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Risk Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Lymphocytosis, lymphocytes in blood &gt; 15,000/mcL and &gt; 40% lymphocytes in the bone marrow</td>
<td>Good</td>
</tr>
<tr>
<td>I</td>
<td>Stage 0 with enlarged node(s)</td>
<td>Intermediate</td>
</tr>
<tr>
<td>II</td>
<td>Stage 0-I with splenomegaly, hepatomegaly, or both</td>
<td>Intermediate</td>
</tr>
<tr>
<td>IIIc</td>
<td>Stage 0-II with hemoglobin &lt; 11.0 g/dL or hematocrit &lt; 33%</td>
<td>High</td>
</tr>
<tr>
<td>IVc</td>
<td>Stage 0-III with platelets &lt; 100,000/mcL</td>
<td>High</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Hemoglobin ≥ 10 g/dL and Platelets ≥ 100,000/mm³ and &lt; 3 enlarged areas</td>
</tr>
<tr>
<td>B</td>
<td>Hemoglobin ≥ 10 g/dL and Platelets ≥ 100,000/mm³ and ≥ 3 enlarged areas</td>
</tr>
<tr>
<td>Cc</td>
<td>Hemoglobin &lt; 10 g/dL and/or Platelets &lt; 100,000/mm³ and any number of enlarged areas</td>
</tr>
</tbody>
</table>

---

Notes:
- Immune-mediated cytopenias are not the basis for these stage definitions.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### SUPPORTIVE CARE FOR PATIENTS WITH CLL

| Recurrent Infections (requiring IV antibiotics or hospitalization) | • Antimicrobials as appropriate  
  • Evaluate serum IgG, if < 500 mg/dl  
  ‣ begin monthly IVIG 0.3-0.5 mg/kg,  
  ‣ adjust dose/interval to maintain nadir level > 500-700 mg/dl |
|---|---|
| Antibiotic Prophylaxis | • Consider for patients during treatment and thereafter, if tolerated  
  ‣ Frontline treatment: Herpes virus (acyclovir or equivalent)  
  ‣ Retreatment: Herpes virus (acyclovir or equivalent)  
  ‣ PCP (bactrim or equivalent)  
  • Alemtuzumab: CMV monitoring of antigen during treatment every 1-2 wks or valganciclovir during and for 2 mo after |
| Autoimmune Cytopenias | • Auto-immune hemolytic anemia (AIHA) diagnosis with reticulocyte count, haptoglobin, DAT  
  ‣ AIHA that develops in setting of treatment with fludarabine, stop, treat, and avoid subsequent fludarabine  
  • Immune thrombocytopenia purpura (ITP): Evaluate bone marrow for cause of low PLT  
  • Pure red blood cell aplasia (PRCA): Evaluate for parvo B19  
  • Treatment: Corticosteroids, rituximab, IVIG, cyclosporin A, splenectomy, eltrombopag (ITP) |
| Vaccination | • Annual Influenza vaccine  
  • Pneumococcal vaccine every 5 yrs  
  • Avoid all live vaccines, including Zoster |
| Blood Product Support | • Transfuse according to institutional or published standards  
  • Irradiate all blood products |

---

**a**In patients who have received rituximab, B-cell recovery occurs by approximately 9 months. Prior to B-cell recovery, patients generally do not respond to influenza vaccine and if given should not be considered vaccinated.

**Note:** All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### SUGGESTED TREATMENT REGIMENS

*In order of preference*

#### CLL without del (17p)

<table>
<thead>
<tr>
<th>First line therapy</th>
<th>Second line therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age ≥ 70 y</strong></td>
<td><strong>Short response &lt; 1-2 y (Age ≥ 70 y)</strong></td>
</tr>
<tr>
<td>Chlorambucil ± prednisone</td>
<td>Purine-analogue therapy&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Alkylating agent-based chemotherapy</td>
<td></td>
</tr>
<tr>
<td>CVP (cyclophosphamide + vincristine + prednisone)</td>
<td></td>
</tr>
<tr>
<td>Alemtuzumab&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Bendamustine&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td></td>
</tr>
<tr>
<td>Fludarabine&lt;sup&gt;f&lt;/sup&gt; ± rituximab</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Age &lt; 70 y or older with good co-morbidity index</strong></th>
<th><strong>Short response &lt; 1-2 y (Age &lt; 70 y or older with good co-morbidity index)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemoimmunotherapy&lt;sup&gt;d&lt;/sup&gt; (preferred)</td>
<td>Chemoimmunotherapy&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>FCR (fludarabine&lt;sup&gt;f&lt;/sup&gt;, cyclophosphamide&lt;sup&gt;g&lt;/sup&gt;, rituximab)</td>
<td></td>
</tr>
<tr>
<td>FR (fludarabine&lt;sup&gt;f&lt;/sup&gt;, rituximab)</td>
<td></td>
</tr>
<tr>
<td>PCV (pentostatin, cyclophosphamide&lt;sup&gt;g&lt;/sup&gt;, rituximab)</td>
<td></td>
</tr>
<tr>
<td>Purine-analogue therapy&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>FC (fludarabine&lt;sup&gt;f&lt;/sup&gt;, cyclophosphamide&lt;sup&gt;g&lt;/sup&gt;)</td>
<td></td>
</tr>
</tbody>
</table>

| **Monotherapy** |  |
| Chlorambucil ± prednisone |  |
| Fludarabine<sup>f</sup> |  |
| Alemtuzumab<sup>c</sup> |  |
| Bendamustine<sup>d,e</sup> |  |

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

---

See Rituximab and Viral Reactivation (NHODG-D)

See Suggested Regimens for CLL with del (17p) (2 of 4)

See Footnotes for CLL with del (17p) on CSLL-D (2 of 4)
**SUGGESTED TREATMENT REGIMENS**
*(in order of preference)*

**CLL with del (17p) with > 20% cells**

<table>
<thead>
<tr>
<th>First line therapy</th>
<th>Second line therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCR (fludarabine&lt;sup&gt;f&lt;/sup&gt;, cyclophosphamide, rituximab)</td>
<td>CHOP + R (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab)</td>
</tr>
<tr>
<td>FR (fludarabine&lt;sup&gt;f&lt;/sup&gt;, rituximab)</td>
<td>CFAR (FCR&lt;sup&gt;f&lt;/sup&gt; + alemtuzumab)</td>
</tr>
<tr>
<td>HDMP + R (high-dose methylprednisone + rituximab)</td>
<td>HyperCVAD + R (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine)</td>
</tr>
<tr>
<td>CFAR (FCR&lt;sup&gt;f&lt;/sup&gt; + alemtuzumab)</td>
<td>OFAR (oxaliplatin, fludarabine&lt;sup&gt;f&lt;/sup&gt;, cytarabine and rituximab)</td>
</tr>
<tr>
<td>Alemtuzumab&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Alemtuzumab + rituximab&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>High dose dexamethasone</td>
</tr>
</tbody>
</table>

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*a* See references for regimens [CSLL-D 3 of 4](#) and [CSLL-D 4 of 4](#).

*b* Prophylactic therapy for shingles and pneumocystis should be considered in purine analog-based combination therapy.

*c* Less effective for bulky (> 5 cm) lymphadenopathy; monitor for CMV reactivation.

*d* Monitor for myelosuppression.


*f* Autoimmune hemolytic anemia (AIHA) should not preclude the use of combination therapy containing fludarabine and patients should be observed carefully.

*g* Cyclophosphamide should be included for 11q del.

*h* Rituximab and alemtuzumab should be used in combination only when there is existing literature to support its use in combination.
SUGGESTED TREATMENT REGIMENS

REFERENCES

**Alemtuzumab**

**Alemtuzumab plus rituximab**

**Bendamustine**

**Chlorambucil**

**Chlorambucil plus prednisone**

**Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)**

**Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR)**

**Fludarabine and cyclophosphamide (FC)**

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**SUGGESTED TREATMENT REGIMENS**

**REFERENCES**

**Fludarabine and cyclophosphamide + rituximab (FCR)**


Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2008;112(11):Abstract 325.


**Fludarabine and alemtuzumab**

**Fludarabine + rituximab**

**High-dose methylprednisolone plus rituximab (HDMP)**

**Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR)**

**Pentostatin, cyclophosphamide and rituximab (PCR)**


**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## RESPONSE DEFINITION AFTER TREATMENT FOR CLL\(^a\)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Complete response</th>
<th>Partial response</th>
<th>Progressive Disease</th>
<th>Stable Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphadenopathy(^b)</td>
<td>None above 1.0 cm</td>
<td>Decrease ≥ 50%</td>
<td>Increase ≥ 50%</td>
<td>Change from -49% to +49%</td>
</tr>
<tr>
<td>Liver and/or spleen size</td>
<td>Normal size</td>
<td>Decrease ≥ 50%</td>
<td>Increase ≥ 50%</td>
<td>Change from -49% to +49%</td>
</tr>
<tr>
<td>Constitutional symptoms</td>
<td>None</td>
<td>Any</td>
<td>Any</td>
<td>Any</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>&gt; 1500/mm(^3)</td>
<td>&gt; 1500/mm(^3) or &gt; 50% improvement</td>
<td>Any</td>
<td>Any</td>
</tr>
<tr>
<td>Circulating B lymphocytes</td>
<td>Normal</td>
<td>Decrease ≥ 50% over baseline</td>
<td>Increase ≥ 50%</td>
<td>Change from -49% to +49%</td>
</tr>
<tr>
<td>Platelet count</td>
<td>&gt; 100,000/mm(^3)</td>
<td>&gt; 100,000/mm(^3) or increase ≥ 50% over baseline</td>
<td>Decrease ≥ 50% over baseline</td>
<td>Change from -49% to +49%</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>&gt; 11.0 g/dL (untransfused)</td>
<td>&gt; 2 g/dL from baseline</td>
<td>Decrease of &gt; 2 g/dL from baseline</td>
<td>Increase &lt; 11.0 g/dL or &lt; 50% over baseline, or decrease &lt; 2 g/dL</td>
</tr>
<tr>
<td>Marrow</td>
<td>Normocellular, &lt; 30% lymphocytes, no B-lymphoid nodules</td>
<td>Hypocellular, or ≥ 30% lymphocytes, or B-lymphoid nodules, or not done</td>
<td>Increase of lymphocytes to more than 30% from normal</td>
<td>No change of marrow infiltrate</td>
</tr>
</tbody>
</table>

\(^a\)Eichhorst B and Hallek M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Practice & Research Clinical Haematology. 2007;20:469-477.

\(^b\)Sum of the products of multiple lymph nodes (as evaluated by CT scans in clinical trials, or by physical exam or ultrasound in general practice).

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Follicular Lymphoma\textsuperscript{a} (grade 1-2)

**DIAGNOSIS\textsuperscript{b}\textsuperscript{a}**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis. Histologic grading cannot be performed on an FNA.
- Adequate immunophenotyping to establish diagnosis\textsuperscript{c,d}
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD5, CD10, CD21, CD23, BCL2, BCL6, Ki67, cyclin D1
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen gene receptor rearrangements; BCL2 rearrangement
- Cytogenetics or FISH: t(14;18); t(6;14) or variants

\textsuperscript{a}Follicular lymphoma, grade 1-2. Follicular lymphoma, grade 3 is an area of controversy. The distinction between follicular grade 3a and 3b has not been shown to have clinical significance to date. Follicular lymphoma, grade 3 is commonly treated according to the \href{https://www.nccn.org/professionals/physician_gls/pdf/hodgkin.pdf}{NCCN Diffuse Large B-Cell Lymphoma Guideline (BCEL-1)}. Any area of diffuse large B-cell lymphoma (DLBCL) in a follicular lymphoma of any grade should be diagnosed and treated as a DLBCL.

\textsuperscript{b}Germinal center or follicular center cell phenotype type is not equivalent to follicular lymphoma and occurs in Burkitt lymphoma and some DLBCL.

\textsuperscript{c}Typical immunophenotype: CD10+, BCL2+, CD23-/+, CD43-, CD5-, CD20+, cyclin D1-, BCL6+. Rare cases of follicular lymphoma may be CD10- or BCL2-.

\textsuperscript{d}See \href{https://www.nccn.org/professionals/physician_gls/pdf/hodgkin.pdf}{Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A)}.

**WORKUP\textsuperscript{c,d}\textsuperscript{b}\textsuperscript{a}**

**ESSENTIAL:**
- Physical exam: attention to node-bearing areas, including Waldeyer's ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Comprehensive metabolic panel
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Hepatitis B testing\textsuperscript{f}
- Bone marrow biopsy + aspirate to document clinical stage I-II disease\textsuperscript{g}
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN SELECTED CASES:**
- MUGA scan/echocardiogram\textsuperscript{h}
- Neck CT
- Beta-2-microglobulin
- PET-CT scan
- Uric acid
- Discussion of fertility issues and sperm banking
- SPEP and/or quantitative immunoglobulin levels
- Hepatitis C testing

\textsuperscript{f}In BCL2 negative young patients with localized disease, consider entity of pediatric follicular lymphoma.

\textsuperscript{g}Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.

\textsuperscript{h}If treatment includes regimens containing anthracyclines or anthracenediones.

\textsuperscript{c}Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
When determining initial treatment, consider excluding profoundly myelotoxic regimens for patients who may be eligible for High dose therapy with autologous stem cell rescue.

Treatment of the involved lymphoid region (24-30 Gy) with additional 6 Gy in selected circumstances of slowly regressing disease.

Initiation of chemotherapy or more extended RT can improve FFS (failure-free survival), but has not been shown to improve overall survival. These are options for therapy.

Observation may be appropriate in circumstances where toxicity of involved-field RT (locoregional) outweighs potential clinical benefit.

Indications for treatment:
- Candidate for clinical trial
- Symptoms
- Threatened end-organ function
- Cytopenia secondary to lymphoma
- Bulky disease
- Steady progression
- Patient preference

No response

Indication present

See Suggested Regimens (FOLL-B) or Clinical trial or Local RT (palliation of locally symptomatic disease)

Progressive disease

Observation

Clinical follow-up every 3 mo for 1 y, then every 3-6 mo

Progressive disease

See Initial Response (FOLL-3)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See GELF criteria (FOLL-A).

See Management of Transformation (FOLL-F).
**INITIAL RESPONSE**

Complete response\(^o\) or partial response\(^o\)  →  Clinical follow-up every 3 mo for 1y, then every 3-6 mo\(^{p,q}\)  →  Progressive disease\(^o,s\)  →  Indications for treatment:  
- Candidate for clinical trial
- Symptoms
- Threatened end-organ function
- Cytopenia secondary to lymphoma
- Bulky disease
- Steady progression
- Patient preference

No response or progressive disease\(^o,s\) (For transformation see FOLL-4)  →  No indication  →  Observe

**ADDITIONAL THERAPY**

No indication  →  Observe

Indication present

See Suggested Regimens (FOLL-B) or Clinical trial\(^t\) or Local RT (palliation of locally symptomatic disease)\(^r\)

\(^m\) See GELF criteria (FOLL-A).
\(^o\) See Response Criteria for Lymphoma (NHODG-C).
\(^p\) Follow-up includes repeat diagnostic tests, including imaging (based on site of disease and clinical presentation) as clinically indicated (about every 6 mo).
\(^q\) Patients in remission may be eligible for clinical trials.
\(^r\) In the palliative setting, involved field doses as low as 4 Gy may be effective.
\(^s\) Progressive disease should be histologically documented to rule out transformation (preferentially, biopsy or FDG uptake on PET), especially if LDH levels are rising, single site is growing disproportionately, extranodal disease develops, new B symptoms develop, or there is marked heterogeneity or sites of intense FDG avidity on PET scan. A directed biopsy should be performed of a suspicious area. If transformation is histologically confirmed, treat with anthracycline-based therapy. Positive functional imaging does not replace biopsy to diagnose transformation. See Management of Transformation (FOLL-4).

\(^t\) Clinical trials may involve novel agents, regimens, or transplantation.

---

**Note:** All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
HISTOLOGICAL TRANSFORMATION TO DIFFUSE LARGE B-CELL LYMPHOMA

- **Multiple prior therapies**
  - Clinical trial or Radioimmunotherapy or Chemotherapy (See BCEL-B) ± rituximab or Involved-field RT or Best Supportive Care (See NCCN Palliative Care Guidelines)
  - Responsive disease
    - Consider high dose therapy with autologous or allogeneic stem cell rescue

- **Minimal or no prior chemotherapy**
  - Chemotherapy (anthracycline-based chemotherapy preferred unless contraindicated) (See BCEL-B) + rituximab ± RT
    - Complete response
      - Consider high dose therapy with autologous or allogeneic stem cell rescue or Clinical trial or Observation
    - Partial response
      - Consider high dose therapy with autologous or allogeneic stem cell rescue or Clinical trial
    - No response or progressive disease
      - Clinical trial or Radioimmunotherapy or Palliative or best supportive care

- **See Response Criteria for Lymphoma (NHODG-C).**
- **If locoregional transformation, consider adding RT.**
- **Strongly recommend this treatment be given in the context of a clinical trial; nonmyeloblative approaches may also be considered.**

__Note:__ All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**FLIPI CRITERIA**

- **Age** ≥ 60 y
- **Ann Arbor stage** III-IV
- **Hemoglobin level** < 12 g/dL
- **Serum LDH level** > ULN (upper limit of normal)
- **Number of nodal sites** ≥ 5

**Risk group according to FLIPI chart**

<table>
<thead>
<tr>
<th>Number of factors</th>
<th>Low</th>
<th>Intermediate</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-1</td>
<td>2</td>
<td>≥ 3</td>
</tr>
</tbody>
</table>

© 2007 Dana-Farber Cancer Institute Inc. All rights reserved. Permission is hereby granted for copying this image by photocopy or similar process for use in the practice of medicine or for research purposes. No other use is permitted which will infringe the copyright without the express written consent of Dana-Farber Cancer Institute, Inc.

---

**GELF CRITERIA**

- Involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3 cm
- Any nodal or extranodal tumor mass with a diameter of ≥ 7 cm
- B symptoms
- Splenomegaly
- Pleural effusions or peritoneal ascites
- Cytopenias (leukocytes < 1.0 x 10^9/L and/or platelets < 100 x 10^9/L)
- Leukemia (> 5.0 x 10^9/L malignant cells)

---

**FOLL-A**

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Follicular Lymphoma

SUGGESTED TREATMENT REGIMENS\textsuperscript{a,b}
(in alphabetical order)

<table>
<thead>
<tr>
<th>First-line Therapy \textsuperscript{c,d}</th>
</tr>
</thead>
<tbody>
<tr>
<td>• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab (category 1)</td>
</tr>
<tr>
<td>• CVP (cyclophosphamide, vincristine, prednisone) + rituximab (category 1)</td>
</tr>
<tr>
<td>• Fludarabine + rituximab</td>
</tr>
<tr>
<td>• FND (fludarabine, mitoxantrone, dexamethasone) + rituximab</td>
</tr>
<tr>
<td>• Rituximab</td>
</tr>
<tr>
<td>• Radioimmunotherapy\textsuperscript{g,h} (category 2B)</td>
</tr>
<tr>
<td>• Chemotherapy followed by radioimmunotherapy\textsuperscript{g,h} (category 1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>First-line for Elderly or Infirm (if none of the above are tolerable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Rituximab, preferred</td>
</tr>
<tr>
<td>• Single agent alkylators (eg, chlorambucil or cyclophosphamide)</td>
</tr>
</tbody>
</table>

\textbf{See Rituximab and Viral Reactivation (NHODG-D)}

\textsuperscript{*}For patients with locally bulky or symptomatic disease, consider IFRT 4-30 Gy ± additional systemic therapy.

\textsuperscript{a}See references for regimens FOLL-B 2 of 3 and FOLL-B 3 of 3

\textsuperscript{b}The choice of initial therapy requires consideration of many factors, including age, comorbidities, and future treatment possibilities (eg, HDT with SCR). Therefore, treatment selection is highly individualized.

\textsuperscript{c}In combination chemotherapy, addition of rituximab has consistently increased overall response rate, response duration, and progression-free survival. In addition some studies have demonstrated an overall survival benefit.

\textsuperscript{d}Initial management of patients with follicular lymphoma should include rituximab; use caution in patients with hepatitis B.

\textsuperscript{e}A randomized trial of rituximab maintenance following CVP induction has demonstrated an improvement in remission duration with a trend toward survival.

\textsuperscript{f}The role of single agent rituximab maintenance after remission induction with rituximab + chemotherapy combination is unknown.

\textsuperscript{g}Selection of patients requires adequate marrow cellularity > 15% and < 25% involvement of lymphoma in bone marrow, and platelets > 100,000. In patients with prior autologous stem cell rescue, referral to a tertiary care center is highly recommended for radioimmunotherapy.

\textsuperscript{h}If radioimmunotherapy is considered, bilateral cores are recommended and the pathologist should provide the percent of overall cellular elements and the percent of cellular elements involved in the marrow. Cytogenetics ± FISH for known MDS markers.

\textsuperscript{i}High dose therapy with autologous stem cell rescue is an appropriate consolidative therapy to patients in second or third remission although the benefit is palliative.

\textsuperscript{j}In highly selected patients, trials of fully ablative and nonmyeloablative allogeneic stem cell transplant have shown long term survival advantage, although there is a 2-year treatment-related mortality rate of approximately 25% for non-myeloablative and 40% for fully ablative.

\textsuperscript{k}In patients previously treated with chemotherapy, rituximab and anthracycline naive, maintenance rituximab extends disease-free, event-free and overall survival.

\textbf{Chemotherapy/Immunotherapy - single and combination therapy*}

<table>
<thead>
<tr>
<th>First-line Extended Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab maintenance\textsuperscript{e,f,k} (category 2B) [It is strongly recommended this treatment be on a prospective clinical study.]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second-line and Subsequent Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Bendamustine ± rituximab</td>
</tr>
<tr>
<td>• FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)</td>
</tr>
<tr>
<td>• Chemoimmunotherapy (as in first-line therapy)</td>
</tr>
<tr>
<td>• High dose therapy with autologous stem cell rescue\textsuperscript{i}</td>
</tr>
<tr>
<td>• High dose therapy with allogeneic stem cell rescue, for highly selected patients\textsuperscript{j}</td>
</tr>
<tr>
<td>• Radioimmunotherapy\textsuperscript{g,h}</td>
</tr>
<tr>
<td>• \textbf{See Second-line Therapy for DLBCL (BCEL-B 1 of 3)}</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second-line Extended Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab maintenance\textsuperscript{g} (category 1)</td>
</tr>
</tbody>
</table>

\textbf{Note:} All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUGGESTED TREATMENT REGIMENS

**First-line therapy**

**Cyclophosphamide**

**CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab**


**CVP (cyclophosphamide, vincristine, prednisone) + rituximab**


**Fludarabine + rituximab**


**FND (fludarabine, mitoxantrone, dexamethasone) + rituximab**


**Rituximab**


**Radioimmunotherapy**


**Chemotherapy followed by radioimmunotherapy**


**Second-line extended dosing**

**Rituximab maintenance**


---

**Continued on next page**

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Follicular Lymphoma

SUGGESTED TREATMENT REGIMENS

References

Second-line therapy

Bendamustine

FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)
Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 2004;104:3064-3071.

Radioimmunotherapy
**Gastric MALT Lymphoma**

### DIAGNOSIS

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.\(^a,b\)
- Diagnosis of Gastric MALT lymphoma requires an endoscopic biopsy and an FNA is never adequate.
- Adequate immunophenotyping to establish diagnosis\(^c,d\)
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD5, CD10, BCL2, kappa/lambda, CD21 or CD23, cyclin D1, Ki-67, BCL6 or
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10
- Helicobacter Pylori stain (gastric), if positive, then PCR or FISH for t(11;18)\(^e\)

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen receptor gene rearrangements
- Cytogenetics or FISH: t(1;14), t(14;18), t(3;14)

### WORKUP

**ESSENTIAL:**
- Physical exam with attention to nongastric sites (eyes, skin)
- Performance status
- CBC, differential, platelets
- Comprehensive metabolic panel
- LDH
- If H. pylori negative by histopathology, then use noninvasive H. pylori testing (Stool antigen test, urea breath test, blood antibody test)
- Hepatitis B testing if rituximab contemplated
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Endoscopy with multiple biopsies of anatomical sites
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN SELECTED CASES**
- Endoscopic ultrasound
- Bone marrow biopsy ± aspirate
- MUGA scan/echocardiogram\(^g\)
- Discussion of fertility issues and sperm banking

\(^a\)Nondiagnostic atypical lymphoid infiltrates that are H. Pylori positive, should be rebiopsied to confirm or exclude lymphoma prior to treatment of H. Pylori.
\(^b\)Any area of DLBCL should be treated according to the NCCN Diffuse Large B-Cell Lymphoma Guidelines (BCEL-1).
\(^c\)Typical immunophenotype: CD10-, CD5-, CD20+, and cyclin D1-, BCL2 follicles-
\(^d\)See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).
\(^e\)Locally advanced disease is more likely in patients with extranodal gastric lymphoma with t(11;18).
\(^f\)Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.
\(^g\)If treatment includes regimens containing anthracyclines or anthracenediones.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Gastric MALT Lymphoma**

### STAGE

<table>
<thead>
<tr>
<th>Stage I or II H. pylori positive</th>
<th>Currently accepted antibiotic therapy for H. pylori</th>
<th>Evaluate for H. pylori eradication with endoscopy (MALT-3)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Stage I or II H. pylori negative</th>
<th>RT (30-33 Gy) (preferred) or Rituximab (if RT is contraindicated)</th>
<th>Endoscopy for restaging, as per MALT-4</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Stage III/IV (advanced-stage disease uncommon)</th>
<th>Indications for treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications present</td>
<td>No indication</td>
</tr>
<tr>
<td>Indication present</td>
<td>Induction chemoinmunotherapy (combination or single agent) or Locoregional RT in specific settings</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------</td>
</tr>
</tbody>
</table>

---

See Lugano Staging System for gastrointestinal lymphoma (MALT-A).

`t(11;18)` is a predictor for lack of response to antibiotics. These patients should be considered for alternative therapy.

If negative by both histology and serum antibodies, RT recommended.

Given incurability with conventional therapy, consider investigational therapy as first line of treatment.

Surgical resection is generally limited to specific clinical situations, ie, life-threatening hemorrhage.

See Suggested Treatment Regimens (FOLL-B).

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
3-MONTH RESTAGING AND FOLLOW-UP ENDOSCOPY

AFTER ANTIBIOTICS

H. pylori negative, Lymphoma negative

- Observe

H. pylori negative, Lymphoma positive

- Asymptomatic
  - Observe
  - Or Locoregional RT

- Symptomatic
  - RT

H. pylori positive, Lymphoma negative

- Stable disease

H. pylori positive, Lymphoma positive

- Progressive or symptomatic disease
  - RT and second-line antibiotic treatment

- Observe for another 3 mo or Locoregional RT

See Follow-up Endoscopy (MALT-5)

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Biopsy to rule out large cell lymphoma. Any area of DLBCL should be treated according to the NCCN Diffuse Large B-Cell Lymphoma Guidelines (BCEL-1).

If re-evaluation suggests slowly responding disease or asymptomatic nonprogression, continued observation may be warranted. RT can be considered as early as 3 mo after observation but can be prolonged to 18 mo (category 2B).
3-MONTH RESTAGING AND FOLLOW-UP ENDOSCOPY

AFTER RT

H. pylori negative
Lymphoma negative
→ Observe

H. pylori negative
Lymphoma positive
→ Locoregional RT, if not previously treated
   or If prior RT, see FOLL-2

H. pylori positive
Lymphoma negative
→ Consider other antibiotic treatment

H. pylori positive
Lymphoma positive
→ Locoregional RT, if not previously treated
   or If prior RT, see FOLL-2

Restage at 3 mo with endoscopy and biopsy\(^n\)

See Follow-up Endoscopy (MALT-5)

\(^n\)Biopsy to rule out large cell lymphoma. Any area of DLBCL should be treated according to the NCCN Diffuse Large B-Cell Lymphoma Guidelines (BCEL-1).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**FOLLOW-UP ENDOSCOPY**

- **Complete response**
  - Follow-up every 3 mo for 1 y, then every 3-6 mo
  - Recurrence post RT
  - See follicular lymphoma indications for treatment (FOLL-3)

- **No response**
  - Recurrence post antibiotics
  - Systemic
  - Locoregional RT

- **Repeat endoscopy after 3 mo**

- **Previous RT**
  - See follicular lymphoma indications for treatment (FOLL-3)

- **Previous antibiotic treatment**
  - Locoregional RT

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

^nBiopsy to rule out large cell lymphoma. Any area of DLBCL should be treated according to the NCCN Diffuse Large B-Cell Lymphoma Guidelines (BCEL-1).

^pOptimal interval for follow-up endoscopy is not known. Follow-up endoscopy (category 2B) at NCCN centers is driven by symptoms.

^qFollow-up includes repeat diagnostic tests, including imaging (based on site of disease and clinical presentation) as clinically indicated (about every 6 mo).
## STAGING OF GASTRIC MALT LYMPHOMA: COMPARISON OF DIFFERENT SYSTEMS

<table>
<thead>
<tr>
<th>Staging System</th>
<th>TNM Staging System adapted for gastric lymphoma</th>
<th>Ann Arbor stage</th>
<th>Tumor extension</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stage I</strong></td>
<td>Confined to GI tract (single primary or multiple, noncontiguous)</td>
<td>T1 N0 M0</td>
<td>I_E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T2 N0 M0</td>
<td>I_E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T3 N0 M0</td>
<td>I_E</td>
</tr>
<tr>
<td><strong>Stage II</strong></td>
<td>Extending into abdomen</td>
<td>T1-3 N1 M0</td>
<td>II_E</td>
</tr>
<tr>
<td><strong>II₁</strong></td>
<td>Local nodal involvement</td>
<td>T1-3 N2 M0</td>
<td>II_E</td>
</tr>
<tr>
<td><strong>II₂</strong></td>
<td>Distant nodal involvement</td>
<td>T4 N0 M0</td>
<td>I_E</td>
</tr>
<tr>
<td><strong>Stage II_E</strong></td>
<td>Penetration of serosa to involve adjacent organs or tissues</td>
<td>T1-4 N3 M0</td>
<td>III_E</td>
</tr>
<tr>
<td><strong>Stage III - IV</strong></td>
<td>Disseminated extranodal involvement or concomitant supradiaphragmatic nodal involvement</td>
<td>T1-4 N0-3 M1</td>
<td>IV</td>
</tr>
</tbody>
</table>


---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Nongastric MALT Lymphoma
(Extranodal Marginal Zone B-Cell Lymphoma)

**DIAGNOSIS**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- Adequate immunophenotyping to establish diagnosis.
- Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD5, CD10, BCL2, kappa lambda, CD21 or CD23, cyclin D1
- Cell surface marker analysis by flow cytometry: kappa/lamba, CD19, CD20, CD5, CD23, CD10

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; PCR for t(11;18)
- Cytogentic or FISH: t(11;18); t(11;14); t(3;14); t(14;18)

**WORKUP**

**ESSENTIAL:**
- Physical exam with performance status
- CBC, differential, platelets
- Comprehensive metabolic panel
- LDH
- Hepatitis B testing if rituximab contemplated
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN SELECTED CASES**
- MUGA scan/echocardiogram
- Bone marrow biopsy ± aspirate (for patients with multifocal disease)
- Endoscopy with multiple biopsies of anatomical sites
- PET-CT scan
- Discussion of fertility issues and sperm banking
- MRI

---

*Typical sites of extranodal marginal zone lymphoma include the following: lung, parotid, small bowel, large bowel, ovary, prostate, and ocular adnexa. Infectious agents have been reported to be associated with many nongastric sites but testing for these agents is not required for management.*

*Non-cutaneous, for Cutaneous Marginal Zone B-cell Lymphoma, see CUTB.*

*Typical immunphenotypotype: CD10-, CD5-, CD20+, CD23-/+, CD43-/-+ and cyclin D1-, BCL2 follicles-.*

*See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).*

*Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.*

*If treatment includes regimens containing anthracyclines or anthracenediones.*

---

*Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.*
**Practice Guidelines in Oncology – v.1.2009**

**Nongastric MALT Lymphoma**

---

### STAGE TREATMENT

#### Stage I-II
- Locoregional RT (20-30 Gy)
- Surgery may be considered for certain sites (lung, breast, thyroid, colon/small bowel)

#### Extranodal (multiple sites)
- Locoregional RT

#### Stage III, IV: extranodal disease and multiple nodal sites
- Manage per Follicular Lymphoma Guidelines for advanced stage (FOLL-2)

#### Stage I-IV, MALT lymphomas coexistent with large cell lymphoma
- Treat per NCCN Diffuse Large B-Cell Lymphoma Guidelines (BCEL-1)

---

**Local recurrence**
- Follow-up every 3 mo for 1 y, then every 3-6 mo for 3 y
- Consider locoregional RT

**Systemic recurrence**
- Manage per NCCN Follicular Lymphoma Guidelines for advanced stage (FOLL-3)

---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Nodal Marginal Zone Lymphoma

**DIAGNOSIS**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis. Histologic grading cannot be performed on an FNA.
- Adequate immunophenotyping to establish diagnosis
  - Paraffin panel: CD20, CD3, CD5, CD10, BCL2, kappa/lambda, CD21 or CD23, cyclin D1
  - or
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10
- Pediatric nodal marginal zone lymphoma should be considered with localized disease in a young patient.

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; PCR for t(11;18)
- Cyto genetics or FISH: t(11;18); t(1;14); t(14;18); del(13q); del(7q)

**WORKUP**

**ESSENTIAL:**
- Physical exam with performance status
- CBC, differential, platelets
- Comprehensive metabolic panel
- LDH
- Hepatitis B testing if rituximab contemplated
- Hepatitis C testing
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Bone marrow biopsy + aspirate to document clinical stage I-II disease
- Evaluation to rule out extranodal primary sites
  - Neck nodes: ocular, parotid, thyroid and salivary gland
  - Axillary nodes: lung, breast and skin
  - Mediastinal/hilar nodes: lung
  - Abdominal nodes: splenic and GI
  - Inguinal/iliac nodes: GI and skin
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN SELECTED CASES**
- MUGA scan/echocardiogram
- Additional imaging as appropriate
- PET-CT scan
- Discussion of fertility issues and sperm banking

---

*a Nodal MZL is rare and occurs most commonly as spread from extranodal MALT; must also be distinguished from nodal FL, MCL, lymphoplasmacytic lymphoma and CLL, all of which are more common.

*b Typical immunophenotype: CD10-, CD5-, CD20+, CD23/-, CD43/- and cyclin D1-, BCL2 folicies.-

*c See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).

*d Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.

*e Bilateral or unilateral provided core biopsy is > 2 cm. If radioimmunotherapy is considered, bilateral cores are recommended and the pathologist should provide the percent of overall cellular elements and the percent of cellular elements involved in the marrow. If observation is initial therapy, bone marrow biopsy may be deferred.

*f If treatment includes regimens containing anthracyclines or anthracenediones.
**DIAGNOSIS**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.

- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.

- Adequate immunophenotyping to establish diagnosis
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD5, CD10, BCL2, kappa/lambda, CD21 or CD23, cyclin D1, IgD, CD43, annexin-1 or
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10, CD43, CD103

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; PCR for t(11;18)
- Cytogenetics or FISH: CLL panel; t(11;18); t(11;14); t(14;18); del(7q)
- Cryoglobulins

**WORKUP**

**ESSENTIAL:**
- Physical exam with performance status
- CBC, differential, platelets
- Comprehensive metabolic panel
- LDH
- Hepatitis B testing if rituximab contemplated
- Hepatitis C testing
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Bone marrow biopsy ± aspirate
- SPEP and/or quantitative immunoglobulin levels
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)
- Additional imaging as appropriate
- PET-CT scan
- Discussion of fertility issues and sperm banking
- Immunofixation of blood (for elevated immunoglobulins or positive SPEP)

See Initial Therapy (SPLN-2)

---

*SPLN-1*  
SMZL is typically diagnosed at splenectomy, since the immunophenotype is nonspecific. However if a characteristic intrasinusoidal lymphocytic infiltrate can be demonstrated on bone marrow biopsy, and the immunophenotype is consistent, the diagnosis can strongly be suggested on bone marrow biopsy.

Typical immunophenotype: CD10-, CD5-, CD20+, CD23-/+, CD103-(distinction from hairy cell leukemia).

Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
CLINICAL PRESENTATION

Asymptomatic, no splenomegaly, no cytopenias

Splenomegaly

Hepatitis C positive
Hepatitis C negative

MANAGEMENT

Observe

Indications for treatment of hepatitis
No indications for treatment of hepatitis

Appropriate treatment

Follow-up every 3 mo for 1 y, then every 3-6 mo

If progression of disease, manage per NCCN Follicular Lymphoma Guidelines for advanced stage (FOLL-2)

• Cytopenias
• Symptoms

Splenectomy or Rituximab

Observation

No symptoms

Hepatology consult

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.


Follow-up includes repeat diagnostic tests, including imaging if clinically indicated (based on site of disease and clinical presentation).
Mantle Cell Lymphoma

**DIAGNOSIS**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis\(^a,b\)
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD5, cyclin D1, CD10, CD21, CD23, BCL2, BCL6, Ki67
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD19, CD20, CD5, CD23, CD10 and FISH for t(11;14)

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; BCL1 rearrangements
- Cytogenetics or FISH: t(11;14); t(14;18); CLL panel

\(^a\) Typical immunophenotype: CD5+, CD20+, CD43+, CD23-/+; cyclin D1+, CD10-/+; Note: Some cases of MCL may be CD5- or CD23+. If the diagnosis is suspected, cyclin D1 staining or FISH for t(11;14) should be done.

\(^b\) See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).

**WORKUP**

**ESSENTIAL:**
- Physical exam: Attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- Comprehensive metabolic panel
- LDH
- Bone marrow biopsy ± aspirate
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Hepatitis B testing if rituximab contemplated
- MUGA scan/echocardiogram
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)
- Endoscopy/colonoscopy\(^e\)
- Uric acid
- Discussion of fertility issues and sperm banking
- Lumbar puncture (for blastic variant or CNS symptoms)
- Beta-2-microglobulin
- PET-CT scan

\(^c\) If treatment includes regimens containing anthracyclines or anthracenediones.

\(^d\) Recommended for patients receiving aggressive treatment.

\(^e\) Recommended for patients receiving aggressive treatment.

**See Induction Therapy (MANT-2)**
Mantle Cell Lymphoma

**INDUCTION THERAPY**

- **Stage I, II** (localized presentation, extremely rare)
  - See Suggested Regimens (MANT-A) ± RT or RT (30-36 Gy)

- **Stage III, IV**
  - Clinical trial or See Suggested Regimens (MANT-A) ± RT or Observation only in highly selected cases

**INITIAL RESPONSE**

- Complete response → Relapse
- Partial response
- Progression

**RELAPSE**

- Clinical trial or Second-line treatment
  - RT
  - See Suggested Regimens (MANT-A)

---

**Notes:**

- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**References:**


---

**Key Points:**

- Early referral for high dose therapy with stem cell rescue is advisable for planning purposes.
- Patients who are leukemic phase without adenopathy, asymptomatic with stable adenopathy and nonbulky disease, usually have a nodular pattern.
- Option for clinical trials of adjuvant therapy or for relapsed disease involving high dose therapy with autologous or allogeneic stem cell rescue, immunotherapy with nonmyeloablative stem cell rescue, or evaluation of treatment with new agents are appropriate.

---

**Prognostic Index:**

- See MIPI: Mantle Cell Lymphoma International Prognostic Index (MANT-B).
- See Response Criteria for Lymphoma (NHODG-C).
**Mantle Cell Lymphoma**

### Suggested Treatment Regimens

#### (in alphabetical order)

<table>
<thead>
<tr>
<th>First-line Therapy&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Second-line Therapy&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab&lt;sup&gt;c&lt;/sup&gt; in selected older patients who cannot tolerate more intensive therapy</td>
<td>• Bendamustine (category 2B) ± rituximab</td>
</tr>
<tr>
<td>• R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine)</td>
<td>• Bortezomib</td>
</tr>
<tr>
<td>• Rituximab + EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)</td>
<td>• Cladribine</td>
</tr>
<tr>
<td>• Modified HyperCVAD with rituximab maintenance in patients older than 65 y</td>
<td>• FC (fludarabine, cyclophosphamide) ± rituximab</td>
</tr>
<tr>
<td>• NORDIC regimen (dose-intensified induction immunochemotherapy with rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone [maxi-CHOP]) alternating with rituximab + high-dose cytarabine)</td>
<td>• FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)</td>
</tr>
<tr>
<td>• Cladribine ± rituximab</td>
<td>• FMR (fludarabine, mitoxantrone, rituximab)</td>
</tr>
</tbody>
</table>

#### First-line Consolidation

• Clinical trial
• High dose therapy with autologous stem cell rescue<sup>d</sup>

#### Second-line Consolidation

• High dose therapy with allogeneic stem cell rescue (nonmyeloablative or myeloablative)

---

<sup>a</sup>See references for regimens MANT-A 2 of 3 and MANT-A 3 of 3.
<sup>b</sup>There are no prospective randomized comparative trials with induction therapy regimens for mantle cell lymphoma.
<sup>c</sup>There is a randomized trial that demonstrated that RCHOP was not superior to CHOP.
<sup>d</sup>Randomized data with anthracycline-containing regimens suggest an improvement in progression free survival with the addition of first-line high dose therapy with autologous stem cell consolidation. Overall survival benefit has not been demonstrated.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUGGESTED TREATMENT REGIMENS

References

First-line Therapy
Rituximab + HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with methotrexate and cytarabine

Rituximab + CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)

R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin)

Modified HyperCVAD with Rituximab Maintenance

Nordic trial regimen (Dose-intensified induction immunochemotherapy with rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone [machi-CHOP]) alternating with rituximab + high-dose cytarabine)

First-line Consolidation
High dose therapy with autologous stem sell rescue (category 2B)

Continued on next page
SUGGESTED TREATMENT REGIMENS

References

Second-line Therapy

Bendamustine

Bortezomib

Cladribine

Fludarabine and cyclophosphamide (FC) with or without rituximab

FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab) ± rituximab maintenance

FMF (fludarabine, mitoxantrone, rituximab)

Lenalidomide

PEP-C with or without rituximab

Temsirolimus

Thalidomide + rituximab

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
MIPI: Mantle Cell Lymphoma International Prognostic Index\textsuperscript{a}

- MIPI is for patients with advanced stage mantle cell lymphoma.
- The patient is assigned to one of three prognostic groups: low risk, intermediate risk and high risk group.

### MIPI- Simplified Prognostic Index

<table>
<thead>
<tr>
<th>Points</th>
<th>Age, y</th>
<th>ECOG\textsuperscript{b}</th>
<th>LDH/ULN\textsuperscript{c}</th>
<th>WBC, 10\textsuperscript{9}/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>&lt; 50</td>
<td>0-1</td>
<td>&lt; 0.67</td>
<td>&lt; 6.70</td>
</tr>
<tr>
<td>1</td>
<td>50-59</td>
<td>N/A</td>
<td>0.67-0.99</td>
<td>6.70-9.99</td>
</tr>
<tr>
<td>2</td>
<td>60-69</td>
<td>2-4</td>
<td>1.00-1.49</td>
<td>10.00-14.99</td>
</tr>
<tr>
<td>3</td>
<td>≥ 70</td>
<td>N/A</td>
<td>≥ 1.50</td>
<td>≥ 15.00</td>
</tr>
</tbody>
</table>

N/A: Not applicable

- For each prognostic factor, 0 to 3 points are given to each patient and points are summed up to a maximum of 11.

- Low risk: 0 to 3 points
- Intermediate risk: 4 to 5 points
- High risk: 6 to 11 points


\textsuperscript{b}ECOG performance status was weighted with 2 points if patients were unable to work or bedridden (ECOG 2-4).

\textsuperscript{c}LDH/ULN is the ratio of measured LDH divided by upper limit of normal (ULN) is determined in local laboratories.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Diffuse Large B-Cell Lymphoma**

**Diagnosis**

**Essential:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis.
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD5, CD10, CD45, BCL2, BCL6, Ki-67, IRF-4/MUM1
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20

**Useful Under Certain Circumstances:**
- Additional immunohistochemical studies to establish lymphoma subtype
  - Paraffin panel: cyclin D1, kappa/lambda, CD138, EBV, ALK, HTLV
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; BCL1, BCL2, MYC rearrangements
- Cytogenetics or FISH: t(14;18); t(3;14); t(8;14)

**Workup**

**Essential:**
- Physical exam: attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Comprehensive metabolic panel
- Uric acid
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Unilateral or bilateral bone marrow biopsy (1-2 cm) ± aspirate
- Calculation of International Prognostic Index (IPI)
- Hepatitis B testing
- MUGA scan/echocardiogram
- PET-CT scan
- Pregnancy testing in women of child-bearing age
- Beta-2-microglobulin (category 2B)

**Useful in Selected Cases:**
- Neck CT, Head CT or MRI
- Discussion of fertility issues and sperm banking
- HIV
- Lumbar puncture, if paranasal sinus, testicular, epidural, bone marrow with large cell lymphoma, HIV lymphoma, or ≥ 2 extranodal sites

---

*a* DLBCL coexistent with follicular lymphoma of any grade, DLBCL coexistent with gastric MALT lymphoma, DLBCL coexistent with nongastric MALT lymphoma are treated according to this guideline. This pathway is commonly used to treat Follicular Lymphoma grade 3. Germinal center (or follicular center) cell phenotype is not equivalent to follicular lymphoma and can occur in DLBCL and Burkitt’s lymphoma. Morphology is required to establish diagnosis. Primary cutaneous follicle center lymphoma (which may be misdiagnosed as diffuse large B-cell lymphoma) and cutaneous DLBCL of leg type may be treated according to this guideline. This pathway is commonly used to treat Follicular Lymphoma grade 3.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

See International Prognostic Index (BCEL-A).

---

Typical immunophenotype: CD20+, CD45+, CD3-; other markers used for subclassification.

See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).

Hepatitis B testing is indicated because of the risk of reactivation with immunotherapy + chemotherapy. Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen. If positive, check viral load and consult with gastroenterologist.

If treatment includes regimens containing anthracyclines or anthracyclinediones.
**Diffuse Large B-Cell Lymphoma**

**INDUCTION THERAPY**

<table>
<thead>
<tr>
<th>Stage I, II</th>
<th>Nonbulky (&lt; 10 cm)</th>
<th>Adverse risk factors present:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Elevated LDH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Stage II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Age &gt; 60 y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Performance status ≥ 2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage III, IV</th>
<th>Bulky (≥ 10 cm)</th>
<th>Adverse risk factors not present</th>
</tr>
</thead>
</table>

**Consider prophylaxis for tumor lysis syndrome (See NHODG-B)**

- **RCHOP x 3 cycles + locoregional RT (30-36 Gy)**
- **RCHOP 6-8 cycles ± locoregional RT (30-36 Gy to involved region)**

- **RCHOP x 3 cycles + locoregional RT (30-36 Gy)**
- **RCHOP 6-8 cycles ± RT (category 2B for RT)**

- **RCHOP 6-8 cycles ± locoregional RT (30-40 Gy to involved region) (category 1)**

- **RCHOP 6-8 cycles (category 1)**

- **Clinical trial (preferred)**

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**In testicular lymphoma**, after completion of chemotherapy, RT should be given to contralateral testis (30-36 Gy).

**In patients who are not candidates for chemotherapy** involved field radiation therapy (IFRT) is recommended.

**In selective settings** (paranasal sinus, testicular, epidural, bone marrow with large cell lymphoma, HIV lymphoma, or ≥ 2 extranodal sites), CNS prophylaxis should be given (4-8 doses of intrathecal methotrexate and/or cytarabine during the course of treatment.)

**Recommendations are for HIV-negative lymphoma only.**

**k** Based on current clinical trials, CHOP is preferable due to reduced toxicities, but other comparable anthracycline-based regimens are acceptable.

**l** For other regimens, see **BCEL-B**.

**m** In selected cases, RT to initially bulky sites of disease may be beneficial (category 2B).

**n** May include high-dose therapy.
**Diffuse Large B-Cell Lymphoma**

**Pre RT Evaluation**

- Complete response
- Partial response
- No response or progressive disease

**Follow-up Therapy**

- Complete planned course of treatment
- Complete course of therapy with higher RT dose (40-45 Gy)
- High dose therapy with autologous stem cell rescue
- Clinical trial (may include high dose therapy with allogeneic stem cell rescue)

**End of Treatment Restaging**

- At completion of treatment, repeat all positive studies.
- If PET-CT scan positive, rebiopsy before changing course of treatment.

**Initial Response**

- Complete response
- Partial response
- No response or progressive disease

**Relapse, See Relapse or Refractory Disease (BCEL-5)**

**Stage I, II:**

- Pre RT evaluation, repeat all positive studies. If PET-CT scan positive, rebiopsy before changing course of treatment.

- Follow-up every 3 mo for 24 mo, then every 6 mo for 36 mo

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**INTERIM RESTAGING**

<table>
<thead>
<tr>
<th>Stage III, IV: After 3-4 cycles, repeat all positive studies</th>
<th>FOLLOW-UP THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial response</td>
<td>Continue RCHOP (^1) to a total of 6-8 cycles</td>
</tr>
<tr>
<td>No response or progressive disease</td>
<td>Continue RCHOP (^1) to a total of 6-8 cycles or Clinical trial</td>
</tr>
</tbody>
</table>

**END OF TREATMENT RESTAGING**

<table>
<thead>
<tr>
<th>Complete response</th>
<th>At completion of treatment, repeat all positive studies. If PET-CT scan positive, rebiopsy before changing course of treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial response</td>
<td>No response or progressive disease</td>
</tr>
</tbody>
</table>

**INITIAL RESPONSE (after completion of induction chemotherapy)**

<table>
<thead>
<tr>
<th>Complete response (^0,^s)</th>
<th>Consider RT to initially bulky disease (category 2B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial response (^o)</td>
<td>Follow-up every 3 mo for 24 mo, then every 6 mo for 36 mo</td>
</tr>
</tbody>
</table>

**FOLLOW-UP THERAPY**

| No response or progressive disease \(^o\) | See Additional Therapy for Relapse (BCEL-5) or RT in select patients who are not candidates for chemotherapy |

\(^1\) For other regimens, see BCEL-B.

\(^0\) See Response Criteria for Lymphoma (NHODG-C).

\(^p\) Documented PR includes a biological measure of disease: positive PET-CT scan, or ideally positive biopsy.

\(^t\) There is evidence that the addition of maintenance rituximab does not improve survival.

\(^s\) Patients in first remission may be candidates for consolidation trials including high dose therapy with autologous stem cell rescue.

\(^r\) Patients in first remission may be candidates for consolidation trials including high dose therapy with autologous stem cell rescue.

\(^t\) PET-CT scan at interim restaging can lead to increased false positives and should be carefully considered in select cases. If PET-CT scan performed and positive, rebiopsy before changing course of treatment.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Diffuse Large B-Cell Lymphoma**

### RELAPSE/REFRACTORY DISEASE

- **Candidate for high-dose therapy**
  - Second-line therapy
    - See Suggested Regimens (BCEL-B)
  - Clinical trial or Palliative RT

- **Not candidate for high-dose therapy**
  - Clinical trial or Second-line therapy
    - See Suggested Regimens (BCEL-B) or Palliative RT

### RESPONSE #2

- **Complete response**
  - Second-line therapy
    - See Suggested Regimens (BCEL-B) or Clinical trial or Clinical trial or High dose therapy with autologous stem cell rescue (category 1 for CR, category 2A for all others) ± involved field RT or Clinical trial or High dose therapy with allogeneic stem cell rescue in selected cases

- **Partial response**
  - Second-line therapy
    - See Suggested Regimens (BCEL-B) or Clinical trial or Clinical trial or High dose therapy with autologous stem cell rescue (category 1 for CR, category 2A for all others) ± involved field RT or Clinical trial or High dose therapy with allogeneic stem cell rescue in selected cases

- **No response**
  - Clinical trial

### CONSOLIDATION/ADDITIONAL THERAPY

- **High dose therapy with autologous stem cell rescue (category 1 for CR, category 2A for all others) ± involved field RT or Clinical trial or High dose therapy with allogeneic stem cell rescue in selected cases**

### RELAPSE #2 OR GREATER

- **Clinical trial**

---

*See Response Criteria for Lymphoma (NHODG-C).*

Additional RT can be given before or after high dose therapy with stem cell rescue to sites of previous positive disease.

Selected cases include mobilization failures and persistent bone marrow involvement.

Clinical trials or individual regimens: Patients who progress after three successive regimens are unlikely to derive additional benefit from currently utilized combination chemotherapy regimens, except for patients with a long disease-free interval.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### INTERNATIONAL PROGNOSTIC INDEX

<table>
<thead>
<tr>
<th>ALL PATIENTS:</th>
<th>INTERNATIONAL INDEX, ALL PATIENTS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age &gt; 60 years</td>
<td>• Low</td>
</tr>
<tr>
<td>• Serum LDH &gt; 1 x normal</td>
<td>• Low intermediate</td>
</tr>
<tr>
<td>• Performance status 2-4</td>
<td>• High intermediate</td>
</tr>
<tr>
<td>• Stage III or IV</td>
<td>• High</td>
</tr>
<tr>
<td>• Extranodal involvement &gt; 1 site</td>
<td>0 or 1</td>
</tr>
</tbody>
</table>

### AGE-ADJUSTED INTERNATIONAL PROGNOSTIC INDEX

<table>
<thead>
<tr>
<th>PATIENTS ≤ 60 YEARS:</th>
<th>INTERNATIONAL INDEX, PATIENTS ≤ 60 YEARS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Stage III or IV</td>
<td>• Low</td>
</tr>
<tr>
<td>• Serum LDH &gt; 1 x normal</td>
<td>• Low/intermediate</td>
</tr>
<tr>
<td>• Performance status 2-4</td>
<td>• High/intermediate</td>
</tr>
<tr>
<td></td>
<td>• High</td>
</tr>
</tbody>
</table>

Notes:
- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUGGESTED TREATMENT REGIMENS
(in alphabetical order)

First-line Therapy
• Rituximab + CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) (category 1)
• Dose dense RCHOP 14 (category 2B)
• Dose adjusted R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) (category 2B)

First-line Consolidation
• High dose therapy with autologous stem cell rescue in high risk patients (category 2B)

Second-line Therapy (candidates for high dose therapy with autologous stem cell rescue)
• DHAP (dexamethasone, cisplatin, cytarabine) ± R
• ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) ± R
• GDP (gemcitabine, dexamethasone, cisplatin) ± R
• GemOx (gemcitabine, oxaliplatin) ± R
• ICE (ifosfamide, carboplatin, etoposide) ± R
• miniBEAM (carmustine, etoposide, cytarabine, melphalan) ± R
• MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± R

Second-line Therapy (not candidates for high dose therapy)
• Clinical trial
• Rituximab
• CEPP ± R (cyclophosphamide, etoposide, prednisone, procarbazine) - PO and IV
• PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) - all PO
• EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)

See Rituximab and Viral Reactivation (NHODG-D)

See references for regimens BCEL-B 2 of 3 and BCEL-B 3 of 3.
If additional anthracycline is administered after a full course of therapy, careful cardiac monitoring is essential. Dexrazoxane may be added as a cardioprotectant.
SUGGESTED TREATMENT REGIMENS

References

First-line Therapy
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with RT

RCHOP

Dose dense RCHOP 14

R-EPOCH

Continued on next page
SUGGESTED TREATMENT REGIMENS

References

**Second-line Therapy**

**DHAP with or without rituximab**

**ESHAP with or without rituximab**

**GDP (gemcitabine, dexamethasone, cisplatin) ± R**

**GemOX plus rituximab**

**ICE with or without rituximab**

**MiniBEAM with or without rituximab**

**CEPP with or without rituximab**

**PEP-C with or without rituximab**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**DIAGNOSIS**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis
  - Paraffin panel: CD45 (LCA), CD20, CD3, CD10, Ki-67, BLC2, BCL6, TdT
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD20, CD3, CD5, CD19, CD10, TdT
  - Cytogenetics or FISH: t(8;14) or variants; MYC; IgH; BCL2; BCL6 rearrangements

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Additional immunohistochemical studies to establish lymphoma subtype
  - Frozen: kappa/lambda
  - Paraffin panel: TdT; kappa/lambda; ISH for EBER
  - Molecular genetic analysis to detect: antigen receptor gene rearrangements; MYC rearrangement

---

**WORKUP**

**ESSENTIAL:**
- Physical exam: attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Comprehensive metabolic panel
- Uric acid
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Lumbar puncture
- Unilateral or bilateral bone marrow biopsy ± aspirate
- HIV (category 2B)
- Hepatitis B testing
- MUGA scan/echocardiogram
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)
- Beta-2-microglobulin

---

**See Risk Assessment and Induction Therapy (BURK-2)**

---

- WHO 2008 classification recognizes that it may not always be possible to distinguish between DLBLC and Burkitt’s lymphoma. In the setting where it is not possible to distinguish, leave as unclassified and individualize therapy.
- This disease is complex and curative; it is preferred that treatment occur at centers with expertise in the management of the disease.
- Typical immunophenotype: slg+, CD10+, CD20+, TdT-, Ki67+ (100%), BCL2-, BCL6+, MYC rearrangement only by cytogenetics or FISH.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**RISK ASSESSMENT**

- Low risk
  - Normal LDH
  - Completely resected abdominal lesion or single extra-abdominal mass < 10 cm

- High risk

**INDUCTION THERAPY**

- Low risk
  - Clinical trial or See Suggested Regimens (BURK-A)

- High risk
  - Clinical trial or See Suggested Regimens (BURK-A)

**INITIAL RESPONSE**

- Complete response
  - Follow-up after complete response: every 2-3 mo for 1 y, then every 3 mo for 1 y, then every 6 mo

- < Complete response
  - Clinical trial or Best supportive care

**RELAPSE**

- Follow-up after complete response: every 2-3 mo for 1 y, then every 3 mo for 1 y, then every 6 mo

- Observe

- Complete response
  - Clinical trial or Best supportive care

- Consolidation in clinical trial

- < Complete response
  - Clinical trial or Individual approach or Palliative RT

---

9 Clinical trials may include high dose therapy with allogeneic or autologous stem cell rescue.

h See Response Criteria for Lymphoma (NHODG-C).

i Relapse after 2 y is rare, therefore, follow-up should be individualized according to patient characteristics.
**SUGGESTED TREATMENT REGIMENS**
*(in alphabetical order)*

**Low Risk- Combination Regimens**
- CODOX-M: cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate ± rituximab
  (regimen includes intrathecal methotrexate)
- HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with methotrexate + cytarabine, + rituximab
  (regimen includes intrathecal methotrexate)
- Dose adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + R
  (regimen includes intrathecal methotrexate)

**High Risk- Combination Regimens**
- CODOX-M (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide, and high-dose cytarabine) ± rituximab
  (regimen includes intrathecal methotrexate)
- HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with methotrexate + cytarabine, + rituximab
  (regimen includes intrathecal methotrexate)
- Dose adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + R
  (For high risk patients not able to tolerate aggressive treatments)
  (regimen includes intrathecal methotrexate)

Consider SCT for patients in relapse

CHOP is not adequate therapy.

See [Rituximab and Viral Reactivation (NHODG-D)](http://www.nccn.org/professionals/physician_gls/pdf/nahodg.pdf)
SUGGESTED TREATMENT REGIMENS

Low Risk- Combination Regimens
CODOX-M: cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate ± rituximab (regimen includes intrathecal methotrexate)

HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with methotrexate + cytarabine, ± rituximab (regimen includes intrathecal methotrexate)

Dose adjusted EPOCH plus rituximab (regimen includes IT methotrexate)

High Risk- Combination Regimens
CODOX-M/IVAC: cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate + ifosfamide, etoposide, high-dose cytarabine, ± rituximab (regimen includes intrathecal methotrexate)

HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) + methotrexate + cytarabine ± rituximab (regimen includes intrathecal methotrexate)

Dose adjusted EPOCH plus rituximab (regimen includes IT methotrexate)
Lymphoblastic Lymphoma

**DIAGNOSIS**

**ESSENTIAL:**
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis
  - Paraffin panel: CD45 (LCA), CD20, CD79a, CD3, CD2, CD5, TdT, CD1a, CD10, cyclin D1
  - or
  - Cell surface marker analysis by flow cytometry:
    - kappa/lambda, CD45, CD3, CD5, CD4, CD7, CD8, CD19, CD20, CD10, TdT, CD13, CD33, CD1a, cytoplasmic CD3, CD22, myeloperoxidase

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Additional immunohistochemical studies to establish lymphoma subtype
  - Frozen: kappa/lambda
  - Paraffin panel: CD22, CD4, CD8, cyclin D1
- Molecular genetic analysis to detect: antigen receptor gene rearrangements
- Cyto genetics or FISH: MYC; t(9;22); t(8;14) and variants

---

**WORKUP**

**ESSENTIAL:**
- Physical exam: attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Comprehensive metabolic panel
- Uric acid, phosphate
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Lumbar puncture
- Bilateral or unilateral bone marrow biopsy ± aspirate with flow and cytogenetics
- Hepatitis B testing
- MUGA scan/echocardiogram
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN SELECTED CASES:**
- Head MRI
- Discussion of fertility issues and sperm banking
- Beta-2-microglobulin

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**See Clinical Assessment and Induction Therapy (BLAST-2)**

---

**BLAST-1**
CLINICAL ASSESSMENT

Stage I–IV (disease is considered to be systemic)

INDUCTION THERAPY

Clinical trialf or See Suggested Regimens (BLAST-A)

INITIAL RESPONSE

Complete responseg

Observe or Clinical trial

Partial responseg

Clinical trialf or Best supportive care

RELAPSE

Relapse

Attempt reinduction with combination chemotherapy or Allogeneic HSCT or Clinical trial

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

For poor risk patients, consideration of high dose therapy with autologous or allogeneic stem cell rescue is appropriate.

Prophylaxis for tumor lysis syndrome is mandatory (See NHODG-B)

See Response Criteria for Lymphoma (NHODG-C)
SUGGESTED TREATMENT REGIMENS
(in alphabetical order)

- BFM (Berlin–Frankfurt–Munster)
  **Standard BFM regimen:**
  - Induction phase:
    - Vincristine, daunomycin, prednisone, L-asparaginase, intrathecal cytarabine, and intrathecal methotrexate.
  - Consolidation phase (5 weeks):
    - Prednisone, cyclophosphamide, mercaptopurine, vincristine, cytarabine, intrathecal methotrexate, and RT.
  - Interim Maintenance phase (8 weeks):
    - Mercaptopurine and methotrexate (PO)
  - Delayed intensification (7 weeks):
    - *Reinduction phase (4 weeks)*:
      - Dexamethasone, vincristine, and doxorubicin.
    - *Reconsolidation phase (3 weeks)*:
      - L-asparaginase, vincristine, cyclophosphamide, thioguanine, cytarabine, and intrathecal methotrexate.
  - Long-term maintenance (12 weeks):
    - Vincristine, prednisone, mercaptopurine, methotrexate (PO and IT).

- Augmented BFM regimen:
  - Induction phase:
    - Vincristine, daunomycin, prednisone, L-asparaginase, intrathecal cytarabine
  - Consolidation phase (9 weeks):
    - Cyclophosphamide, cytarabine, mercaptopurine, vincristine, asparaginase, intrathecal methotrexate, and RT.
  - Interim Maintenance phase (8 weeks):
    - Vincristine, methotrexate (IV), and asparaginase
  - Delayed intensification phase I (8 weeks):
    - *Reinduction phase (4 weeks)*:
      - Dexamethasone, vincristine, and doxorubicin.
    - *Reconsolidation phase (4 weeks)*:
      - L-asparaginase, vincristine, cyclophosphamide, thioguanine, cytarabine, and intrathecal methotrexate.
  - Interim maintenance phase II (8 weeks):
    - Vincristine, methotrexate (IV), L-asparaginase, and intrathecal methotrexate
  - Delayed intensification phase II (8 weeks): same as delayed intensification phase I
  - Long-term maintenance (12 weeks):
    - Vincristine, prednisone, mercaptopurine, methotrexate (PO and IT).

---

\(^a\)See references for regimens [BLAST-A 3 of 3](https://www.nccn.org/professionals/physician_gls/pdf/blast.pdf).

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUGGESTED TREATMENT REGIMENS\textsuperscript{a}
(in alphabetical order)

- CALGB ALL regimen
  - Induction therapy (4 weeks):
    - Cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase.
    - For patients with 60 years and older: cyclophosphamide, daunorubicin, and prednisone
  - Early intensification (4 weeks):
    - Intrathecal methotrexate, cyclophosphamide, 6-mercaptopurine, cytarabine, vincristine, and L-asparaginase.
  - CNS prophylaxis and interim maintenance:
    - Cranial irradiation, intrathecal methotrexate, 6-mercaptopurine, and methotrexate (PO).
  - Late intensification (8 weeks):
    - Doxorubicin, vincristine, dexamethasone, cyclophosphamide, 6-thioguanine, and cytarabine.
  - Prolonged maintenance (until 24 months from diagnosis):
    - Vincristine, prednisone, methotrexate (PO), and 6-mercaptopurine.

- HyperCVAD\textsuperscript{b} (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with methotrexate + cytarabine, including intrathecal methotrexate

In the cases of CD20 positive ($\geq$ 20\%) acute lymphoblastic lymphoma (ALL), the addition of rituximab should be considered.

In cases of Philadelphia chromosome positive ALL, consider the addition of imatinib.

Maintenance chemotherapy - Up to 2 y of maintenance based on the treatment protocol is recommended.
CNS prophylaxis to 24 Gy XRT may be considered (category 2B).

See Suggested Treatment Regimens on BLAST-A 1 of 3

\( ^{a}\)See references for regimens BLAST-A 3 of 3.

\( ^{b}\)For T-cell lymphoblastic lymphomas with primary mediastinal presentation, residual masses are irradiated.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**BFM (Berlin–Frankfurt–Munster)**

**CALGB ALL regimen**

**HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate-cytarabine)**
AIDS-Related B-Cell Lymphomas

DIAGNOSIS

ESSENTIAL:
- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis
  - Recommended panel for paraffin section immunohistochemistry: CD45 (LCA), CD20, CD3, CD10, BCL2, BCL6, Ki-67, CD138, kappa/lambda, HHV8
  - Cell surface marker analysis by flow cytometry:
    - kappa/lambda, CD45, CD3, CD5, CD19, CD10, TdT, CD14, CD20
- Epstein-Barr virus (EBER-ISH)

USEFUL UNDER CERTAIN CIRCUMSTANCES:
- Additional immunohistochemical studies to establish lymphoma subtype
  - DLBCL, Burkitt’s, Plasmablastic, Primary effusion: CD10, BCL2, Ki-67, BCL6, CD138
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; BCL2, BCL6, MYC rearrangements
- Cytogenetics or FISH: BCL2, BCL6; MYC

WORKUP

ESSENTIAL
- Physical exam: attention to node-bearing areas, including Waldeyer’s ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Comprehensive metabolic panel
- Uric acid, phosphate
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- PET-CT scan
- Bone marrow biopsy ± aspirate
- CD4 count
- LP
- Viral load
- Hepatitis B testing
- Hepatitis C testing
- MUGA scan/echocardiogram
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)
- Liver ultrasound
- Brain MRI with gadolinium, or head CT

USEFUL IN SELECTED CASES
- UGI/barium enema/endoscopy
- Neck CT
- Plain bone radiographs and bone scan
- Discussion of fertility issues and sperm banking
- Stool guaiac, if anemic
- Beta-2-microglobulin
- Brain MRI with gadolinium, or head CT

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
AIDS-Related B-Cell Lymphomas

TREATMENT AND FOLLOW-UP

- Antiretrovirals
- CODOX-M/IVAC: cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate alternating with ifosfamide, etoposide, high-dose cytarabine ± rituximab
- Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) ± rituximab
- CDE (cyclophosphamide, doxorubicin, etoposide)
- Consider CHOP with high-dose methotrexate ± rituximab
- Avoid methotrexate dose > 3 g/m²
- GCSF for all patients

- Suggested regimens: Dose-adjusted EPOCH, CDE, CHOP
- Antiretrovirals
- GCSF for all patients
- Intrathecal therapy (IT)
- If CD20+, ± rituximab

- Suggested regimens: CODOX-M/IVAC, EPOCH, HyperCVAD
- Standard CHOP is not adequate therapy
- Antiretrovirals
- Consider high-dose methotrexate
- Consider RT alone
- Antiretrovirals
- Best Supportive Care (See NCCN Palliative Care Guidelines)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

- Most cases are CD20 negative and addition of rituximab is not indicated. See references for regimens AIDS-A.
- Prophylactic IT methotrexate is used at some institutions for all patients. At other NCCN institutions, patients with HIV-associated DLBCL receive IT methotrexate in selective settings (paranasal sinus, testicular, epidural, bone marrow with large cell lymphoma, HIV lymphoma, or ≥2 extranodal sites). See Rituximab and Viral Reactivation (NHODG-D)
SUGGESTED TREATMENT REGIMENS

References

**CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)**

**CHOP plus high dose methotrexate**

**CDE (Cyclophosphamide, Doxorubicin, and Etoposide)**

**EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)**

**CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate + ifosfamide, etoposide, high-dose cytarabine)**

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**DIAGNOSIS**

**ESSENTIAL:**
- Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic.
- An FNA alone is not sufficient for the initial diagnosis of peripheral T-Cell lymphoma.
- Adequate immunophenotyping to establish diagnosis
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, CD4, CD8, CD7, CD56, CD21, CD23, EBER, ALK
  - or
  - Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Molecular genetic analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants
- Additional immunohistochemical studies to establish lymphoma subtype
- Cyto genetics or FISH
- CXCL-13

**WORKUP**

**ESSENTIAL:**
- Physical exam: attention to node-bearing areas, including Waldeyer's ring, size of liver and spleen, skin rash and nasopharynx
- Performance status
- B symptoms
- CBC, differential, platelets
- Bone marrow biopsy
- LDH
- Comprehensive metabolic panel
- Uric acid
- Chest/abdominal/pelvic CT with contrast of diagnostic quality
- Calculation of International Prognostic Index (IPI)
- MUGA scan/echocardiogram
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN SELECTED CASES:**
- PET-CT scan
- Neck CT
- Head CT or MRI
- Skin biopsy
- Discussion of fertility issues and sperm banking
- HIV, HTLV-1

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

© 2009 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Peripheral T-Cell Lymphomas, Noncutaneous
PTCL NOS, AITL, ALCL (ALK positive), ALCL (ALK negative)

**Stage III, IV**

- Clinical trial (preferred) or Multiagent chemotherapy
- 6-8 cycles + locoregional RT (30-40 Gy to involved region)

**Stage I, II**

- Clinical trial (preferred) or Multiagent chemotherapy
- 6-8 cycles ± RT for localized disease

**Stage III, IV**

- Clinical trial (preferred) or Multiagent chemotherapy
- 6-8 cycles ± RT for localized disease

**Consider prophylaxis for tumor lysis syndrome** (See NHODG-B)

**Partial response or no response or progressive disease**

- At completion of treatment, repeat all positive studies. If PET-CT scan positive, rebiopsy before changing course of treatment.
  - Complete response
  - ALCL ALK-1 positive
  - Observe
- ALCL ALK-1 negative
- PTCL NOS
- AITL
- Enteropathy
- Consider high dose therapy with stem cell rescue
- Observe

**Interim restaging:** Repeat all positive studies. If PET-CT scan positive, rebiopsy before changing course of treatment.

**Relapse, See Additional Therapy (TCEL-4)**

**Note:** All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Peripheral T-Cell Lymphomas, Noncutaneous**

**STAGE I/II, LOW/LOW-INTERMEDIATE**

**INTERIM RESPONSE**

- Complete response
  - Complete planned course of treatment (RT)
  - Follow-up every 3 mo for 24 mo, then every 6 mo for 36 mo

- Partial response
  - RT (30-40 Gy) or High dose therapy with stem cell rescue or Clinical trial (may include allogeneic stem cell transplant)

- No response or progressive disease
  - RT or See Additional Therapy for Relapse (TCEL-4)

**END OF TREATMENT RESTAGING**

- Complete response
  - Follow-up every 3 mo for 24 mo, then every 6 mo for 36 mo

- Partial response
  - See Additional Therapy (TCEL-4)

- No response or progressive disease
  - See Additional Therapy (TCEL-4)

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Peripheral T-Cell Lymphomas, Noncutaneous
PTCL NOS, AITL, ALCL (ALK positive), ALCL (ALK negative)

**RELAPSE/REFRACTORY DISEASE**

**ADDITIONAL THERAPY**

**RESPONSE #2**

**CONSOLIDATION/ADDITIONAL THERAPY**

**RELAPSE #2 OR GREATER**

---

**Candidate for high-dose therapy**

Clinical trial preferred or Second-line therapy See Suggested Regimens (TCEL-B)

---

**Clinical trial or** High dose therapy with autologous stem cell rescue¹ or high dose therapy with allogeneic stem cell rescue¹ (non myeloablative or ablative)

---

**Clinical trial**

---

**Clinical trial or** Best supportive care or Palliative RT

---

**Non candidate for high-dose therapy**

Clinical trial or Second-line therapy See Suggested Regimens (TCEL-B) or Palliative RT

---

**No response**

---

**Complete response or partial response**

---

**Localized areas can be irradiated before or after high dose therapy.**

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### INTERNATIONAL PROGNOSTIC INDEX\(^a\)

<table>
<thead>
<tr>
<th>RISK FACTORS</th>
<th>PROGNOSTIC RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 60 years</td>
<td>Group 1 0</td>
</tr>
<tr>
<td>Serum LDH &gt; 1 x normal</td>
<td>Group 2 1</td>
</tr>
<tr>
<td>Performance status 2-4</td>
<td>Group 3 2</td>
</tr>
<tr>
<td>Bone marrow involvement</td>
<td>Group 4 3 or 4</td>
</tr>
</tbody>
</table>


### AGE-ADJUSTED INTERNATIONAL PROGNOSTIC INDEX\(^a\)

<table>
<thead>
<tr>
<th>RISK FACTORS</th>
<th>PROGNOSTIC RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage III or IV</td>
<td>Group 1 0</td>
</tr>
<tr>
<td>Serum LDH &gt; 1 x normal</td>
<td>Group 2 1</td>
</tr>
<tr>
<td>Performance status 2-4</td>
<td>Group 3 2</td>
</tr>
<tr>
<td>Bone marrow involvement</td>
<td>Group 4 3 or 4</td>
</tr>
</tbody>
</table>


### Prognostic Index for PTCL-U(PIT)\(^b\)

<table>
<thead>
<tr>
<th>RISK FACTORS</th>
<th>PROGNOSTIC RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 60 years</td>
<td>Group 1 0</td>
</tr>
<tr>
<td>Serum LDH &gt; 1 x normal</td>
<td>Group 2 1</td>
</tr>
<tr>
<td>Performance status 2-4</td>
<td>Group 3 2</td>
</tr>
<tr>
<td>Bone marrow involvement</td>
<td>Group 4 3 or 4</td>
</tr>
</tbody>
</table>


---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUGGESTED TREATMENT REGIMENS\(^a\)
(in alphabetical order)

**First-line therapy:**
- Clinical trial preferred
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
- EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
- HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone)
  alternating with high-dose methotrexate and cytarabine

**First-line Consolidation:**
All patients, except low risk (aaIPI), consider consolidation with high dose therapy and stem cell rescue
ALK-1\(^+\) ALC is a subtype with good prognosis and does not need consolidative transplant if in remission.

**Second-line therapy (candidate for high dose therapy):**
- Clinical trial preferred
- DHAP (dexamethasone, cisplatin, cytarabine)
- ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin)
- GDP (gemcitabine, dexamethasone, cisplatin)
- GemOx (gemcitabine, oxaliplatin)
- ICE (ifosfamide, carboplatin, etoposide)
- miniBEAM (carmustine, etoposide, cytarabine, melphalan)
- MINE (mesna, ifosfamide, mitoxantrone, etoposide)

**Second-line therapy (non-candidates for high dose therapy):**
- Clinical trial preferred
- Alemtuzumab
- Bortezomib
- Denileukin diftitox
- Gemcitabine
- Radiation therapy

\(^a\)See references for regimens [TCEL-B 2 of 2](#).
SUGGESTED TREATMENT REGIMENS

First line therapy

CHOP

HyperCVAD alternating with high-dose methotrexate and cytarabine

Second-line therapy (candidates for high dose therapy)

DHAP

ESHAP

GDP (gemcitabine, dexamethasone, cisplatin)

GemOX

Second-line therapy (not candidates for high dose therapy)

ICE

MiniBEAM

References


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**DIAGNOSIS**

**ESSENTIAL:**
- Biopsy of suspicious skin sites
- Dermatopathology review of slides

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- Immunohistochemical studies of skin biopsy\(^a\)
- Molecular study for T-cell receptor (TCR) gene rearrangements (assessment of clonality) of skin biopsy\(^b\)
- Assessment of peripheral blood for Sezary cells (in cases where skin is not diagnostic, especially T4)
- Biopsy of suspicious lymph nodes (in absence of definitive skin diagnosis)

**WORKUP\(^d\)**

**ESSENTIAL:**
- Complete physical examination
  - Examination of entire skin:
    - Assessment of %BSA (palm plus digits \(\approx 1\%\) BSA) and type of skin lesion (patch/plaque, tumor, erythroderma)
    - Palpation of peripheral lymph node regions
    - Palpation for organomegaly/masses
- Laboratory studies:
  - CBC with Sezary screen (manual slide review, "Sezary cell prep")
  - Sezary flow cytometric study (optional for T1); CD3, CD4, CD7, CD8, CD26 to assess for expanded CD4+ cells with increased CD4/CD8 ratio or with abnormal immunophenotype including loss of CD7 or CD26
  - TCR gene rearrangement of peripheral blood lymphocytes if Sezary Syndrome suspected
  - Comprehensive metabolic panel
  - LDH

**USEFUL IN SELECTED CASES:**
- Bone marrow biopsy (not required for staging but used to document visceral disease in those suspected to have marrow involvement including B2 blood involvement and in patients with unexplained hematologic abnormality)
- Imaging studies
  - Chest x-ray (in T1 or limited T2 where there is no indication of palpable adenopathy or blood involvement chest x-ray may be the only imaging study)
  - Neck/chest/abdominal/pelvic contrast-enhanced CT or integrated whole body PET-CT (\(\geq T2\), large cell transformed or folliculotropic MF, or with palpable adenopathy or abnormal laboratory studies)
  - Biopsy of suspicious lymph nodes (recommend assessment of clonality for all but particularly NCI LN 2-3) or suspected extracutaneous sites
- Pregnancy testing in women of child-bearing age\(^f\)


\(^b\)See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).

\(^c\)TCR gene rearrangement results should be interpreted with caution. TCR clonal rearrangement can be seen in non-malignant conditions or may not be demonstrated in all cases of Mycosis Fungoides/Sezary Syndrome.

\(^d\)See TNMB Classification and Staging of Mycosis Fungoides and Sezary Syndrome (MFSS-B).

\(^e\)Sezary syndrome (B2) defined by Sezary cell count \(\geq 1,000/mm^3\) (Sezary cell prep) or expanded CD4+ cells with CD4/CD8 ratio \(\geq 10\), CD4+/CD7- \(\geq 40\%\), or CD4+/CD26- \(\geq 30\%\) of lymphs in the presence of a positive clonal TCR gene rearrangement.

\(^f\)Many skin-directed and systemic therapies are contraindicated or of unknown safety in pregnancy. Refer to individual drug information.

---

**Stage IA** → See Primary Treatment (MFSS-2)

**Stage IB-IIA** → See Primary Treatment (MFSS-3)

**Stage IIB** → See Primary Treatment (MFSS-4)

**Stage III** → See Primary Treatment (MFSS-5)

**Stage IV** → See Primary Treatment (MFSS-6)

---

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**STAGE**

**PRIMARY TREATMENT**

- **Stage IA**
  - Skin-directed therapies (may be alone or in combination with other skin-directed therapies): See Suggested Treatment Regimens "Skin-directed therapies (skin-limited/local)" (MFSS-A)
  - CR/PR or inadequate response
  - Refractory disease or progression to > stage IA on skin-directed therapies

- **Stage IA with B1 blood involvement**
  - See Primary Treatment for Stage III, B1 MFSS-5

- **Histologic evidence of folliculotropic or large cell transformed MF**
  - See Primary Treatment for Stage IIB Limited disease on page MFSS-4

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### STAGE IB-IIA PRIMARY TREATMENT

**Stage IB-IIA**
- **Generalized skin treatment**
  - See Suggested Treatment Regimens "Skin-directed therapies (Skin-generalized)” (MFSS-A)
  - ± adjuvant local skin treatment
    - See stage IA on MFSS-2

**Stage IB-IIA with B1 blood involvement**
- See Primary Treatment for Stage III, B1 MFSS-5

**Histologic evidence of folliculotropic or large cell transformed MF**
- See Primary Treatment for Stage IIB Generalized disease on page MFSS-4 (except for SYST-CAT B)
- Refractory disease or progression to > stage IB-IIA

**Relapse with or persistent T1-T2 disease:**
- T1 (see stage IA on MFSS-2)
- T2 (see generalized skin treatment) (MFSS-A)
- See Suggested Treatment Regimens
  - Clinical trial
  - Systemic Therapies (SYST-CAT A) (MFSS-A)
  - Combination Therapies ± skin-directed therapy

**CR/PR or inadequate response**
- Refractory disease or progression to > stage IB-IIA
- CR/PR or inadequate response
- Refractory disease or progression to > stage IB-IIA

**Refractory disease or progression**
- Clinical trial
- TSEBT (if not previously administered)
- Systemic chemotherapy agents used in ≥ stage IIB disease
- See Suggested Treatment Regimens "Systemic Therapies (SYST-CAT B)” (MFSS-A)

---

9 Folliculotropic, large cell transformed MF, or B1 involvement has been associated with worse outcome, thus, may be managed as "tumor (IIB)" disease (MFSS-4) or stage III with B1 involvement (MFSS-5), respectively.

h It is preferred that treatment occur at centers with expertise in the management of the disease.

i Patients achieving a response should be considered for maintenance or taper regimens to optimize response duration. Patients who relapse often respond well to the same treatment. Patients with a PR should be treated with the other options in the primary treatment list to improve response before moving onto treatment for refractory disease. Patients with relapse or persistent disease after initial primary treatment may be candidates for clinical trials.

j Refractory or intolerant to multiple previous therapies.

k For patients with recalcitrant sites after generalized skin treatment, additional local treatment may be needed.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
It is preferred that treatment occur at centers with expertise in the management of the disease.

Patients achieving a response should be considered for maintenance or taper regimens to optimize response duration. Patients who relapse often respond well to the same treatment. Patients with a PR should be treated with the other options in the primary treatment list to improve response before moving onto treatment for refractory disease. Patients with relapse or persistent disease after initial primary treatment may be candidates for clinical trials.

R...
**STAGE IIIp PRIMARY TREATMENT**

1. Skin-directed therapy
   - See Suggested Treatment Regimens "Skin-directed therapies (Skin-generalized)" (MFSS-A) and/or
   - Systemic therapies
     - See Suggested Treatment Regimens "Systemic Therapies (SYST-CAT A)"

   CR/PR\textsuperscript{i} or inadequate response \rightarrow Relapse or persistent disease

   Refractory disease\textsuperscript{i} or progression

2. Systemic therapies
   - See Suggested Treatment Regimens "Systemic Therapies (SYST-CAT A)" ± skin-directed therapy

   CR/PR\textsuperscript{h} or inadequate response \rightarrow Relapse or persistent disease

   Refractory disease\textsuperscript{i} or progression

   • Combination therapies
     - See Suggested Treatment Regimens - Combination Therapies\textsuperscript{j} (MFSS-A)
     - Clinical trial
     - See Suggested Treatment Regimens "Systemic Therapies (SYST-CAT B)"
     - Alemtuzumab
     - Consider non-ablative allogeneic transplant,\textsuperscript{o} as appropriate

   CR/PR\textsuperscript{i} or inadequate response \rightarrow Relapse or persistent disease

   Refractory disease\textsuperscript{i} or progression

\textsuperscript{h}It is preferred that treatment occur at centers with expertise in the management of the disease.

\textsuperscript{i}Patients achieving a response should be considered for maintenance or taper regimens to optimize response duration. Patients who relapse often respond well to the same treatment. Patients with a PR should be treated with the other options in the primary treatment list to improve response before moving onto treatment for refractory disease. Patients with relapse or persistent disease after initial primary treatment may be candidates for clinical trials.

\textsuperscript{j}Refractory or intolerant to multiple previous therapies.

\textsuperscript{o}Data on allogeneic HSCT, particularly using non-myeloablative conditioning, suggest the existence of a graft versus T-cell lymphoma effect. Success has been reported in highly selected patients. Patients with Stage ≥ IIIB MF who have failed multiple systemic therapies + adequate trial of (or whose disease is not amenable to) skin-directed therapy, may be referred for a BMT consultation. Ideal time for allogeneic HSCT is when their disease is well controlled with induction therapy and before their disease has progressed to a state where the chance of response or survival with allogeneic HSCT is low. When appropriate, TSEBT may be considered as cytoreductive therapy before transplant.

\textsuperscript{p}Generalized skin-directed therapies (other than topical steroids) may not be well-tolerated in stage III and should be used with caution. Phototherapy (PUVA or UVB) or TSEBT can be used successfully.

\textsuperscript{q}Mid-potency topical steroids should be included (± occlusive modality) with any of the primary treatment modalities to reduce skin symptoms. Erythrodermic patients are at increased risk for secondary infection with skin pathogens and systemic antibiotic therapy should be considered.

\textsuperscript{r}Combination therapy options can be considered earlier (primary treatment) depending on treatment availability or symptom severity.

\textsuperscript{O}Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Mycosis Fungoides/Sezary Syndrome

STAGE

Sezary syndrome ± lymph node disease

Stage IV

Lymph node disease (not Sezary)

Visceral disease (solid organ)

PRIMARY TREATMENT

• See Suggested Treatment Regimens
  ▶ Systemic Therapies (SYST-CAT A) (MFSS-A)
  ▶ Combination Therapies

CR/PR or inadequate response

Relapse or persistent disease

• Consider allogeneic transplant, as appropriate

Refractory disease or progression

• See Suggested Treatment Regimens "Systemic Therapies (SYST-CAT B)" (MFSS-A)
  ▶ Alemtuzumab
  ▶ Clinical trial

CR/PR or inadequate response

Relapse or persistent disease

• Consider allogeneic transplant, as appropriate

Refractory disease or progression

Clinical trial

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Data on allogeneic HSCT, particularly using non-myeloablative conditioning, suggest the existence of a graft versus T-cell lymphoma effect. Success has been reported in highly selected patients. Patients with Stage ≥ IIIB MF who have failed multiple systemic therapies ± adequate trial of (or whose disease is not amenable to) skin-directed therapy, may be referred for a BMT consultation. Ideal time for allogeneic HSCT is when their disease is well controlled with induction therapy and before their disease has progressed to a state where the chance of response or survival with allogeneic HSCT is low. When appropriate, TSEBT may be considered as cytoductive therapy before transplant.

Systemic category B agents in general have a more rapid onset of responses and are more often used for that reason. In certain circumstances, systemic category A agents or even radiation therapy alone may be used. Consider adjuvant systemic biologic therapy (SYST-CAT A) after chemotherapy to improve response duration.

\(^h\) It is preferred that treatment occur at centers with expertise in the management of the disease.

\(^i\) Patients achieving a response should be considered for maintenance or taper regimens to optimize response duration. Patients who relapse often respond well to the same treatment. Patients with a PR should be treated with the other options in the primary treatment list to improve response before moving onto treatment for refractory disease. Patients with relapse or persistent disease after initial primary treatment may be candidates for clinical trials.

\(^j\) Refractory or intolerant to multiple previous therapies.

\(^o\) Data on allogeneic HSCT, particularly using non-myeloablative conditioning, suggest the existence of a graft versus T-cell lymphoma effect. Success has been reported in highly selected patients. Patients with Stage ≥ IIIB MF who have failed multiple systemic therapies ± adequate trial of (or whose disease is not amenable to) skin-directed therapy, may be referred for a BMT consultation. Ideal time for allogeneic HSCT is when their disease is well controlled with induction therapy and before their disease has progressed to a state where the chance of response or survival with allogeneic HSCT is low. When appropriate, TSEBT may be considered as cytoreductive therapy before transplant.

\(^s\) Systemic category B agents in general have a more rapid onset of responses and are more often used for that reason. In certain circumstances, systemic category A agents or even radiation therapy alone may be used. Consider adjuvant systemic biologic therapy (SYST-CAT A) after chemotherapy to improve response duration.
### SUGGESTED TREATMENT REGIMENS

#### SKIN-DIRECTED THERAPIES

**For limited/localized skin involvement (Skin-Limited/Local)**
- Topical corticosteroids
- Topical chemotherapy (nitrogen mustard, carmustine)
- Local radiation (particularly unilesional presentation, 24-36 Gy)
- Topical retinoids (bexarotene)
- Phototherapy (UVB for patch/thin plaques; PUVA for thicker plaques)

**For generalized skin involvement (Skin-Generalized)**
- Topical corticosteroids
- Topical chemotherapy (mechlorethamine, carmustine)
- Phototherapy (UVB, nbUVB, or PUVA for patch/thin plaques; PUVA for thicker plaques)
- Total skin electron beam therapy (30-36 Gy) (reserved for those with severe skin symptoms or generalized thick plaque or tumor disease, or poor response to other therapies)

#### SYSTEMIC THERAPIES

**Category A (SYST-CAT A)**
- Retinoids (bexarotene, all-trans retinoic acid, isotretinoin [13-cis-retinoic acid])
- Interferons (IFN-alpha, IFN-gamma)
- HDAC-inhibitors (vorinostat)
- Extracorporeal photopheresis
- Denileukin difftitox
- Methotrexate (≤ 100 mg q week)

**Category B (SYST-CAT B)**
- First-line therapies
  - Liposomal doxorubicin
  - Gemcitabine
- Second-line therapies
  - Chlorambucil
  - Pentostatin
  - Etoposide
  - Cyclophosphamide
  - Temozolomide
  - Methotrexate (>100 mg q week)
  - Bortezomib

#### COMBINATION THERAPIES

**Skin-directed + Systemic**
- Phototherapy + retinoid
- Phototherapy + IFN
- Phototherapy + photopheresis
- Total skin electron beam + photopheresis

**Systemic + Systemic**
- Retinoid + IFN
- Bexarotene + denileukin difftitox
- Photopheresis + retinoid
- Photopheresis + IFN
- Photopheresis + retinoid + IFN

---

aSee references for regimens MFSS-A 2 of 3 and MFSS-A 3 of 3.
bLong-term use of topical steroid may be associated with skin atrophy and/or striae formation. This risk worsens with increased potency of the steroid. High-potency steroid used on large skin surfaces may lead to systemic absorption.
cCumulative dose of UV is associated with increased risk of UV-associated skin neoplasms; thus, phototherapy may not be appropriate in patients with history of extensive squamoproliferative skin neoplasms or basal cell carcinomas or who have had melanoma.
dIt is common practice to follow TSEBT with systemic therapies such as interferon or bexarotene to maintain response.
eSafety of combining TSEBT with systemic retinoids or vorinostat or combining phototherapy with vorinostat is unknown.
fPhotopheresis may be more appropriate as systemic therapy in patients with some blood involvement (B1 or B2).

---

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUGGESTED TREATMENT REGIMENS

References

### Skin directed therapies

#### Topical corticosteroids


#### Carmustine


### Nitrogen mustard (Mechlorethamine hydrochloride)


#### Topical Bexarotene


#### TSEBT


#### Phototherapy (UVB and PUVA)


### Systemic therapies

#### Extracorporeal photopheresis (ECP)


#### Interferon


#### Retinoids


#### Denileukin diftitox


#### Vorinostat


#### Methotrexate


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**SUGGESTED TREATMENT REGIMENS**

**References**

**Gemcitabine**

**Pentostatin**

**Temozolomide**

**Bortezomib**

**Liposomal doxorubicin**

**Combination therapies**

*Skin-directed + Systemic*

*Systemic + Systemic*

**Note:** All recommendations are category 2A unless otherwise indicated.
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### TNMB Classification and Staging of Mycosis Fungoides and Sezary Syndrome

<table>
<thead>
<tr>
<th>TNMBa</th>
<th>TNMB Classification and Staging of Mycosis Fungoides and Sezary Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>T1 Limited patches, papules and/or plaques covering &lt; 10 % of the skin surface</td>
</tr>
<tr>
<td></td>
<td>T2 Patches, papules and/or plaques covering ≥ 10 % of the skin surface</td>
</tr>
<tr>
<td></td>
<td>T3 One or more tumors (≥ 1 cm in diameter)</td>
</tr>
<tr>
<td></td>
<td>T4 Confluence of erythema ≥ 80 % body surface area</td>
</tr>
<tr>
<td>Node</td>
<td>N0 No clinically abnormal peripheral lymph nodes; biopsy not required</td>
</tr>
<tr>
<td></td>
<td>N1 Clinically abnormal peripheral lymph nodes; histopathology Dutch Gr 1 or NCI LN 0-2</td>
</tr>
<tr>
<td></td>
<td>N2 Clinically abnormal peripheral lymph nodes; histopathology Dutch Gr 2 or NCI LN 3</td>
</tr>
<tr>
<td></td>
<td>N3 Clinically abnormal peripheral lymph nodes; histopathology Dutch Gr 3-4 or NCI LN 4</td>
</tr>
<tr>
<td></td>
<td>NX Clinically abnormal peripheral lymph nodes; no histologic confirmation</td>
</tr>
<tr>
<td>Visceral</td>
<td>M0 No visceral organ involvement</td>
</tr>
<tr>
<td></td>
<td>M1 Visceral involvement (must have pathology confirmation and organ involved should be specified)</td>
</tr>
<tr>
<td>Blood</td>
<td>B0 Absence of significant blood involvement: ≤ 5 % of peripheral blood lymphocytes are atypical (Sezary) cells</td>
</tr>
<tr>
<td></td>
<td>B1 Low blood tumor burden: &gt; 5 % of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2</td>
</tr>
<tr>
<td></td>
<td>B2 High blood tumor burden: ≥ 1000/mcL Sezary cells with positive clone</td>
</tr>
</tbody>
</table>

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Guidelines Index**

- Practice Guidelines in Oncology – v.1.2009
- NHL Table of Contents
- Staging, Discussion, References

---

**Note:** Abnormal peripheral lymph node(s) = any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or ≥ 1.5 cm in diameter. Node groups examined on physical examination = cervical, supraclavicular, epitrochlear, axillary and inguinal. Central nodes, which are not generally amenable to pathologic assessment, are not currently considered in the nodal classification unless used to establish N3 histopathologically.

**Note:** Spleen and liver may be diagnosed by imaging criteria.

**Note:** Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells are not able to be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead. (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio ≥ 10, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26.

**Note:** A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene.
Clinical Staging/Classification of MF and SS<sup>a</sup>

<table>
<thead>
<tr>
<th></th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>I A</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>I B</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>II</td>
<td>1-2</td>
<td>1,2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIB</td>
<td>3</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIIA</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>IIIB</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IVA&lt;sub&gt;1&lt;/sub&gt;</td>
<td>1-4</td>
<td>0-2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>IVA&lt;sub&gt;2&lt;/sub&gt;</td>
<td>1-4</td>
<td>3</td>
<td>0</td>
<td>0-2</td>
</tr>
<tr>
<td>IVB</td>
<td>1-4</td>
<td>0-3</td>
<td>1</td>
<td>0-2</td>
</tr>
</tbody>
</table>


Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Primary Cutaneous B-Cell Lymphoma

**DIAGNOSIS**

**ESSENTIAL:**
- Review of all slides with at least one paraffin block representative of the tumor should be done by a pathologist with expertise in the diagnosis of primary cutaneous B-cell lymphoma. Rebiopsy if consult material is nondiagnostic.
- Histopathology review of adequate biopsy (punch, incisional, excisional).
- Adequate immunophenotyping to establish diagnosis
  - Recommended panel for paraffin section immunohistochemistry: CD20, CD79a, CD3, CD5, CD10, BCL2, BCL6, Ki-67, kappa/lambda, MUM1

**USEFUL IN CERTAIN CIRCUMSTANCES:**
- Peripheral blood flow cytometry
- Additional immunohistochemical studies to establish lymphoma subtype
  - Paraffin panel: cyclin D1
  - Molecular genetic analysis to detect: antigen receptor gene rearrangements; IgH gene rearrangement by PCR
  - Cytogenetics or FISH: t(14;18)

**WORKUP**

**ESSENTIAL:**
- Complete history and physical examination-including complete skin exam
- CBC, differential, comprehensive metabolic panel
- LDH
- Hepatitis B testing if rituximab considered
- Chest/abdominal/pelvic CT
- Bone marrow biopsy, if PC-DLBCL, Leg type
- Pregnancy testing in women of child-bearing age (if chemotherapy planned)

**USEFUL IN CERTAIN CIRCUMSTANCES:**
- PET-CT scan
- Bone marrow biopsy
  - Consider if PCFCL
  - Optional if PCMZL
- SPEP/quantitative immunoglobulins for PCMZL

---

**a** For non-cutaneous, see Nongastric MALT Lymphoma, see NGMLT-1.

**b** See Use of Immunophenotyping in Differential Diagnosis of Mature B-cell and T/NK-cell Neoplasms (NHODG-A).

**c** Rule out drug-induced lymphoma.

**d** Tests include hepatitis B antibody and surface antigen for a patient with no risk factors. For patients with risk factors or previous history of hepatitis B, add core antibodies and e-antigen.

---

See Initial Therapy for Primary Cutaneous Marginal Zone Lymphoma (CUTB-2)

See Initial Therapy for Primary Cutaneous Follicle Center B-Cell Lymphoma (CUTB-2)

See Initial Therapy for Primary Cutaneous B-Cell Lymphoma, Leg Type (CUTB-4)
**PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER B-CELL LYMPHOMA**

**STAGE**

<table>
<thead>
<tr>
<th>Solitary/regional, T1-2 (Ann Arbor Stage IE)</th>
<th>INITIAL THERAPY</th>
<th>SECONDARY THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local/regional RT or Excision or Observation (selected cases) or Topicals (selected cases)</td>
<td>CR/PR</td>
<td>Persistent or progressive disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Generalized disease (extracutaneous disease)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Generalized disease (skin only)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relapsed disease, See CUTB-3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generalized disease (skin only), T3</th>
<th>Observation or Rituximab or Topicals or Locoregional RT for palliation of symptoms or Palliative chemotherapy such as chlorambucil or CVP ± rituximab</th>
<th>Persistent or progressive disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Relapsed disease, See CUTB-3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Extracutaneous disease</th>
<th>Manage as per FOLL-2</th>
</tr>
</thead>
</table>

---

*Note: All recommendations are category 2A unless otherwise indicated.*

*Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.*

*See TNM Classification of Cutaneous Lymphoma other than MF/SS (CUTB-A).*

*Selected cases such as elderly with co-morbid conditions.*

*Topicals may include steroids, imiquimod, nitrogen mustard, bexarotene.*

*When RT or surgical treatment is either not feasible or desired.*

*In rare circumstances for very extensive disease, other combination chemotherapy regimens listed in FOLL-B are used.*

*See Rituximab and Viral Reactivation (NHODG-D)*
PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER B-CELL LYMPHOMA

RELAPSED DISEASE

STAGE

ADDITIONAL THERAPY

Observation or Excision or Topicals or Injected steroids or Locoregional RT

CR/PR

Persistency or progressive disease

Regional Generalized disease (extracutaneous disease)

Extracutaneous disease

Solitary/regional, T1-2 (Ann Arbor Stage IE)

Generalized disease (skin only), T3

CR/PR

Refactory

Generalized disease (skin only)

Manage as per FOLL-2

Relapsed disease

Persistency or progressive disease

Regional

CR/PR

Refactory

Manage as per FOLL-2

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See TNM Classification of Cutaneous Lymphoma other than MF/SS (CUTB-A).

Topicals may include steroids, imiquimod, nitrogen mustard, bexarotene.

In rare circumstances for very extensive disease, other combination chemotherapy regimens listed in FOLL-B are used.

Refractory to all previous treatments.

See Rituximab and Viral Reactivation (NHODG-D)
### PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE

<table>
<thead>
<tr>
<th>STAGE&lt;sup&gt;e&lt;/sup&gt;</th>
<th>INITIAL THERAPY</th>
<th>SECONDARY THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary regional, T1-2 (Ann Arbor Stage IE)</td>
<td>R-CHOP&lt;sup&gt;k&lt;/sup&gt; + locoregional RT or Locoregional RT&lt;sup&gt;l&lt;/sup&gt;</td>
<td>CR/PR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generalized disease (skin only), T3</td>
<td>R-CHOP ± locoregional RT</td>
<td>CR/PR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extracutaneous disease</td>
<td>Manage as per BCEL-2</td>
<td></td>
</tr>
</tbody>
</table>

<sup>e</sup>See TNM Classification of Cutaneous Lymphoma other than MF/SS (CUTB-A).

<sup>k</sup>For alternate regimens, see BCEL-B.

<sup>l</sup>For patients not able to tolerate chemotherapy.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### TNM CLASSIFICATION OF CUTANEOUS LYMPHOMA OTHER THAN MF/SS\(^{a,b}\)

<table>
<thead>
<tr>
<th>T</th>
<th>Solitary skin involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>T1a: a solitary lesion &lt; 5 cm diameter</td>
</tr>
<tr>
<td>T1</td>
<td>T1b: a solitary &gt; 5 cm diameter</td>
</tr>
<tr>
<td>T2</td>
<td>Regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous body regions(^{b})</td>
</tr>
<tr>
<td>T2</td>
<td>T2a: all-disease-encompassing in a &lt; 15-cm-diameter circular area</td>
</tr>
<tr>
<td>T2</td>
<td>T2b: all-disease-encompassing in a &gt; 15- and &lt; 30-cm-diameter circular area</td>
</tr>
<tr>
<td>T2</td>
<td>T2c: all-disease-encompassing in a &gt; 30-cm-diameter circular area</td>
</tr>
<tr>
<td>T3</td>
<td>Generalized skin involvement</td>
</tr>
<tr>
<td>T3</td>
<td>T3a: multiple lesions involving 2 noncontiguous body regions(^{b})</td>
</tr>
<tr>
<td>T3</td>
<td>T3b: multiple lesions involving (\geq 3) body regions(^{b})</td>
</tr>
</tbody>
</table>

| N   | No clinical or pathologic lymph node involvement                                            |
| N0  | Involvement of 1 peripheral lymph node region\(^{c}\) that drains an area of current or prior skin involvement |
| N1  | Involvement of 2 or more peripheral lymph node regions\(^{c}\) or involvement of any lymph node region that does not drain an area of current or prior skin involvement |
| N2  | Involvement of central lymph nodes                                                         |

| M   | No evidence of extracutaneous non–lymph node disease                                       |
| M0  |                                                                                           |
| M1  | Extracutaneous non-lymph node disease present                                               |

\(^{a}\)This work was originally published in Blood. Kim YH, Willemze R, Pimpinell Ni, et al, for the ISCL and the EORTC. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 2007; 110:479-484. © the American Society of Hematology.

\(^{b}\)For definition of body regions, See Body Regions for the Designation of T (skin Involvement) Category (CUTB-A 2 of 2).

\(^{c}\)Definition of lymph node regions is consistent with the Ann Arbor system: Peripheral sites: antecubital, cervical, supraclavicular, axillary, inguinal-femoral, and popliteal. Central sites: mediastinal, pulmonary hilar, paraaortic, iliac.
**BODY REGIONS FOR THE DESIGNATION OF T (SKIN INVOLVEMENT) CATEGORY**

<table>
<thead>
<tr>
<th>Body Region</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>HN</td>
<td>Head &amp; Neck</td>
</tr>
<tr>
<td>C</td>
<td>Chest</td>
</tr>
<tr>
<td>LUA</td>
<td>Left Upper Arm</td>
</tr>
<tr>
<td>LLAH</td>
<td>Left Lower Arm &amp; Hand</td>
</tr>
<tr>
<td>AG</td>
<td>Abdominal &amp; Genital</td>
</tr>
<tr>
<td>LUL</td>
<td>Left Upper Leg</td>
</tr>
<tr>
<td>LLLF</td>
<td>Left Lower Leg &amp; Feet</td>
</tr>
<tr>
<td>RUA</td>
<td>Right Upper Arm</td>
</tr>
<tr>
<td>RLAH</td>
<td>Right Lower Arm &amp; Hand</td>
</tr>
<tr>
<td>RUL</td>
<td>Right Upper Leg</td>
</tr>
<tr>
<td>RLLF</td>
<td>Right Lower Leg &amp; Feet</td>
</tr>
<tr>
<td>UB</td>
<td>Upper Back</td>
</tr>
<tr>
<td>LBB</td>
<td>Lower Back &amp; Buttock</td>
</tr>
</tbody>
</table>

- **Left and right extremities are assessed as separate body regions.** The designation of these body regions are based on regional lymph node drainage patterns.

**Note:** All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

© 2009 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
**USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND T/NK-CELL NEOPLASMS**

**B-CELL ANTIGENS POSITIVE (CD19, CD20, CD79a, PAX5)**

- **Small cells:** Panel: CD5, CD10, CD23, CD25, CD103

  - **CD23 +** → CLL → cyclin D1 - t(11;14) -
  - **CD5 +**
    - **CD23 -** → MCL → cyclin D1 + t(11;14) +
  - **CD10 +** → FL → BCL6 + BCL2 +
    - **t(14;18) +**
  - **CD5 -** → CD103 + CD25 + → HCL → annexin 1 +
    - **Cytoplasmic IG -** → MZL
    - **Psuedofollicular pattern, clinical features (BM)** → CD5 - CLL
      - **Cytoplasmic IG +** → LPL vs MZL

**Small cells:**
- Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
- Mantle cell lymphoma (MCL)
- Splenic marginal zone lymphoma
- Hairy cell leukaemia (HCL)
- Lymphoplasmacytic lymphoma (LPL)
- Extranodal marginal zone lymphoma (MALT lymphoma)
- Nodal marginal zone lymphoma
- Follicular lymphoma (FL)

\[a\] These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.

\[b\] 85% of Follicular Lymphoma will be BCL2 + or t(14;18) +.
USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS
OF MATURE B-CELL AND T/NK-CELL NEOPLASMS

B-CELL ANTIGENS POSITIVE (CD19, CD20, CD79a, PAX5)

Medium cells
- Burkitt’s lymphoma (BL)
- Diffuse large B-cell lymphoma (DLBCL)
- Mantle cell lymphoma (MCL), blastoid variant
- B-cell lymphoma (BCL), unclassifiable, intermediate between DLBCL and BL (U-DLBCL/BL)

Panel: CD5, CD10, BCL2, BCL6, IRF4/MUM1, Ki67

CD5 +
- cyclin D1 +
  - blastoid MCL
- cyclin D1 -
  - BCL6 +/-
  - IRF4/MUM1 +/-
  - CD5 + DLBCL

CD5 -
- BCL6 +
  - BCL2 -
  - Ki67 95%
  - Fish for MYC, BCL2, BCL6
- BCL6 -
  - U-DLBCL/BL

CD10 +
- BCL6 +
  - BCL2 +
  - BCL unclassifiable, DLBCL/BL
  - Fish for MYC, BCL2, BCL6 to check for “double hit”
- BCL6 +
  - BCL2 -
  - IRF4/MUM1 -
  - Ki67 > 90%
  - Fish for MYC, BCL2, BCL6

CD10 -
- BCL6 +
  - BCL2 -
  - IRF4/MUM1 -
  - Ki67 60-90%
  - U-DLBCL/BL
  - Fish for MYC, BCL2, BCL6 to check for “double hit”
- BCL6 +
  - BCL2 +
  - IRF4/MUM1 +/-
  - U-DLBCL/BL

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.
USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS
OF MATURE B-CELL AND T/NK-CELL NEOPLASMS

B-CELL ANTIGENS POSITIVE (CD19, CD20, CD79a, PAX5)

Large cells: CD5 +, CD10, BCL6, IRF4/MUM1

- Large cells:
  - Diffuse large B-cell lymphoma (DLBCL), NOS
    - T-cell/histiocyte rich large B-cell lymphoma (THRLBCL)
    - Primary DLBCL of the CNS
    - Primary cutaneous DLBCL, leg type
    - EBV positive DLBCL of the elderly (EBV + DLBCL)
  - DLBCL associated with chronic inflammation
  - Lymphomatoid granulomatosis
  - Primary mediastinal (thymic) large B-cell lymphoma (PMBL)
  - Intravascular large B-cell lymphoma
  - ALK positive large B-cell lymphoma
  - Plasmablastic lymphoma
  - Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease
  - Primary effusion lymphoma
  - B-cell lymphoma, unclassifiable, intermediate between DLBCL (U-DLBCL) and classical Hodgkin lymphoma (CHL)
  - Mantle cell lymphoma (MCL), pleomorphic variant

- Panel: CD5, CD10, BCL6, IRF4/MUM1

- cyclin D1 + → blastoid MCL
- CD5 + → CD5 + DLBCL-NOS
- cyclin D1 - → BCL6 +/- IRF4 +/-
- Panel: CD138, ALK1, CD30, CD15, EBV-EBER, HHV8, Ig light and heavy chains

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

a These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.
Large cells (continued)

CD30 -
- EBER - HHV8 -
  - CD30 +
  - Elderly or immunosuppressed
  - Morphologically borderline with CHL
    - CD15 - PMBL
    - CD15 + U-DLBCL/CHL
- EBV + DLBCL
- Extramedulmonary, T-cell rich, angiocentric
- Chronic inflammation
- DLBCL associated with chronic inflammation

CD30 -
- EBER - HHV8 -
  - CD30 +
    - THRLBCL (May be BCL6 +, IRF4 -)
    - DLBCL, non-GCB

CD30 +
- EBER + HHV8 -
  - CD30 +
    - Mediastinal PMBL
    - MAL + TRAF + REL + (nuc)
      (May be BCL6 +, IRF4 -)

CD20 + (PAX5 +)
- EBER + HHV8 -
  - EBV + HHV8 -
  - EBV +/- HHV8 +
    - PEL (CD30+)

CD20 - (PAX5 -)
- CD138 +/-
  - EBV + HHV8 -
  - EBV +/- HHV8 +
    - ALK + DLBCL
    - IgA lambda + EMA +
  - EBV - ALK - HHV8 -
    - Anaplastic/Plasmablastic myeloma/plasmacytoma
      - IgG, A, kappa or lambda

Note: All recommendations are category 2A unless otherwise indicated. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.

These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.
USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND T/NK-CELL NEOPLASMS

B-CELL ANTIGENS POSITIVE (CD19, CD20, CD79a, PAX5)

Cutaneous localization

Panel: CD10, BCL2, BCL6, IRF4/MUM1, CD21/23 (FDC markers)

- **Cutaneous marginal zone lymphoma (CMZL)**
- **Primary cutaneous follicle center lymphoma (PCFCL)**
- **Primary cutaneous DLBCL, leg type (PC-DLBCL, leg type)**

**CD10 +**

- **BCL2 -**
  - **BCL6 -**
    - IRF4 +/-(FDC -)
      - Large round cells
    - IRF4 +/- (FDC +)
      - Small/medium cells
  - **BCL6 +**
    - IRF4 -(FDC +/-)
      - Small/medium/large cells

**CD10 -**

- **BCL2 -**
  - **BCL6 +/-**
    - IRF4 + (FDC -)
      - PC-DLBCL, leg type
    - IRF4 +/- (FDC +)
      - CMZL
  - **BCL6 +**
    - IRF4 -(FDC +, follicular)
      - Small/medium/large cells

**FDC = Follicular dendritic cells**

Notes:
- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.
Non-Hodgkin’s Lymphomas

USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND T/NK-CELL NEOPLASMS

T-CELL ANTIGENS POSITIVE (CD2, CD3, CD5, CD7) [and B-cell antigens negative]

- Anaplastic morphology
- Panel: CD30, CD15, Pax5, ALK, EBV-EBER

- ALK + → ALCL, ALK +
- CD30 +
- Pax5 +
- CD15 + EBER +/- Classical Hodgkin lymphoma
- PTCL- NOS
- DLBCL (T-cell antigen expression artifactual)
- ALK -
- Pax5 -

Anaplastic morphology
- Anaplastic large cell lymphoma (ALCL), ALK positive
- Anaplastic large cell lymphoma (ALCL), ALK negative
- Adult T-cell leukemia/lymphoma (ATLL), anaplastic large cell type
- Enteropathy associated T-cell lymphoma (EATL)
- Primary cutaneous CD30 positive T-cell lymphoproliferative disorders
  - Lymphomatoid papulosis (LyP)
  - Primary cutaneous anaplastic large cell lymphoma (PC-ALCL)

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS OF MATURE B-CELL AND T/NK-CELL NEOPLASMS

T-CELL ANTIGENS POSITIVE (CD2, CD3, CD5, CD7) [and B-cell antigens negative (Pax5)]

- **CD30 +**
  - **CD30+ Cutaneous LPD**
  - **CD4 +**
    - **MFb (CD2+ CD5+ CD7- CD8- βF1+ CGP-)**
    - **HTLV1 + = ATLL**
  - **CD8 +**
    - **CD8 + AECTCLc (CD2- CD5- CD7+/ CD56- βF1+ CGP+)**
    - cutaneous γδTCL (CD2+ CD5- CD7+/ CD56+ βF1- CGP+) (dermis and subcutis often involved)
  - **CD4 -**
    - **CD8 -**
      - **CD8 -**
        - **Cutaneous γδTCL (CD2+ CD5- CD7+/ CD56+ CGP+)**
  - **CD4 -**
    - **CD8 -**
      - **CD4 -**
        - **CD8 -**
          - **Cutaneous γδTCL (CD2+ CD5- CD7+/ CD56+ CGP+)**

**CD30 -**

- **CD30 -**
  - **Panel: CD2, CD5, CD7, CD4, CD8, CD30, C56, βF1, cytotoxic granule proteins (CGP = perforin, granzyme B, TIA1), EBV-EBER; Optional: CD25**
  - **Epidermotropic**
    - **CD4 +**
      - **Dermis and subcutis**
        - **CD4 -**
          - **CD8 -**
            - **CD8 -**
              - **Primary cutaneous γδTCL (CD2+ CD5- CD7+/ CD56+ CGP+)**
    - **CD8 -**
      - **βF1 +**
        - **PTCL-NOS**
      - **βF1 -**
        - **NK/T nasal type CD2+ CD7- CD56+ CGP+**

**Cutaneous localization (non-anaplastic morphology)**
- **Primary cutaneous CD30 positive T-cell lymphoproliferative disorders (LPD)**
- **Mycosis fungoides, Sézary syndrome (MF, SS)**
- **Subcutaneous panniculitis-like T-cell lymphoma**
- **Primary cutaneous gamma-delta T-cell lymphoma (γδTCL)**
- **Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma (AECTCL)**
- **Primary cutaneous CD4 positive small/medium T-cell lymphoma**
- **Extranodal NK/T cell lymphoma, nasal type**
- **Peripheral T-cell lymphoma, NOS**
- **Blastic plasmacytoid dendritic cell neoplasm (BPDC)**

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.

A minority of MF cases can be CD4 - and either CD8 +/-, TIA1 +.

AECTCL has distinctive morphology and clinical presentation.
Non-Hodgkin’s Lymphomas

USE OF IMMUNOPHENOTYPING IN DIFFERENTIAL DIAGNOSIS
OF MATURE B-CELL AND T/NK-CELL NEOPLASMS

Extranodal, noncutaneous localization

Panel: CD5, CD7, CD4, CD8, CD30, C56, βF1, cytotoxic granule proteins (CGP = perforin, granzyme B, TIA1), EBV-EBER

EBER +
- ENK/TCL (CD5- CD4- CD8- CD30- CD56+ CGP+, midline face, upper aerodigestive tract, testis, GI tract)
  - Intestinal, other abdominal/visceral sites, celiac disease or markers positive = EATL (CD 5- CD7- CD4- CD8-/+ CD56-/+ TIA1+ GRB+ Perf+)
  - Other sites, celiac disease markers negative = PTCL-NOS

EBER -
- CD30 +
  - EATL (CD 5- CD7- CD4- CD8-/+ CD56-/+ TIA1+ GRB+ Perf+)
- CD30 -
  - Other sites, celiac disease markers negative = PTCL-NOS

Extranodal, noncutaneous localization

- Extranodal NK/T cell lymphoma, nasal type (ENKTCL)
- Enteropathy-associated T-cell lymphoma (EATL)
- Hepatosplenic T-cell lymphoma (HSTCL)
- Peripheral T-cell lymphoma, NOS (PTCL-NOS)

Nodal localization

CD10 + BCL6 + PD1 + CD4 +/-
- Vascular proliferation, expanded CD23+ FDC = AITL
- Nodular 23+ FDC = Nodular PTCL

CD10 - BCL6 -
- HTLV1 + = ATLL (CD2+ CD5+ CD7- CD56-)
- HTLV1 - = PTCL-NOS

HTLV1 + = ATLL (CD2+ CD5+ CD7- CD56-)

HTLV1 - = PTCL-NOS

a These are meant to be general guidelines. Interpretation of results should be based on individual circumstances and may vary. Not all tests will be required in every case.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
TUMOR LYSIS SYNDROME

The most likely histologies are Lymphoblastic Lymphoma and Burkitt’s Lymphoma; however, bulky presentation of Diffuse Large B-cell Lymphoma and patients with CLL and high white blood cell count may experience Tumor Lysis Syndrome (TLS) at a moderately high frequency.

Laboratory hallmarks of TLS:
- High potassium
- High uric acid
- High phosphorous
- Low calcium

Symptoms of TLS:
- Nausea and vomiting, shortness of breath, irregular heartbeat, clouding of urine, lethargy, and/or joint discomfort.

Treatment of TLS:
- TLS is best managed if anticipated and treatment started prior to chemotherapy.
- Centerpiece of treatment includes
  - Rigorous hydration
  - Management of hyperuricemia
  - Frequent monitoring of electrolytes and aggressive correction is essential
- First line and at retreatment
  - Allopurinol beginning 2-3 days prior to chemotherapy and continued for 10-14 days or
  - Rasburicase as indicated (rising uric acid despite allopurinol, high creatinine)

- If TLS is untreated, its progression may cause acute kidney failure, cardiac arrhythmias, seizures, loss of muscle control, and death.
# RESPONSE CRITERIA FOR LYMPHOMA

(Not including PET)

## Physical Examination
- **CR**: Normal
- **CRu (unconfirmed)**: Normal
- **PR**: Normal
- **Relapse/Progression**: Enlarging liver/spleen

## Lymph Nodes
- **CR**: Normal
- **CRu (unconfirmed)**: Normal
- **PR**: Normal
- **Relapse/Progression**: New or increased

## Lymph Node Masses
- **CR**: Normal
- **CRu (unconfirmed)**: >75% decrease
- **PR**: 50% decrease
- **Relapse/Progression**: New or increased

## Bone Marrow
- **CR**: Normal
- **CRu (unconfirmed)**: Indeterminate
- **PR**: Positive
- **Relapse/Progression**: Reappearance

---


![See Response Designations and PET findings NHODG-C 2 of 2](https://example.com)
<table>
<thead>
<tr>
<th>Response</th>
<th>Definition</th>
<th>Nodal Masses</th>
<th>Spleen, Liver</th>
<th>Bone Marrow</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CR</strong></td>
<td>Disappearance of all evidence of disease</td>
<td>(a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT</td>
<td>Not palpable, nodules disappeared</td>
<td>Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative</td>
</tr>
<tr>
<td><strong>PR</strong></td>
<td>Regression of measurable disease and no new sites</td>
<td>≥ 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT</td>
<td>≥ 50% decrease in SPD of nodules(for single nodule in greatest transverse diameter); no increase in size of liver or spleen</td>
<td>Irrelevant if positive prior to therapy; cell type should be specified</td>
</tr>
<tr>
<td><strong>SD</strong></td>
<td>Failure to attain CR/PR or PD</td>
<td>(a) FDG-avid or PET positive prior to therapy; PET positive at prior sites of disease and no new sites on CT or PET (b) Variably FDG-avid or PET negative; no change in size of previous lesions on CT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed disease or PD</td>
<td>Any new lesion or increase by ≥ 50% of previously involved sites from nadir</td>
<td>Appearance of a new lesion(s) &gt; 1.5 cm in any axis, ≥ 50% increase in SPD of more than one node, or ≥ 50% increase in longest diameter of a previously identified node &gt; 1 cm in short axis Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy</td>
<td>&gt; 50% increase from nadir in the SPD of any previous lesions</td>
<td>New or recurrent involvement</td>
</tr>
</tbody>
</table>


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Recommended for use with Diffuse Large B-Cell Lymphoma and Hodgkin Disease/Lymphoma.
RITUXIMAB AND VIRAL REACTIVATION

Consult hepatologist in hepatitis positive patients (positive by hepatitis B surface antigen, core antibody, e-antigen, viral load)

**Hepatitis B**
- Options when giving chemotherapy and rituximab to a hepatitis B positive patient:
  - Prophylaxis with lamivudine
  - During treatment with chemotherapy and rituximab, monitor for rising viral load (not antigen) and treat with lamivudine, if increasing

**Hepatitis C**
- Consequences of increased viral load do not appear to be clinically significant
- Options when giving chemotherapy and rituximab to a hepatitis C positive patient:
  - During treatment with chemotherapy and rituximab, monitor for rising viral load (not antigen)

**Progressive multifocal leukoencephalopathy (PML)**
- Caused by the JC virus and is usually fatal
- No known effective treatments
- Check for changes in behavior such as confusion, dizziness or loss of balance, difficulty talking or walking, and vision problems
## Staging

**Table 1**

**WHO Classification of the mature B-cell, T-cell, and NK-cell neoplasms (2008)**

**Mature B-Cell Neoplasms**

- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- B-cell prolymphocytic leukemia
- Splenic marginal zone lymphoma
- Hairy cell leukemia
- Splenic lymphoma/leukemia, unclassifiable*
  - *Splenic diffuse red pulp small B-cell lymphoma*
  - *Hairy cell leukemia-variant*
- Lymphoplasmacytic lymphoma
  - Waldenström’s macroglobulinemia
- Heavy chain diseases
  - Alpha heavy chain disease
  - Gamma heavy chain disease
  - Mu heavy chain disease
- Plasma cell myeloma
- Solitary plasmacytoma of bone
- Extraosseous plasmacytoma
- Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT type)
- Nodal marginal zone lymphoma
  - *Pediatric nodal marginal zone lymphoma*
- Follicular lymphoma
  - *Pediatric follicular lymphoma*
- Primary cutaneous follicle center lymphoma
- Mantle cell lymphoma
- Diffuse large B-cell lymphoma (DLBCL), NOS
  - T-cell/histiocyte rich large B-cell lymphoma
  - Primary DLBCL of the CNS
  - Primary cutaneous DLBCL, leg type
  - *EBV positive DLBCL of the elderly*
  - DLBCL associated with chronic inflammation
  - Lymphomatoid granulomatosis
  - Primary mediastinal (thymic) large B-cell lymphoma
  - Intravascular large B-cell lymphoma
  - ALK positive large B-cell lymphoma
  - Plasmablastic lymphoma
  - Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease
  - Primary effusion lymphoma
  - Burkitt lymphoma
  - B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
  - B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma

*The italicized histologic types are provisional entities, for which the WHO Working Group felt there was insufficient evidence to recognize as distinct diseases at this time.*
Staging

**Mature T-Cell and NK-Cell Neoplasms**
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
  - *Chronic lymphoproliferative disorder of NK-cells*
- Aggressive NK cell leukemia
- Systemic EBV positive T-cell lymphoproliferative disorder of childhood
- Hydroa vacciniforme-like lymphoma
- Adult T-cell leukemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides
- Sézary syndrome
- Primary cutaneous CD30 positive T-cell lymphoproliferative disorders
  - Lymphomatoid papulosis
  - Primary cutaneous anaplastic large cell lymphoma
- Primary cutaneous gamma-delta T-cell lymphoma
- Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma
- Primary cutaneous CD4 positive small/medium T-cell lymphoma
- Peripheral T-cell lymphoma, NOS
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large-cell lymphoma, ALK positive
- Anaplastic large-cell lymphoma, ALK negative

**Hodgkin Lymphoma**
- Nodular lymphocyte predominant Hodgkin lymphoma
- Classical Hodgkin lymphoma
  - Nodular sclerosis classical Hodgkin lymphoma
  - Lymphocyte-rich classical Hodgkin lymphoma
  - Mixed cellularity classical Hodgkin lymphoma
  - Lymphocyte-depleted classical Hodgkin lymphoma

**Post-Transplant Lymphoproliferative Disorders (PTLD)**
- Early lesions
  - Plasmacytic hyperplasia
  - Infectious mononucleosis-like PTLD
  - Polymorphic PTLD
- Monomorphic PTLD (B- and T/NK-cell types)
- Classical Hodgkin lymphoma type PTLD


*The italicized histologic types are provisional entities, for which the WHO Working Group felt there was insufficient evidence to recognize as distinct diseases at this time.

#These lesions are classified according to the leukemic or lymphoma to which they correspond.
### Table 2

**Cotswolds Modification of Ann Arbor Staging System**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Area of Involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Single lymph node group</td>
</tr>
<tr>
<td>II</td>
<td>Multiple lymph node groups on same side of diaphragm</td>
</tr>
<tr>
<td>III</td>
<td>Multiple lymph node groups on both sides of diaphragm</td>
</tr>
<tr>
<td>IV</td>
<td>Multiple extranodal sites or lymph nodes and extranodal disease</td>
</tr>
<tr>
<td>X</td>
<td>Bulk &gt; 10 cm</td>
</tr>
<tr>
<td>E</td>
<td>Extranodal extension or single isolated site of extranodal disease</td>
</tr>
<tr>
<td>A/B</td>
<td>B symptoms: weight loss &gt; 10%, fever, drenching night sweats</td>
</tr>
</tbody>
</table>

NCCN Categories of Evidence and Consensus

**Category 1:** The recommendation is based on high-level evidence, and there is uniform NCCN consensus.

**Category 2A:** The recommendation is based on lower-level evidence including clinical experience, and there is uniform NCCN consensus.

**Category 2B:** The recommendation is based on lower-level evidence including clinical experience, and there is nonuniform NCCN consensus (but no major disagreement).

**Category 3:** Based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80-85% of the cases with 15-20% being T-cell lymphomas. NK lymphomas are very rare. An estimated 66,120 new cases of NHL will be diagnosed in 2008 and 19,160 deaths will occur. NHL is the fifth leading site of new cancer cases among men and women, accounting for 4-5% of new cancer cases and 3% of cancer-related deaths. NHL is also the ninth leading cause of cancer deaths among men and the sixth among women.

The incidence of NHL has increased dramatically between 1970 and 1995; the increase has moderated since the mid-90s. This increase has been attributed partly to the human immunodeficiency virus (HIV) epidemic and the development of AIDS-related NHL. However, much of the increase in incidence has been observed in patients in their sixth and seventh decades; a large part of this increase incidence has paralleled a major decrease in mortality from other causes. The median age of individuals with NHL has risen in the last two decades. As a result, patients with NHL may also have significant comorbid conditions, which complicate treatment options.

Classification

The International Working Formulation (IWF) classified NHL into three major categories as low, intermediate and high grade, based on the morphology and natural history. The Revised European-American Classification of Lymphoid neoplasms (REAL) was developed in 1994, which classified based the classification on cell of origin (B, T, or NK) and included morphology, immunophenotype, genetic and clinical features. The currently internationally accepted World Health Organization (WHO) classification is a refinement of the REAL classification (ST-1).

The REAL/WHO classification of NHL includes several additional, newly identified entities not recognized by the IWF. After consideration of cell of origin (B, T, or NK) the classification subdivides lymphomas into those derived from precursor lymphocytes versus those derived from mature lymphocytes. The classification is further refined based on immunophenotype and genetic features. These considerations have aided in defining active treatment for specific subtypes of lymphoma.

Currently, a comprehensive description of the natural history and clinical features of all NHL diagnoses recognized by the WHO classification does not exist. However, the International Lymphoma Classification Project evaluated 1,403 lymphoma cases and identified the thirteen most common histologic types, comprising about 90% of the cases of NHL in the United States. The findings were as follows: diffuse large B-cell (DLBCL), 31%; follicular lymphoma (FL), 22%; small...
lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), 6%; mantle cell lymphoma (MCL), 6%; peripheral T-cell lymphoma (PTCL), 6%; and marginal zone B-cell lymphoma (MZL), mucosa-associated lymphoid tissue (MALT) lymphoma, 5%. The remaining subtypes each occurred in less than 2% of cases. Composite lymphomas were not included in these distribution figures. Importantly, in the United States more than 50% of cases of lymphoma are either DLBCL or FL. In a study performed by the International T-cell Lymphoma Project, PTCL-not otherwise specified (PTCL-NOS) was the most common subtype of PTCL (29.3%).

Response Criteria
The International Working Group (IWG) published the guidelines for response criteria for lymphoma in 1999. These response criteria are based on the reduction in the size of the enlarged lymph node as measured by CT scan and the extent of bone marrow involvement that is determined by bone marrow aspirate and biopsy. These guidelines were revised in 2007 by the International Harmonization Project to incorporate immunohistochemistry (IHC) flow cytometry and 18-flouro-deoxyglucose (FDG)-positron emission tomography (PET) scans in the definition of response for lymphoma. In the revised guidelines, the response category of complete response uncertain (CRu) was essentially eliminated because residual masses were defined as a partial response (PR) or a complete response (CR) based on the result of a PET scan. Using the revised system, response is categorized as CR, PR, stable disease (SD) and relapsed disease or progressive disease (PD). However, the application of PET to responses is limited to histologies where there is reliable FDG-uptake in active tumor. Response criteria for lymphoma are summarized in NHODG-C.

NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) guidelines were developed for the most common subtypes of NHL:

B-cell lymphomas:

**Indolent lymphomas**
- Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- Marginal Zone Lymphoma
  - MALT Lymphoma
  - Splenic MZL
  - Nodal MZL

**Aggressive lymphomas**
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma

**Highly aggressive lymphomas**
- Burkitt lymphoma
- Lymphoblastic lymphoma
- AIDS-related B-cell lymphoma

T-cell lymphomas:
- Peripheral T-cell lymphoma
- Mycosis fungoides/Sezary syndrome

B-cell Lymphomas

Diagnosis
In all cases, the most important first step is to make an accurate pathologic diagnosis. The basic pathological evaluation is the same in...
each guideline though some further evaluation may be useful in certain circumstances to clarify a particular diagnosis; these are outlined in the pathological evaluation of the individual guideline.

An incisional or excisional lymph node biopsy is recommended to establish the diagnosis of NHL. Core needle biopsy is discouraged unless the clinical situation dictates that this is the only safe means of obtaining diagnostic tissue. Fine needle aspiration (FNA) biopsy is widely used in the diagnosis of malignant neoplasms, but its role in the diagnosis of lymphoma is still controversial. Since the revised REAL/WHO classification is based on both morphology and immunophenotyping, FNA alone is not acceptable as a reliable diagnostic tool for NHL. However, its use in combination with ancillary techniques may provide precise diagnosis thereby obviate the need for a more invasive biopsy. Recent studies have shown that the diagnostic accuracy of FNA improves significantly when it is used in combination with immunohistochemistry, flow cytometry or excisional biopsy.

In the NCCN guidelines, FNA alone is not suitable for an initial diagnosis of NHL, though it may be sufficient to establish relapse. However, in certain circumstances, when a lymph node is not easily accessible, a combination of excisional or incisional biopsy and flow cytometry may provide better information to provide a diagnosis. This is particularly true for the diagnosis of CLL. In other entities presenting in leukemic phase, such as FL or MCL, a biopsy is still preferred to clarify histological subtype.

Immunophenotypic analysis is essential for the differentiation of various subtypes of NHL, proper diagnosis and choice of treatment for each subtype. It can be performed by flow cytometry and/or immunohistochemistry; the choice depends on the antigens as well as the expertise and resources available to the hematopathologist. In some cases flow cytometry and immunohistochemistry are complementary diagnostic tools. Molecular cytogenetic analysis may be necessary under certain circumstances to identify the specific chromosomal translocations that are more commonly seen in particular NHL subtypes.

Dysregulated expression of cyclin D1 is a cell-cycle protein that results from the chromosomal translocation, t(11;14) seen in the vast majority of cases of MCL. This translocation is not seen in other NHLs though can be seen in multiple myeloma (MM). Cyclin D1 expression is the most reliable marker for differentiating between CLL and MCL. Thus, Cyclin D1 immunohistochemistry or cytogenetic analysis with fluorescent in situ hybridization (FISH) for t(11;14) should be considered for cases of CLL with atypical immunophenotype (CD 23 dim or negative). Analysis of cyclin D1 is helpful in confirming the diagnosis when morphology suggests MCL, though the immunophenotype demonstrates expression of CD 23 positive. BCL2 is over-expressed as the consequence of the t(14;18) translocation seen in 90% of cases of FL and about 20% of cases of DLBCL. However, BCL2 expression is commonly seen in other lymphoma and cannot be used reliably to establish the diagnosis of FL. CD10 expression is useful in differentiating FL from MZL.

The monoclonal antibody Ki-67 is used to detect proliferation index (PI) which has been found to have prognostic significance in FL as well as in other lymphomas. The Southwest Oncology Group (SWOG) trial evaluated the utility of Ki-67 for predicting survival in patients with aggressive NHL. Overall survival (OS) was significantly reduced in patients with high Ki-67 (high PI) compared to those lower PI. Estimated one-year survival was found to be 18% (high PI) compared to 82% for those with low PI. In two other reports, disease-specific survival was significantly better in patients who had FL with a low PI as determined by the staining of Ki-67. Immunohistochemical staining with Ki-67 may be useful in the histological grading of FL. Higher grade follicular lymphomas had greater number of Ki-67 cells.
Work-up

Essential work-up procedures include a complete physical exam with particular attention to node bearing areas and the size of liver and spleen, symptoms present, performance status, laboratory studies including CBC, serum lactate dehydrogenase (LDH), hepatitis B testing (see below), chest/abdominal/pelvic CT, and comprehensive metabolic panel. MUGA scan or echocardiograms are recommended when anthracyclines and anthracedione containing regimens are used. Bone marrow biopsy with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred (see below).

Optional procedures (depending on specific lymphoma type) include beta-2-microglobulin, CT or PET-CT scans, endoscopic ultrasound (gastric MALT lymphoma), head CT or brain MRI and lumbar puncture to analyze cerebrospinal fluid (MCL and DLBCL). Discussion of fertility issues and sperm banking ought to be performed under certain circumstances.

Hepatitis B reactivation has been reported in several patients treated with rituximab in combination with chemotherapy. In some cases viral infections occurred up to one year following discontinuation of rituximab. Due the risk of hepatitis B reactivation, the panel has included hepatitis B testing as part of essential work-up prior to initiation of treatment in all patients who will receive rituximab. However, hepatitis B reactivation has also been seen with chemotherapy alone and any patient with risk factors (including history of blood transfusion) should be evaluated. Hepatitis B testing should include surface antigen/antibody and core antigen/antibody. Antiviral prophylaxis may be beneficial in preventing hepatitis B reactivation. Hepatitis C testing is needed only in high-risk patients.

Bone marrow biopsy is usually included in the work-up for all patients with NHL. Bone marrow involvement occurs in 39% of low-grade, 36% of intermediate-grade and 18% of high-grade lymphomas. Bone marrow involvement was associated with significantly shorter survivals in patients with intermediate or high-grade lymphomas. In a recent retrospective analysis, the incidence of bone marrow involvement and the parameters predicting bone marrow involvement were analyzed in 192 patients with stage I and II in DLBCL. Overall incidence of BM involvement was 3.6%. The authors concluded that bone marrow biopsy may be safely omitted in selected patients with early-stage DLBCL.

The effect of bone marrow biopsy on the management of patients or on the prognosis of lymphoma has not been proven in prospective clinical trials.

In the NCCN guidelines, bone marrow biopsy with or without aspirate is included as part of essential work-up for all lymphomas. However, in the case of patients with low bulk indolent disease with radiographic clinical stage III disease, an initial staging bone marrow evaluation can be deferred if immediate treatment will not be offered as it will not change the clinical recommendations. However, in early stage FL, bone marrow biopsy and aspirate is essential. Unilateral or bilateral core biopsy can be used. Bilateral cores are recommended if radioimmunotherapy is considered.

PET scan has been used for initial staging, restaging and follow-up of patients with NHL. In a recent meta-analysis, PET showed a high positivity and specificity when used for the staging and restaging of patients with lymphoma. However, PET scans can be misleading since other organs in addition to the malignant tumors can take up radioactive FDG. Lesions smaller than 1 cm are not reliably visualized with PET scans. PET scan is currently not used routinely for staging in lymphoma because PET scans detect additional disease sites with the modification of clinical stage only in 15-20% of patients; the impact on
therapy was even less frequent at 8%. PET scan has generally been used in conjunction with a diagnostic CT scans.

Integrated PET-CT is a new imaging technology that has distinct advantages in both staging and restaging compared to full-dose diagnostic CT or PET alone.\textsuperscript{26,27} In a retrospective study, PET-CT performed with low-dose non-enhanced CT was found to be more sensitive and specific than the routine contrast-enhanced CT in the evaluation of lymph node and organ involvement in patients with Hodgkin disease or high-grade non-Hodgkin lymphoma.\textsuperscript{26} Preliminary results of another recent prospective study (47 patients; patients who had undergone prior diagnostic CT were excluded) showed a good correlation between low-dose unenhanced PET-CT and full-dose enhanced PET-CT in the evaluation of lymph nodes and extranodal disease in lymphomas.\textsuperscript{27} However, the lack of intravenous contrast and the diminished resolution can make it difficult in some cases to interpret the anatomical localization and significance of FDG-avid sites. Further studies are needed to determine the role of PET-CT scans in the initial staging of lymphomas. The panel has included PET-CT scan as an optional work-up procedure for selected patients.

**Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)**

**Diagnosis**

Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are different manifestations of the same disease and are managed in much the same way. The diagnosis of SLL is typically applied if the presentation is predominantly nodal and the diagnosis of CLL is made when the principal involvement is bone marrow and blood; however, classification of mixed cases is often arbitrary and the designation SLL/CLL recognizes this fact. As with all the lymphoid neoplasms, adequate hematopathologic review is essential to establish an accurate diagnosis of CLL/SLL. Additional paraffin-embedded material may be used for immunophenotyping to determine lineage and clonality.

Standard paraffin panel of immunohistochemical studies includes a Pan B-cell and a Pan T-cell marker to distinguish B-cell and T-cell malignancies. Immunohistochemical reagents can detect CD3, CD5, CD10, CD20, CD23 and cyclin D1. These can be useful, particularly for diagnosing CLL/SLL type without circulating cells. Flow cytometric studies performed on patients with leukemic cell burden include kappa/lambda to access clonality. The typical immunophenotype in CLL/SLL is CD5+, CD10-, CD19+, CD20, dim expression of surface immunoglobulin, CD23+, CD43+/−, and cyclin D1-. Distinguishing CLL/SLL from MCL is essential, as they are both CD5+ B-cell tumors. Though CD23 is often helpful, cyclin D1- is critical in this differentiation of tumor types.

There are important genetic determinants of prognosis in of SLL/CLL. Mutation of the immunoglobulin variable region (IgV\textsubscript{H}) is associated with a favorable outcome. CD38 expression and zeta-associated protein 70 (ZAP-70) expression have been reported to inversely correlate with mutation status and therefore are predictors of clinical outcome in patients with CLL.\textsuperscript{28,29,30} Evaluation of ZAP-70 expression can be challenging and it should only be used if it has been shown to correlate with mutation status. Furthermore, chromosomal aberrations have important prognostic significance. FISH for detection of t(11;14), t(11q32), del 13q, trisomy 12 and del17p (p53 gene deletions) can be performed on paraffin-embedded or fresh tissue. FISH for the t(11;14) chromosomal translocation can help distinguish MCL from CLL. Del17p is associated with short progression free survival (PFS) and predicts resistance to chemotherapy. The genetic lesions can evolve over time and therefore FISH analysis should be repeated prior to each treatment.
Staging

The Ann Arbor staging system has proven to be of limited utility in CLL because patients universally have bone marrow and peripheral blood involvement. In rare instances, patients may have nodal-only presentations of SLL. Two different staging systems, Rai and Binet system are currently used worldwide. The modified Rai classification is most useful clinically and provides important prognostic information. Survival of patients with good-risk disease (Rai stage 0) is essentially the same as the survival rate of age-matched controls. Patients with intermediate-risk disease (Rai stage I-II) have a shorter survival, particularly when other adverse factors coexist, such as a lymphocyte doubling time of less than one year. Patients with high-risk disease (Rai stage III-IV) have a poor prognosis. Binet staging system is based on the number of involved areas and the level of hemoglobin and platelets and like the Rai system has a good correlation with clinical outcome.

Workup

The workup for CLL/SLL is similar to the workup for other lymphoid neoplasms. Quantitative immunoglobulins may be particularly informative in patients with recurrent infections. Though classically the pattern of bone marrow involvement (diffuse versus nodular) had prognostic significance, this is no longer a factor when one uses more reliable prognostic markers such as immunoglobulin variable gene mutation (or its surrogate Zap 70) and cytogenetic abnormalities determined by FISH all of which can be obtained by analysis of circulating lymphocytes. Thus, bone marrow biopsy is no longer considered a required part of the evaluation of patients with CLL though it remains useful to evaluate the etiology of cytopenias.

Beta-2-microglobulin may have prognostic significance though whether or not this adds to the other factors is uncertain. Computed tomography (CT) scans is useful to follow and monitor disease progression when adenopathy is present. For anemic patients, reticulocyte counts and a direct Coombs’ test should be performed to evaluate for the possibility of hemolysis.

The National Cancer Institute sponsored working group (NCI-WG) first published the guidelines for the diagnosis and treatment of CLL in 1996. The recent developments in the use of prognostic markers and treatment options for CLL have led to the revision of these guidelines, particularly the response criteria. Complete and partial responses are considered clinically beneficial. Relapse is defined as the disease progression after a period of 12 months or more following complete or partial responses. Refractory disease is defined as the one which does respond to purine analog-based therapy or which progresses within 12 months after receiving such therapy.

Treatment

Locoregional radiation therapy (RT) is an appropriate induction therapy for patients with localized SLL (Ann Arbor stage I). In rare patients, radiation may be contraindicated or it may be a sub-optimal therapy due to the presence of comorbidities or the potential of long-term toxicity. Patients with localized SLL that has progressed after initial RT and those with advanced CLL or SLL (Ann Arbor stage II-IV) are treated with chemoimmunotherapy or chemotherapy. Chemotherapy regimens that have shown efficacy in clinical trials include chlorambucil or cyclophosphamide given with or without prednisone, purine analog-based regimen, or an alkylating agent-based combination chemotherapy regimen such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone).

In the CALGB 9011 study, 509 patients were randomized to receive fludarabine, chlorambucil or the combination. The combination arm was stopped due to excessive toxicity. Complete remission (20% vs. 4% for chlorambucil), partial remission (43% vs. 33% for chlorambucil), median duration of remission and median PFS were significantly better.
in patients treated with fludarabine. The study found no significant difference in OS between the two arms suggesting that in some circumstances, chlorambucil as initial therapy may be appropriate. A European randomized study compared fludarabine with two alkylating agent-based combination regimens, CAP (cyclophosphamide, doxorubicin and prednisone) and CHOP as first-line treatment in patients with advanced CLL. Fludarabine and CHOP produced similar overall remission rates (71%) compared to CAP (58%). However, fludarabine was better tolerated than CHOP.

In large randomized trials (US Intergroup E2997 and UK Leukemia Research Fund CLL 4), the combination of fludarabine and cyclophosphamide was associated with an increase in overall response, CR and PFS compared to fludarabine alone. E2297 trial also reported that IgVH, CD38 or ZAP-70 expression did not predict outcome of fludarabine-based therapy.

Rituximab is a monoclonal antibody against CD 20, which has been approved by FDA for the treatment of indolent lymphoma. Rituximab has been evaluated in combination with fludarabine-based chemotherapy. CALGB study 9712 compared the efficacy of fludarabine with concurrent or sequential administration of rituximab in untreated patients with CLL. The concurrent regimen was associated with a higher overall response rate (90% vs. 77% for the sequential regimen) at the expense of higher grade 3 or 4 toxicity. However, comparison of the outcomes of patients treated with fludarabine alone in the CALGB 9011 trial and the pooled results from the CALGB 9712 study, suggested that the addition of rituximab to fludarabine prolongs PFS and OS. The combination of fludarabine, cyclophosphamide and rituximab (FCR) has been evaluated at MD Anderson Cancer Center both as initial therapy for progressive or advanced CLL and as second-line therapy for relapsed or refractory CLL. FCR regimen produced high overall response rate and CR.

The combination of pentostatin and cyclophosphamide (PC) with or without rituximab (R) has shown significant activity in previously treated patients with relapsed or refractory disease. In a small number of previously treated patients, the response rates were similar for PC and PCR. However, based on a historical retrospective comparison with PC regimen, the median duration of response for PCR (25 months) is longer than that of PC (7 months) as well as median survival (44 months for PCR and 16 months for PC). The addition of rituximab showed a survival advantage. Based on these results, the CLL Research Consortium members initiated a trial of PCR in previously in untreated patients. Responses were observed in 91% of patients (41% CR, 21% nodular PR and 28% PR).

Alemtuzumab is a monoclonal antibody targeting CD 52. In a large international study, alemtuzumab induced significant responses in patients who had failed fludarabine-based therapy. Median time to progression was 4.7 months and median OS was 16 months (32 months for responders). Alemtuzumab has also been effective in patients with fludarabine refractory CLL and del(17p) or p53 gene mutations. In an international, multicenter randomized study (CAM307), PFS and overall response rate (83% vs. 55%) were significantly better for alemtuzumab compared to chlorambucil, as first-line treatment for patients with CLL. However, nodal sites of disease have generally not responded well with single agent alemtuzumab.

In patients with localized SLL (Ann Arbor stage I) that has progressed after initial RT or those with advanced disease (Ann Arbor stage II-IV disease) with no del (17p), treatment options depend on the presence or absence of the following indications: symptoms, threatened end-organ function, cytopenia, bulky disease, steady progression, histologic transformation, recurrent infections and/or patient's preference. Patients with no indications for treatment can be observed.
until disease progression. Those presenting with any of the above indications should be treated with chemotherapy (single agent or combination) or chemoimmunotherapy regimens suggested in CSLL-D. Purine analog-based therapy is preferred. Prophylaxis for tumor lysis syndrome (TLS) should be considered since patients with CLL are at risk of developing TLS.

NCCN guidelines suggest the following regimens (which by convention are listed in alphabetical order) for first-line therapy, with or without rituximab: Chlorambucil with or without prednisone; cyclophosphamide with or without vincristine and/or prednisone; CHOP regimen for patients who are unable to tolerate fludarabine; fludarabine (F) alone or in combination with cyclophosphamide (FC) and PCR regimen (pentostatin, cyclophosphamide and rituximab).

Bendamustine is an alkylating agent with a low cross-resistance with other alkylating agents (chlorambucil, cyclophosphamide, ifosfamide) and fludarabine. In a pivotal phase III study, bendamustine was compared to chlorambucil in patients with untreated CLL. At a median follow-up of 18.5 months, bendamustine produced an overall response rate (ORR) of 68% with a CR of 30%, which was significantly higher than that of chlorambucil (39% with CR of 2%). Median progression-free survival (21.7 months vs. 9.3 months for chlorambucil) and median duration of remission (18.9 months vs. 6.1 months with chlorambucil) were also better for bendamustine. However, there were no differences in OS between the two groups.

Based on the results of this study, FDA recently approved bendamustine for the treatment of patients with CLL. However, the efficacy of bendamustine compared to other first-line therapies for CLL other than chlorambucil has not yet been established. NCCN guidelines have included bendamustine as a single agent for first-line therapy; single agent or in combination with rituximab for second-line therapy.

Patients who achieve a complete or PR following induction therapy are generally observed. Additional therapy for patients in remission is investigational and should be given only in the context of a clinical trial. Treatment options for patients with disease progression are similar to those available as initial therapy. Allogeneic stem cell rescue is an alternate treatment option for patients with relapsed disease but would generally be used after re-induction of remission. The choice of second-line therapy should take into account the remission duration as well as the initial agents used. Any of the chemotherapy regimens recommended for first-line therapy can be used for progressive disease, in combination with either rituximab or alemtuzumab. The panel has also included alemtuzumab as a single agent for second-line therapy in all patients with relapsed or refractory CLL.

Presence of del(17p) is associated with a poor response to conventional therapy; treatment options for patients with del(17p) depend on their age. Alemtuzumab is a treatment option for patients 70 years or older. Those younger than 70 years are treated with chemotherapy or chemoimmunotherapy regimens suggested in CSLL-D. Patients with CR are usually observed. High dose therapy with allogeneic stem cell rescue is a treatment option for those who achieve CR or PR. Patients who are not responsive to chemotherapy are treated with alemtuzumab. High dose therapy with allogeneic stem cell rescue can be considered for patients showing response.

Patients with autoimmune cytopenia may require therapy targeted to the hemolysis. Initial therapy for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) is administration of corticosteroids. Intravenous immunoglobulin may be used in the treatment of refractory disease. Patients with AIHA should be observed carefully during treatment and the presence of AIHA should not absolutely preclude the use of fludarabine-based therapy. Rituximab or splenectomy are options in select patients. Immunosuppressive agents
such as prednisone, cyclosporine, and antithymocyte globulin (ATG) are indicated for the treatment of pure red cell aplasia. Patients with recurrent infections, particularly those patients with encapsulated organisms in the setting of hypogammaglobulinemia, may benefit from intravenous gamma globulin.

Cytomegalovirus (CMV) reactivation is well documented in patients receiving alemtuzumab. Due to the high risk of CMV reactivation, CMV viremia should be measured by PCR quantization at least every 2-3 weeks. The current management is controversial. Ganciclovir is used either prophylactically if viremia present, or in some cases only if viral load is rising.

**Follicular Lymphoma**

**Diagnosis**

Follicular lymphoma has a characteristic immunophenotype, which includes CD20+, CD10+, bcl-2+, CD23+/−, CD43−, CD5−, and cyclin D1−. Rare cases of FL may be CD10- or bcl-2-. Additional paraffin-embedded material is useful, under certain circumstances, for immunophenotyping to evaluate the expression of bcl-6, cyclin D1 (if CD10- and/or CD5+ or CD43+), CD43, kappa/lambda, CD21, and Ki-67. Ninety percent of cases have a chromosome translocation, t(14;18), which juxtaposes the bcl-2 gene with the immunoglobulin heavy-chain locus that results in the deregulated expression of bcl-2. The diagnosis is easily established on histological grounds, but immunophenotyping is encouraged to distinguish from a nodular MCL or SLL. Molecular genetic analysis to detect bcl-2 rearrangement, cytogenetics or FISH to identify t(14;18) will be useful under certain circumstances.

In the REAL/WHO classification FL is classified into three histological grades according to the number of centroblasts utilizing the counting method of Mann and Berard (Grade 1: 0-5 centroblasts per high power field (HPF); Grade 2: 6-15 centroblasts per HPF and Grade 3: greater than 15 centroblasts per HPF). NCCN guidelines apply to FL (grades 1-2). FL (grade 3) is commonly treated according to DLBCL.

**Workup**

The diagnostic workup for FL is similar to the workup for other indolent lymphomas. The majority of patients present with disseminated disease. The approach to therapy differs dramatically between patients with localized and those with disseminated disease. Bone marrow biopsy with aspirate is essential to document clinical stage I-II disease. This can be deferred if observation is the initial treatment option. The FLIPI (Follicular Lymphoma International Prognostic Index) may be used in determining treatment prognosis but has not been established as a means of selecting treatment options. FLIPI includes patient characteristics (age), tumor burden which is determined by Ann Arbor stage and number nodal sites involved, hemoglobin levels and tumor aggressiveness as determined by serum LDH levels. The majority of NCCN investigators routinely employ chest, abdominal and pelvic CT as part of the diagnostic evaluation. CT scan of the neck may also assist in defining the extent of local disease. In patients presenting with what appears to be localized disease, a PET scan may be helpful in identifying occult sites of disease or if there is concern about histologic transformation.

**Treatment**

The therapeutic approach to follicular lymphomas (grades 1 and 2, WHO classification) depends on the extent of initial disease involvement. Follicular lymphomas, grade 3 (WHO/REAL classification) are generally treated according to the guidelines for DLBCL, though they are recognized to have a much higher risk of relapse. It should be noted that in most centers the proportion of patients diagnosed with FL, grade 3 is greater than that previously diagnosed as follicular large cell lymphoma in the International Working Formulation.
In a prospective randomized study conducted by M.D. Anderson Cancer Center, the addition of adjuvant CHOP to RT did not improve relapse free survival in patients with low-grade lymphoma.\textsuperscript{55} Locoregional RT (24-30 Gy, with an additional 600 cGy in selected patients with bulky or slowly regressing disease) is the preferred treatment option for patients with non-bulky localized (Ann Arbor stage I-II) disease. The NCCN guidelines have included immunotherapy with or without chemotherapy or RT as an alternate treatment option with a category 2B recommendation. In circumstances where toxicity of IFRT outweighs the potential clinical benefit, observation may be appropriate. If there is no response to initial therapy, patients should be managed in the same manner as patients with systemic presentation of FL, as described below.

Patients who present with bulky abdominal (Ann Arbor stage II) or stage III-IV disease, the decision to treat is based on the following indications: symptoms, threatened end-organ function, cytopenia secondary to lymphoma, bulky disease, steady progression, and/or patient preference. The selection of treatment should be highly individualized according to age, extent of disease, comorbid conditions, and the goals of therapy. When choosing an initial therapy, care should be given to avoid excessively myelotoxic regimens in patients who may subsequently be candidates for high-dose therapy with autologous stem cell support. Since FL is currently incurable with conventional therapy participation in a clinical trial should be considered for first-line treatment. In the absence of an appropriate clinical trial, patients with indications for treatment should be treated with systemic therapy. In selected cases, IFRT may be used for local palliation. Asymptomatic patients can be observed.\textsuperscript{56}

Single agent cyclophosphamide had equivalent OS and CR rates compared to cyclophosphamide-based combination chemotherapy.\textsuperscript{57} Rituximab produced an overall response rate of 67% in chemotherapy-naïve patients compared to 46% in pretreated patients with FL. Prolonged administration of rituximab (one dose every 8 weeks four times) significantly improved event-free survival in chemotherapy-naïve patients but did not extend OS.\textsuperscript{58} However, retreatment with rituximab at progression provided the same duration of benefit as did maintenance (4 weekly doses every six months for two years) with fewer doses of rituximab.\textsuperscript{59} NCCN guidelines recommend rituximab (preferred), or alkylating agents such as cyclophosphamide or chlorambucil as single agents for first-line therapy in elderly or infirm patients.

Chemoimmunotherapy is another option for first-line therapy in patients with advanced disease. The addition of rituximab to combination chemotherapy regimens has consistently increased the overall response rate, response duration and PFS. In addition, some studies have demonstrated OS benefit; a recent meta-analysis has confirmed the benefit in OS despite what is still limited follow up for FL.\textsuperscript{60}

The safety and efficacy of R-CHOP was demonstrated in a small study that demonstrated excellent long-term results.\textsuperscript{61,62} The superiority of R-CHOP to CHOP in treatment naïve patients was established in a prospective randomized phase III study conducted by the German Low-Grade Lymphoma Study Group (GLSG) involving 428 patients. R-CHOP was associated with a 60% reduction in the relative risk for treatment failure, significantly prolonged time to treatment failure, higher overall response rate and prolonged duration of remission.\textsuperscript{63} Overall survival analysis is complicated by a second randomization which included HDT/ASCR. There OS was the same with and without rituximab, if there was consolidation with HDT/ASCR. However, OS was significantly improved for patients receiving R-CHOP followed by interferon compared to CHOP followed by interferon. R-CHOP also improved outcome of elderly patients with previously untreated FL.\textsuperscript{64} In the ECOG 1496 trial, addition of rituximab to CVP (cyclophosphamide,
vincristine and prednisone) chemotherapy significantly improved outcome in patients with previously untreated FL, with no significant increase in toxicity. At a median follow-up of 30 months, prolonged time to progression was 32 months for patients treated with R-CVP versus 15 months for those treated with CVP.

The addition of rituximab to fludarabine or fludarabine-based combination has improved outcomes in various clinical studies. In a prospective randomized trial, FCM-R regimen (fludarabine, cyclophosphamide, mitoxantrone and rituximab) was associated with superior outcomes in patients with relapsed or refractory FL and MCL. In another randomized trial, concurrent administration of rituximab with FND regimen (fludarabine, mitoxantrone and dexamethasone) resulted in a significantly higher 3-year failure-free survival rate (84% vs. 59% for sequential arm) in a subset of patients with FL.

Radioimmunotherapy (RIT) with [131I]-tositumomab and 90Y-ibritumomab tiuxetan is an alternate treatment option for relapsed, refractory or histologically transformed FL. Recent reports from clinical trials using [131I]-tositumomab or [90Y]-ibritumomab tiuxetan as first-line treatment, either alone or following chemotherapy, have demonstrated high response rates and PFS. Initial treatment with single one-week course of [131I]-tositumomab induced prolonged clinical and molecular remissions in patients with advanced FL. In the Southwest oncology Group (S9911) trial, CHOP followed by RIT with [131I]-tositumomab resulted in an overall response rate of 91%, including a 69% complete remission (CR) rate in patients with previously untreated FL. After a median follow-up of 5 years, the estimated 5-year OS rate was 87%, and PFS rate was 67%. In historical comparison, these statistics were better than those reported for CHOP alone. In a recent phase II study, R-CHOP (3 cycles) followed by 90Y-ibritumomab tiuxetan induced high CR in patients with previously untreated FL. In another recent randomized trial (FIT) of induction chemotherapy with or without adjuvant RIT showed a highly significant improvement in CR rate and prolongation of PFS.

Suggested treatment options for patients with advanced FL are listed in FOLL-B. Based on the reported data, rituximab in combination with CHOP or CVP chemotherapy for first-line therapy in patients with advanced FL now has a category 1 recommendation. Other suggested regimens include rituximab either as a single agent or in combination with fludarabine-based chemotherapy. RIT either alone or following treatment with CHOP with rituximab is included as category 2B option for first-line treatment. CHOP plus rituximab followed by RIT is recommended only in the context of a prospective clinical study.

Bendamustine (recently approved for the treatment of CLL) has also been investigated as a single agent or in combination with other chemotherapeutic agents in low grade NHL. In a recent report from a phase II multicenter study, bendamustine as a single agent showed promising results with acceptable toxicity in heavily pretreated patients with rituximab-refractory indolent or transformed NHL. An ORR of 77% (15% CR, 19% unconfirmed CR and 43% PR) was observed. Among patients with FL, 82% ORR was observed. At a median follow-up of 26 months, median PFS was 7.1 months for all patients. In another study conducted by German study group, the patient population included both relapsed low grade NHL and MCL. Bendamustine in combination with rituximab produced an ORR of 96% (71% CR and 25% PR) in a subset of patients with relapsed or refractory FL. Median duration of follow-up was 20 months.

At ASH 2007, Rummel et al. presented the results of a randomized comparison of bendamustine and rituximab (BR) with R-CHOP as first-line therapy for patients with indolent lymphoma and MCL. The trial, StiL (Study Group Indolent Lymphomas) NHL 1-2003, was designed as an equivalency study and the first interim analysis of 315 evaluable patients suggested that the response rates and response durations are
the same for BR and R-CHOP. Furthermore, BR was associated with less toxicity compared to R-CHOP. However, the NCCN panel felt that these data were preliminary and further follow up of the entire patient population was necessary prior to recommending BR as first-line therapy. In ongoing phase III clinical studies, the combination of bendamustine and rituximab is being compared with fludarabine and rituximab in relapsed low grade NHL.

The panel has included bendamustine with or without rituximab as an option for second-line therapy for patients with relapsed or refractory FL, based on the data available in the literature. However, this is only a category 2B recommendation since no data is available yet from randomized control studies evaluating bendamustine versus other conventional chemotherapy regimens used for the management of low grade NHL and there was not uniform consensus among the panel.

Rituximab should be used with caution in hepatitis-B patients. IFRT with or without systemic therapy can be considered for palliation in patients with locally bulky or symptomatic disease. In patients who may be eligible, at a later time, for high dose therapy followed by autologous stem cell rescue (HDT/ASCR), profoundly myelotoxic regimens should be avoided.

Follow-up of patients with a CR or PR includes repeat diagnostic tests, as indicated, such as imaging tests based on the site of disease and clinical presentation. At recurrence, biopsy is generally indicated to exclude histologic transformations, especially if there are raising LDH levels, disproportional growth in one area, development of extranodal disease or new “B” symptoms.

Transformation to DLBCL is common in patients with FL occurring at a rate of approximately 2-3% per year for at least 15 years and the risk of transformation falls after that time, for reasons that remain unclear. 84 Non-uniform uptake on a FDG-PET scan can be an indication of transformation; areas of high SUV, especially in excess of 13.1 are suspicious for transformation. Transformation to DLBCL is generally associated with a poor clinical outcome; however, in cases where it occurs and the patient has had minimal or no prior chemotherapy, anthracycline-based therapy with or without RT or chemotherapy with or without rituximab are treatment options with good outcomes. 85 If the patient has had multiple prior therapies, the prognosis is much poorer; RIT or IFRT are treatment options. Autologous or allogeneic stem cell rescue can be considered in patients with responsive disease after initial treatment.

In the setting of relapsed/refractory disease, rituximab maintenance following first line therapy has been shown in two large-scale randomized trials to provide a PFS advantage over observation for patients treated with chemoimmunotherapy. 86,87,88 In a phase III Intergroup trial (EORTC 20981), maintenance rituximab considerably improved PFS (51.5 months vs. 14.9 months for observation) and OS (85% at 3 years versus 77% with observation) in patients with relapsed or resistant FL responding to CHOP or R-CHOP. 87 The improvement in PFS was seen in a subset analysis of the patients having received R-CHOP. In another prospective randomized study by the GLSG, rituximab maintenance after second line treatment with R-FCM (rituximab with fludarabine, cyclophosphamide and mitoxantrone) significantly prolonged duration of response in patients with recurring/refractory FL or MCL. 88

Treatment for relapsed or progressive disease is based on the presence or absence of indications for treatment. Patients with indications for treatment can be treated with chemoimmunotherapy as described above for first-line treatment, RIT or any of the second-line regimens used for patients with DLBCL. Rituximab maintenance following initial therapy has demonstrated benefit in PFS for patients with relapsed or refractory disease but its role in improving outcome of
patients in first remission remains investigational. The PRIMA trial evaluating the role of rituximab maintenance following chemoimmunotherapy has completed accrual and preliminary results are anticipated late 2008. This trial should help clarify the role of rituximab maintenance as an adjuvant to initial remission induction. In the NCCN guidelines, its use in this situation is a category 2B recommendation.

HDT/ASCR is an appropriate option for patients with refractory, relapsing or progressive disease, if a subsequent remission can be induced; though HDT/ASCR is generally not curative, the benefit can be durable with median PFS of 3-5 years. In selected patients, ablative and nonmyeloablative allogeneic stem cell rescue have shown long term survival benefit although there is a treatment related mortality rate of 10-25% for non-myeloablative and 40% for myeloablative.

Marginal Zone Lymphomas
Marginal zone lymphomas (MZL) are a heterogeneous group of disorders consisting of extranodal marginal zone lymphoma (MALT lymphoma), nodal MZL, and splenic MZL. MALT lymphomas are subdivided into the gastric and non-gastric lymphomas. Splenic MZL involves the spleen and bone marrow, whereas nodal MZL occurs primarily in the lymph nodes though additional extra nodal sites are common.

Adequate hematopathology and immunophenotyping are needed to establish a diagnosis. The typical immunophenotype of MZL is CD5-, CD10-, CD20+, CD23/-+, CD43/-+, cyclin D1-, bcl-2 follicles-. In addition splenic marginal zone lymphoma is characterized by annexin-1- and CD103-. Immunophenotyping is useful in distinguishing MZLs from CLL (CD5+) and MCL (CD5+) and hairy cell leukemia (annexin-1+ and CD103+). Molecular, cytogenetics or FISH evaluation for the t(11;18) chromosome translocation, is recommended. The t(11:18) is the most common genetic abnormality found in patients with gastric MALT lymphomas. It is associated with disseminated disease and resistance to antibiotic treatment in patients with gastric MALT lymphoma.

In some cases cytogenetic evaluation should include evaluation for t(3;14)(p14.1;q32) [IGH-FOXP1]; t(1;14)(p22;q32) [IGH-BCL10]; t(14;18)(q32;q21) [IGH-MALT1] and del (7q31-32).

Gastric MALT Lymphoma
Gastric MALT lymphomas develop in the stomach. Helicobacter pylori (H. pylori) infection has a critical role in the pathogenesis of this disease and its eradication can lead to tumor remission. Other MZLs have been shown to be associated with infectious agents, but this association has not been validated.

Workup
The workup for gastric MALT lymphoma is similar to the workup for other NHLs. Special aspects of the workup for gastric MALT lymphoma include direct endoscopic assessment of the gastrointestinal tract and additional evaluation of the tumor specimen for the presence of H. pylori. The presence of H. pylori infection must be confirmed by biopsy with PCR (polymerase chain reaction) and urea breath test. Nondiagnostic atypical lymphoid infiltrates that are H. pylori positive should be re-biopsied to confirm or exclude lymphoma prior to treatment of H. pylori. Appropriate imaging studies include CT of the chest, abdomen and pelvis, and in select cases, bone marrow biopsy. At some NCCN institutions, endoscopic ultrasound (EUS) is used to complement conventional endoscopy at the time of the initial workup and at follow-up. EUS also provides information regarding the depth of involvement in the gastric wall that is essential information in some of the currently used staging systems.
Staging
Several different staging systems have been for gastric MALT lymphomas. In the Lugano staging system, Ann Arbor stage III has been removed and supradiaphragmatic nodal disease is included under stage IV. TNM (Tumor-Node-Metastasis) staging system corresponds to the staging in gastric cancer, and the depth of the lymphoma infiltration is measured by EUS. Involvement of multiple extranodal sites in MALT lymphoma appears to be biologically distinct from multiple extranodal involvements in other lymphomas, and these patients may be managed by treating each site separately with excision or RT. In contrast, cases with disseminated nodal involvement appear to behave more like nodal MZL or like disseminated FL.

Treatment
H.pylori infection plays a central role in the pathogenesis of some cases of gastric MALT lymphoma. The efficacy of antibiotic therapy for the treatment for gastric MALT lymphoma has been evaluated in numerous trials. Approximately two thirds of patients with localized gastric MALT lymphoma have a complete tumor remission after eradication of H.pylori infection with antibiotic therapy. However, there is increasing evidence that late relapses occur after antibiotic management and a long duration of follow-up is appropriate.

For disease confined to the stomach (stage IE, H.pylori positive), treatment begins with antibiotics in combination with a proton pump inhibitor to block gastric acid secretion. The tumor response may be slow, and re-evaluation with endoscopy should not be done until 3 months post treatment unless clinical deterioration is evident. If there is evidence of the t(11;18) t(1;14), t(14;18)(q32;q21), treatment of the H.pylori infection with antibiotics may be ineffective and these patients should be considered for alternative therapy. H. Pylori infection is not evident in approximately 10-40% of patients with gastric MALT lymphomas. IFRT is preferred for patients with disease that is extending to the muscularis or disease extending from the GI tract to adjacent organs (stages IE [T2 or T3] or IIE H.pylori negative), particularly if one of the t(11;18), t(1;10), or t(14;18)(q32;q21) translocations is present. Rituximab or chemoimmunotherapy are other treatment options.

In patients with disseminated disease (stage III or IV), treatment is similar to that described for other advanced-stage indolent lymphomas. As with other indolent lymphoma, asymptomatic patients without indications for treatment are monitored without therapy. The decision to treat is guided by end-organ dysfunction or the presence of symptoms (such as bleeding, early satiety), bulky disease at presentation, steady progression of disease, or patient preference. Treatment may include single-agent or combination chemotherapy, or locoregional RT. If there is evidence of recurrence, patients are managed according to the FL guidelines. Surgical resection is generally limited to specific clinical situations. Though disease control is excellent with total gastrectomy, the long-term morbidity has precluded routine surgical resection. Total gastrectomy is necessary because of the multi-focal nature of the disease.

Follow-Up Endoscopy
Following primary antibiotic therapy, patients are restaged with endoscopy and biopsy after 3-months. Patients with responsive disease (microbiologic and tumor response) are just observed. Patients with persistent lymphoma with no evidence of H.pylori are treated with RT, if they are symptomatic or if there is significant disease progression. Asymptomatic patients can be observed for 3 months. Locoregional RT can be considered as early as 3 months after observation but observation can be prolonged for up to 18 months (category 2B). Patients with persistent H.pylori and regressing or stable lymphoma are treated with second-line antibiotics. Lastly, patients who are H.pylori...
positive with persistent lymphoma are treated with RT, if they have progressive disease. Those with stable disease are treated with second-line antibiotics.

Follow-up surveillance at 6 months consists of repeat endoscopy and biopsy. Patients can be subdivided into the same four groups, as above. Patients with complete tumor response continue to be observed if the *H. pylori* is negative, or they can be treated with other antibiotic therapy if *H. pylori* remains positive. Patients with persistent or recurrent lymphoma after antibiotic therapy, irrespective of their *H. pylori* status, are treated with locoregional RT if not previously treated. Patients whose disease does not respond to radiation are managed with single-agent or combination chemotherapy similar to FL. Following second-line antibiotic therapy or RT, patients are again evaluated with endoscopy and biopsy to rule out large cell lymphoma. Systemic therapy as indicated in FOLL-3 is recommended for recurrence following CR to RT or antibiotic therapy, or for patients with no response to prior RT.

**Non-gastric MALT Lymphomas**

Nongastric MALT lymphomas can arise from a large number of non-gastric sites such as lung, thyroid, salivary glands, breast, and tissues surrounding the eye. For patients with stage IE-II disease or extranodal disease involving multiple sites, locoregional RT (20-30 Gy) is appropriate. Surgery may be considered for certain sites of disease (eg, lung, skin, thyroid, colon, small intestine, and breast). If there is no residual disease following surgery, patients are observed, whereas those with positive surgical margins are treated with locoregional RT. Recurrence following primary treatment is managed similar to advanced stage FL. RT is an option for those with local recurrence. Patients with advanced-stage disease (stage III-IV) are managed the same as patients with FL. Aggressive histologies, in which MALT lymphomas coexist with large cell lymphoma, should be managed according to the diffuse large B-cell practice guidelines.

**Nodal Marginal Zone Lymphoma**

Nodal MZL is rare and often presents concurrently with extranodal sites of disease. The diagnosis of nodal MZL requires careful evaluation to rule out extranodal sites of disease and it must be distinguished from nodal FL, MCL, lymphoplasmacytic lymphoma and CLL, all of which are more common. Nodal MZL is managed as per FL.

**Splenic Marginal Zone Lymphoma**

**Diagnosis**

Splenic MZL is often presumptive based on the findings of splenomegaly with peripheral blood flow cytometry usually revealing a monoclonal B cell population. Involvement of the bone marrow is also common. This lymphoma is distinguished from CLL by the absence of CD5 expression, strong CD20 expression and variable CD23 expression. In some cases, the diagnosis can be established by the finding of villous projections on the circulating lymphocytes. Splenectomy can definitively establish the diagnosis and in many cases is therapeutic as well.

**Workup**

The workup is similar to the other indolent lymphomas. Flow cytometry of peripheral blood and bone marrow is essential in identification of a monoclonal B cell population. CT of the chest, abdomen, and pelvis will help in establishing the extent of disease. Hepatitis C has been associated with and implicated in the pathogenesis of splenic MZL and should be evaluated for all patients suspected of having this diagnosis.
Treatment

Most of the patients with no splenomegaly, cytopenia or other symptoms can be observed. Patients presenting with splenomegaly are treated depending on their hepatitis C status. Hepatology evaluation is recommended for hepatitis C positive patients; anecdotal tumor regressions have been reported in responses to hepatitis therapy. In all other patients, in the absence of cytopenias or other symptoms, patients should be observed.

In a retrospective study, rituximab-based treatments resulted in longer failure free survival in patients with splenic MZL compared to patients treated with chemotherapy alone. Rituximab was superior to splenectomy in normalizing white blood cell and absolute lymphocyte counts. Splenomegaly also disappeared in 92% of the patients treated with rituximab alone.

Splenectomy is the preferred option for patients with cytopenias or symptoms of weight loss, early satiety or abdominal pain. Rituximab is another treatment option for this group of patients. Patients should be monitored on a regular basis. If there is disease progression, patients are managed similar to advanced stage FL.

Mantle Cell Lymphoma

Diagnosis

Mantle cell lymphoma can be readily distinguished from other small lymphocytic lymphomas due to the widespread availability of appropriated diagnostic reagents. The diagnosis can be established by histological examination in combination with immunohistochemistry with a profile consisting of CD5+, CD10-/+, CD20+, CD23-, CD43+, and cyclin D1+. Rare cases of MCL may include CD5- or CD 23+ immunophenotype. The diagnosis of MCL requires the expression of cyclin D1, an opinion shared by the panel. However, recent gene profiling data suggests that cyclin D1 expression may not be required for the molecular signature of MCL; in these cases, over-expression of cyclin D2 or D3 can be observed. Cases with a typical immunophenotype, CD5+, CD23-, CD20+ that are cyclin D1- should be evaluated for cyclin D2 and D3 expression; positive cases should be classified as MCL with a variant immunophenotype, negative cases should be classified as variant SLL/CLL. Currently available reagent for immunohistochemistry of cyclin D1 are robust and yield good staining; however, in some cases cytogenetics or FISH for the t(11;14), juxtaposing the cyclin D1 locus with the IgH locus can be diagnostically helpful.

Workup

The workup for MCL is similar to the workup for many indolent lymphomas and certain aggressive lymphomas. MCL is a systemic disease with frequent involvement of the bone marrow, gastrointestinal tract and frequently a leukemic phase. For this reason, both the peripheral blood and bone marrow must be carefully evaluated for the presence of malignant cells. Chest, abdominal, and pelvic CT scans are routinely performed. MCL may present as lymphomatous polyposis coli and colon involvement is common. In the current guideline, colonoscopy is now considered a routine part of the evaluation of MCL. Post treatment colonoscopy is necessary to confirm a CR, if it was not done previously. Upper endoscopy and neck CT scan may be helpful in selected cases. In patients with the blastic variant, lumbar puncture is done to evaluate the spinal fluid for involvement.

Treatment

It has generally been thought that MCL has the worst characteristics of both indolent and aggressive non-Hodgkin’s lymphomas owing to the incurability with conventional chemotherapy and it more aggressive growth pattern. However, emerging data suggests that the long-term outcome of patient with MCL may be improving. There remains no established standard of care. In the absence of standard management
for MCL, patients with this disease should be referred for participation in prospective clinical trials. Like the management of patients with indolent lymphoma patients with MCL often have highly individualized course of care.

Several regimens have shown significant activity in newly diagnosed MCL, but none of these regimens are curative in patients with advanced disease.\textsuperscript{114,115} Recent meta-analysis has shown that the addition of rituximab to chemotherapy increases response rates but it has not yet been proven to extend either progression-free or OS.\textsuperscript{60} R-CHOP was significantly superior to CHOP in terms of overall response rate (94\% v 75\%), complete remission rate (34\% v 7\%).\textsuperscript{116,117} No differences were observed for PFS. In patients with newly diagnosed MCL, R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with R-MA (rituximab plus high-dose methotrexate and cytarabine) produced a 3-year failure-free survival (FFS) rate of 64\% and OS rate of 82\%.\textsuperscript{118} However, in a subset of patients more than 65 years of age, this regimen was associated with shorter FFS and significant toxicity.

R-HyperCVAD was evaluated in a multicenter SWOG study that reported a CR/CRu rate of 58\% and 2-year PFS of only 63\%.\textsuperscript{119} Modified R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen developed by the Wisconsin Oncology Network, produced favorable overall response rate (77\%) and CR rate (64\%) with acceptable toxicity in patients with untreated MCL.\textsuperscript{120} This is being tested more widely in an ongoing ECOG trial. RIT has also been investigated as initial therapy as well as second-line treatment for refractory or relapsed MCL as reviewed by Zelenetz.\textsuperscript{115}

Few patients present with localized MCL and the available published literature on management is retrospective and anecdotal.. In a retrospective analysis of 26 patients with early stage MCL, inclusion of RT was associated with an improved PFS and a trend towards improved OS.\textsuperscript{121} Outside of a clinical trial, the panel recommended IFRT with or without combination chemotherapy. These recommendations are based on treatment principles in the absence of more definitive data.

Majority of patients with MCL will have advanced stage disease and require systemic therapy. Highly selected patients who are asymptomatic with stable adenopathy and non-bulky disease are observed; these patients usually have low bulk, nodular morphology variant and a low proliferation fraction. Based on the available data, the panel has included R-HyperCVAD and R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin)\textsuperscript{122} as options for first-line therapy. In patients older than 65 years of age, the panel recommends the use of modified HyperCVAD regimen with rituximab maintenance. CHOP (with or without rituximab) is recommended for selected older patients who cannot tolerate intensive therapy.

Initial remission should be followed by HDT/ASCR in eligible patients, as this has been associated with some evidence of durable remission. In a study conducted by M.D. Anderson Cancer Center, ASCR following treatment with hyperCVAD regimen for cytoreduction prolonged OS in patients with MCL in first disease remission, especially in those with a low beta-2-microglobulin level.\textsuperscript{123} In a randomized trial conducted by European MCL network, patients 65 years of age or younger with advanced-stage MCL were randomized to ASCR or maintenance with interferon-alpha after achieving of complete or partial remission by CHOP-like chemotherapy. Three-year OS was 83\% after ASCR versus 77\% in the IFN group.\textsuperscript{124}

The optimal approach to recurrent disease remains to be defined. Fludarabine-based combination regimens such as fludarabine in combination with cyclophosphamide\textsuperscript{125} and FCMR (fludarabine,
cyclophosphamide, mitoxantrone, rituximab) have shown activity in MCL. In a prospective randomized study of the GLSG, addition of rituximab to the combination of fludarabine, cyclophosphamide, mitoxantrone, produced significantly longer OS in patients with relapsed and refractory MCL. In a phase II trial, the proteosome inhibitor bortezomib induced 33% response rate including 8% CR in patients with relapsed or refractory MCL. Median time to progression was 6.2 months. Based in these data, bortezomib received FDA approval for the treatment of patients with MCL who have received at least one prior therapy. Studies of bortezomib-based combinations in MCL are ongoing. Marked anti-tumor activity has been shown for rituximab plus thalidomide in patients with relapsed or refractory MCL. Lenalidomide, an immunomodulator related to thalidomide also has activity in MCL either alone or in combination with rituximab.

Bendamustine is an emerging agent (recently approved for the treatment of CLL) that has well-documented activity in patients with MCL. In a phase II study conducted by the German study group (which included low grade NHL and MCL patients), the subset of patients with relapsed or refractory MCL treated with the combination of bendamustine and rituximab has an overall response rate of 75% with a CR rate of 50%. Median follow-up duration was 20 months. The median PFS for MCL patients was 18 months whereas the median PFS for patients with FL had not been reached. Further studies are needed to confirm these findings.

Based on the efficacy data available in the literature, the combination of bendamustine with or without rituximab is included in the guidelines as an option for second-line therapy for patients with relapsed or refractory MCL, with a category 2B recommendation since no data is available yet from randomized studies and there was not uniform consensus among the panel. Ongoing phase III studies are evaluating the efficacy of bendamustine plus rituximab vs. R-CHOP in previously untreated MCL patients. The panel felt that additional follow-up from this study was necessary prior to making recommendations regarding initial therapy. The same combination is also being compared to fludarabine with rituximab in relapsed MCL.

Patients with relapsed disease following CR to induction therapy, those who obtain only a PR to induction therapy or those with progressive disease are appropriate candidates for clinical trials of high-dose therapy with stem cell rescue. Alternatively, these patients can also be treated with second-line chemotherapy or HDT/ASCR. Suggested regimens for second-line therapy for relapsed or refractory disease are listed in MANT-A.

Diffuse Large B-Cell Lymphoma

Diagnosis

Diffuse large B-cell lymphomas are the most common lymphoid neoplasms in adults. FL (grade 3), DLBCL coexistent with FL of any grade, gastric MALT or non-gastric MALT lymphoma are also managed according to the DLBCL guidelines.

Recent studies with gene expression microarray analysis of DLBCL have revealed significant heterogeneity within this diagnosis. However, incorporation of this information into treatment algorithms awaits further investigation. The immunophenotypic studies used to distinguish DLBCL from other lymphoid entities include T-cell markers (peripheral T-cell lymphoma), CD30 (anaplastic large cell lymphoma), and TdT and CD79a (lymphoblastic lymphoma). The typical immunophenotype is CD20+, CD45+, and CD3-.

Immunohistochemical markers CD10, BCL6, and MUM1 have been reported to recapitulate the gene expression profiling separating...
patients into tumors derived from germinal center (GC) origin (CD10+, or BCL6+, MUM1-) and non-GC origin (CD10-, MUM1+ or BCL6-, MUM1-). However, the validity of this classification scheme has been brought into question; further, work needs to be done to identify a robust IHC for GC vs. non-GC.

**Workup**

The staging workup is designed to identify all sites of known disease and determine prognosis with known clinical risk factors. Risk factors used by the IPI include age, stage of disease, serum lactate dehydrogenase (LDH) level, performance status, and the number of extra-nodal sites of disease. In patients who are 60 years or younger, the prognostic factors include tumor stage, performance status, and serum LDH level. The International Prognostic Index (IPI) and age-adjusted IPI can be used to identify specific group of patients who are more or less likely to be cured with standard therapy.

PET or PET-CT scans, have a more clear-cut role in selected cases of DLBCL than in other lymphoid neoplasms. PET scans are particularly informative in the initial staging where upstaging resulting in altered therapy occurs about 9% of the time and for response evaluation after treatment because they can distinguish residual fibrotic masses from masses containing viable tumor. PET scans have now been incorporated into the response criteria. In some centers, beta-2-microglobulin is considered a major determinant of risk (category 2B). Lumbar puncture is indicated in patients with one or more of the following sites of involvement: paranasal sinus, testicular, parameningeal, peri-orbital, CNS, paravertebral, bone marrow (with large cells) or in high risk disease. It is also indicated in the case of HIV-associated lymphoma.

**Treatment**

Treatment options for DLBCL differ between patients with localized (Ann Arbor stage I-II) and advanced (Ann Arbor stage III-IV) disease. Prognosis is extremely good for patients with no adverse risk factors (elevated LDH, stage II bulky disease, older than 60 years or ECOG performance status of 2 or more).

Doxorubicin-based chemotherapy (3 cycles) followed by RT produces excellent long-term outcomes in patients with limited-stage DLBCL (60 years or younger with no adverse risk factors). In the SWOG 8736 study, patients with localized aggressive NHL, treated with CHOP (3 cycles) followed by RT had significantly better PFS (77% vs. 64% for CHOP alone) and OS 82% vs. 72% for CHOP alone) at 5-year follow-up; however, this difference disappeared with further follow-up. Recently, ECOG study (E1484) showed that the addition of RT to CHOP (8 cycles) prolonged disease-free survival in patients who had achieved CR to CHOP alone.

The efficacy of rituximab combined with CHOP (3 cycles) plus RT has also been reported in patients with limited stage DLBCL. PFS at 2 years was 94% for patients treated with R-CHOP plus RT, which was favorable in historical comparison to the PFS observed for CHOP plus RT (85%). However, recent studies from Europe have questioned the role of radiation as reviewed by Fisher et al. In a randomized comparison of CHOP (4 cycles) with and without radiation in older patients, the combined modality arm was inferior. In GELA study, ACVBP regimen was found to be superior to CHOP plus RT. However, this regimen includes vindesine which is not available in the United States.

CHOP chemotherapy has been the standard treatment for patients with stage II bulky or stage III-IV DLBCL. Rituximab has been added to CHOP chemotherapy to improve outcomes in patients with advanced
DLBCL. In the GELA study, 399 elderly patients (60 - 80 years) with untreated advanced DLBCL were randomized to receive 8 cycles of CHOP or R-CHOP. Long-term results of this study showed that event-free survival, PFS, disease-free survival, and OS were statistically significant in favor of R-CHOP, with a median follow-up of 5 and 7 years, in both low and high-risk patients. These findings have been confirmed in three additional randomized trials including the MabThera International Trial (MInT) which extended the findings to young patients with favorable disease, the HOVON study and the ECOG/CALGB study confirmed the findings in patients older than 60. Dose dense CHOP (CHOP-14) was found to be superior to standard CHOP-21. Rituximab added benefit to CHOP-14 compared to CHOP-14 alone. In this study, OS significantly favored 6 cycles of R-CHOP-14 over 8 cycles because of late, non-cancer related deaths. An ongoing study is evaluating the role of R-CHOP-14 versus R-CHOP-21. In phase II studies the dose-adjusted-EPOCH-R regimen has been shown to overcome certain risk features such as high proliferation rate, and a randomized comparison with R-CHOP-21 is ongoing.

R-CHOP combined with RT is recommended for patients with localized disease. IFRT is recommended for patients who are not candidates for chemotherapy. Patients with non-bulky localized disease are treated with a full course (6-8 cycles) or an abbreviated course of R-CHOP (3 cycles), combined with locoregional RT. In patients with adverse risk factors, RT is optional if they are treated with 6-8 cycles of R-CHOP. Patients with no adverse factors can be treated with 6-8 cycles of R-CHOP alone, when RT is contraindicated because of clinical considerations. Patients who present with bulky disease may be more effectively treated with 6-8 cycles of R-CHOP and locoregional RT (category 1).

Patients (low- or high-intermediate risk) with advanced disease (stage III-IV) are treated with a full course (6-8 cycles) of R-CHOP-21. R-CHOP chemotherapy with rituximab is preferable due to reduced toxicities; however, other comparable anthracycline-based regimens are acceptable. In selected cases, RT to bulky sites may be beneficial. Suggested alternate treatment options include dose dense R-CHOP14 and dose adjusted-EPOCH-R (dose adjusted -etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab), both of which are listed as category 2B recommendations. In addition, first-line consolidation with HDT/ASCR is also an option for eligible patients, though there is no consensus on the value of this approach. Participation in clinical trials of new regimens is recommended if available. In patients with bulky disease or impaired renal function, initial therapy should include monitoring and prophylaxis for tumor lysis syndrome.

Patients who are receiving induction therapy should undergo evaluation prior to receiving RT, including all positive studies, after 3-4 cycles of chemotherapy. This interim restaging is performed to identify patients whose disease has not responded or has progressed despite induction therapy. Functional imaging (PET scans) may be particularly useful in determining whether residual masses represent fibrosis or viable tumor. If PET scan is positive, repeat biopsy of residual masses is recommended, before changing the treatment course. Interim PET scan can produce false positive results and should be done in the context of clinical trials, if clinically indicated, for possible primary refractory disease. End of treatment restaging is performed upon completion of induction therapy. The exact timing for end of treatment restaging is not known. The panel recommends that it is beneficial to wait for 8 weeks after completion of therapy before repeating PET scans.
After interim staging, the planned course of treatment is completed for all patients having CR and patients with stage III-IV disease with PR. Consideration of autologous stem cell rescue or completing the course of therapy with a higher dose of RT is recommended for patients with localized disease (stage I-II) with PR. In addition, appropriate clinical trial is recommended for all the PR patients. If there is no response to treatment or progressive disease is observed, patients are treated as described below for relapsed or refractory disease. RT may be given to selected patients with progressive disease and who are not candidates for chemotherapy. After end of treatment restaging, patients with CR to induction therapy are followed-up at regular intervals. Those with PR or progressive disease will be treated as described below for relapsed or refractory disease.

HDT/ASCR is the treatment of choice for patients with relapsed or refractory disease. Several chemotherapy regimens have been used as second-line therapy prior to HDT/ASCR; however, none of these have emerged as a preferred regimen. Patients who achieved a CR to second-line therapy had a superior OS to that of patients who achieved a PR (65% v 30%). Rituximab as a single agent was significantly active in patients with relapsed or refractory DLBCL. However, limited data is available on the use of rituximab in combination with chemotherapy in such patients. Recent data from a phase II study showed that rituximab in combination with ifosfamide, carboplatin and etoposide (ICE) produced a CR rate of 53% in patients with relapsed or refractory DLBCL, which is significantly better, in historical comparison with the response rates observed for such patients treated with ICE alone (27%). In an outpatient setting, rituximab with ICE produced an overall response rate of 71% (25% CR and 46% PR) and an estimated one-year event-free survival rate of 60% in patients with refractory B-cell lymphoma. Rituximab with other regimens (DHAP, EPOCH and MINE) was also effective in patients with relapsed or refractory DLBCL.

Patients with relapsed or refractory disease who are candidates for high-dose chemotherapy should be treated with second-line chemotherapy with or without rituximab. Suggested regimens listed in BCEL-B include the following: ICE, DHAP, GDP (gemcitabine, dexamethasone, cisplatin); MINE (mitoxantrone, ifosfamide, mesna, etoposide); miniBEAM (carmustine, etoposide, cytarabine, melphalan) and ESHAP (methylprednisolone, etoposide, cytarabine, cisplatin). Patients with CR or PR to second-line chemotherapy regimen should be considered for further consolidation with HDT/ASCR (category 1 for CR following relapse). Additional RT can be given before or after stem cell rescue to sites with prior positive disease. Pertinent clinical trials including the option of allogeneic stem cell rescue is another option. Patients who achieve complete remission and are not eligible for high-dose therapy can be treated with single agent rituximab or multiagent chemotherapy regimens such as EPOCH, CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) with or without rituximab, or a low dose oral chemotherapy regimen such as PEPC (prednisone, etoposide, procarbazine, cyclophosphamide). Patients with disease relapse following HDT/ASCR should be treated in the context of a clinical trial or individually. However, those with progressive disease after three successive regimens are unlikely to derive additional benefit from currently available chemotherapy regimens, except for patients with a long disease-free interval.

**Burkitt Lymphoma and Lymphoblastic Lymphoma**

Burkitt lymphoma (WHO classification) and precursor T and B lymphoblastic lymphomas have in common an exponential growth rate, a tendency to disseminate to the bone marrow and meninges, and characteristics overlapping those of acute lymphocytic leukemia. Burkitt lymphomas are rare and aggressive B-cell tumors typically involving extranodal disease sites. The vast majority (90%) of lymphoblastic lymphoma is a T-cell malignancy that occurs most often in young men and typically presents in the mediastinum. Tumor lysis syndrome (TLS)
is more common in patients with Burkitt and lymphoblastic lymphoma. Initial treatment should include prophylaxis and monitoring for TLS.

**Diagnosis**

The typical immunophenotype of Burkitt lymphoma is sIg+, CD10+, CD19+, CD20+, CD22+ TdT-, Ki67+ (100%), bcl-2-, bcl-6+. Most cases (80%) of Burkitt lymphoma have a translocation of c-myc from chromosome 8 to the immunoglobulin (Ig) heavy chain region on chromosome 14 [t(8;14)]. Other variants [t(8;22) or t(2;8)] are less common. Immunophenotyping studies are essential to distinguish between the precursor T and B cell lymphoblastic lymphoma. Typical immunophenotypes of lymphoblastic lymphoma include dim expression of sIg, CD10+, CD19+, CD20-/+, TdT+ for precursor B-cell lymphomas; Precursor T-cell lymphomas are characterized by dim expression of sIg, CD 10-, CD1a+/-, CD2+, CD3-/+, CD4/8+/+, CD7+, CD19/20-, TdT+.

**Workup**

The initial diagnostic workup for these highly aggressive lymphomas includes imaging studies of the chest, abdomen, and pelvis, and a workup similar to that for acute lymphocytic leukemia. Bone marrow aspiration, biopsy, and lumbar puncture are essential. In these highly aggressive lymphomas, as in diffuse large-cell lymphomas, the serum LDH level has prognostic significance. Because Burkitt lymphomas are frequently associated with HIV infection, HIV serology should be part of the diagnostic workup for these diseases. These tumors exhibit a high degree of cellular proliferation, as determined by Ki67 staging, and frequent 8q translocations.

**Treatment**

**Burkitt Lymphoma**

In recent years, the treatment of Burkitt lymphoma with intensive short-course chemotherapy has been successful. CODOX-M (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate), alternating with IVAC (ifosfamide, etoposide and high-dose cytarabine) is a highly effective regimen developed by Magrath et al.\(^\text{167}\) In an international phase II study, CODOX-M regimen was associated with a 2-year OS of 81.5% in low-risk patients and, high risk patients treated with CODOX-M alternating with IVAC had a 2-year OS of 69.9%.\(^\text{168}\) Modified CODOX-M regimen was also effective and well tolerated in elderly patients with Burkitt or Burkitt like lymphomas.\(^\text{169}\) In another phase II trial, R-hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone and rituximab) alternating with R-MA (rituximab, methotrexate, cytarabine)\(^\text{170}\) Patients with Burkitt lymphoma with completely resected abdominal lesions or a single extra-abdominal mass and normal LDH level are considered to be at low-risk. Options for induction therapy for Burkitt lymphoma include clinical trial or combination chemotherapy regimens with or without rituximab. Disease relapse after 2 years is rare following CR to induction therapy, and follow-up should be individualized according to patient’s characteristics. Patients with relapsed or refractory disease should be treated in the context of a clinical trial whenever possible.

**Lymphoblastic Lymphoma**

Lymphoblastic lymphoma has generally been treated with regimens appropriate for acute lymphoblastic leukemia (ALL), such as CALGB ALL regimen (dose-intensive cyclophosphamide and anthracycline, standard-dose vincristine and asparaginase, and intrathecal chemotherapy).\(^\text{171}\) Other novel regimens listed in BLAST-A have also shown encouraging results. The combination of cytarabine and high-dose mitoxantrone, including intrathecal methotrexate was found to be superior to the standard vincristine and prednisone-based regimens when used induction therapy in adult patients with ALL.\(^\text{172,173}\) In a study conducted by M.D. Anderson Cancer Center, hyperCVAD regimen produced 91% CR in patients with lymphoblastic lymphoma.\(^\text{174}\)
The 3-year PFS (66%) and OS (70%) compared favorably with the previously published results for ALL regimens. Two short intensive regimens containing rituximab (high-dose methotrexate with rituximab, and high-dose cytarabine with rituximab) have also shown promising results in ALL therapy.\(^{175}\)

Patients with stage I-IV disease can be treated with any one of the regimens listed in BLAST-A or they can be treated in clinical trials. Poor risk patients can be considered for high dose therapy with autologous or allogeneic stem cell rescue. The use of maintenance chemotherapy is variable at NCCN institutions, with some institutions using up to 2 years of maintenance and others not using maintenance therapy. Enrollment in clinical trials is encouraged to refine these approaches and the most appropriate therapy should be chosen in consultation with an expert in lymphoma.

**AIDS-Related B-Cell Lymphoma**

**Overview**

AIDS-related lymphomas (ARL) are a heterogeneous group of tumors. Burkitt lymphoma and DLBCL are the most common forms of ARLs. The patients who develop Burkitt lymphoma generally have good CD4 counts though a small fraction may present with CD4 counts less than 100. Primary CNS lymphoma (PCNSL) develops in patients with very low CD4 counts and is most often seen in uncontrolled AIDS. DLBCL occur in the patients between these extremes. In the era of highly active antiretroviral therapy (HAART), the incidence of HIV-associated lymphoma has fallen.\(^ {176}\) Overall, patients with HIV-associated lymphoma present with higher risk disease than matched patients with NHL without AIDS.\(^ {177}\)

**Diagnosis**

The diagnostic evaluation of HIV-associated lymphoma is not different from the non-HIV-associated disease. The major factor is to distinguish between Burkitt lymphoma and DLBCL. Hodgkin’s disease and indolent lymphoma can also be seen in HIV patients but are distinctly less common.

**Workup**

The diagnostic evaluation is as outlined above for DLBCL or Burkitt lymphoma. However, all patients should have a lumbar puncture to rule out CNS involvement. In addition, baseline values for CD4 counts and viral load should be obtained.

**Treatment**

Optimal management of HIV-associated lymphoma is not established. Several key features have emerged as being critically important. Most studies that have found good long-term results have included the early introduction of HAART. Improved immune function with HAART has led to the evaluation of several chemotherapy regimens in patients with ARLs.\(^ {178}\) Combination chemotherapy regimens such as CHOP or CDE (cyclophosphamide, doxorubicin and etoposide) given with concomitant HAART,\(^ {179,180,181}\) or EPOCH regimen (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) without HAART,\(^ {182}\) have proven to be effective and tolerable in patients with ARL. In a retrospective analysis, HIV-positive patients with Burkitt lymphoma treated with CODOX-M/IVAC had outcomes similar to that observed in HIV-negative patients treated with the same regimen.\(^ {183}\) In a recent study, Mounier et al reported that HIV score, IPI (international prognostic index) score, and HAART affect survival in patients with ARL but not the intensity of the CHOP-based chemotherapy.\(^ {184}\) The role of HAART and dose-intensive chemotherapy for the treatment of ARLs remains controversial.

The NCCN guidelines recommend CODOX-M alternating with IVAC, dose-adjusted EPOCH or CDE (cyclophosphamide, doxorubicin and etoposide) for AIDS-related Burkitt lymphoma patients with CD4 count
greater than 100. All other patients are treated with CHOP chemotherapy with or without high-dose methotrexate (not exceeding 3 g/m²). Patients with AIDS-related DLBCL should be treated with dose-adjusted EPOCH, CDE or CHOP. Though the outcome in DLBCL is inferior to non-HIV patients, a significant portion of patients derive long-term benefit. Patients should be treated with full dose chemotherapy with growth factor support. Prophylactic therapy with intrathecal chemotherapy has also emerged as an important component of care. Rituximab appears to increase the risk of neutropenia and infection and there is no net benefit in patients with HIV-associated lymphoma. The omission of rituximab is strongly suggested for DLBCL patients with CD4 counts of less than 50 due to the higher risk of infectious toxicities.

PCNSL is associated with severe immunosuppression and poor prognosis. High-dose methotrexate, RT or antiretroviral therapy can be considered for patients with PCNSL.

**T-Cell Lymphomas**

**Peripheral T-Cell Lymphomas**

**Overview**

Peripheral T-cell lymphoma (PTCL) is heterogeneous group of lymphoproliferative disorder arising from mature T-cells of post-thymic origin. In the REAL-WHO classification, PTCLs are divided into three groups: predominantly leukemic, nodal and extranodal. Predominantly nodal PTCL are further divided into three subtypes: PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL).

PTCL-NOS is the most common subtype of PTCL. It is most often nodal, however, many patients present with extranodal involvement including the liver, bone marrow, GI tract and skin. PTCL-NOS is associated with poor OS and event free survival (EFS) rates compared to B-cell lymphomas.

AITL presents with generalized lymphadenopathy, often with associated hepatomegaly or splenomegaly, hypergammaglobulinemia, eosinophilia, skin rash and fever. It occurs mainly in older patients. Prognosis is poor, with most series reporting an 5-year OS of 30% and PFS of only 13%. In the most recent report from the GELA study, which included the largest series of patients with AILT, five and seven-year OS rates were 33% and 29% respectively, reaching an apparent plateau around 6 years. The corresponding event free survival rates were 29% and 23% respectively.

ALCL accounts for less than 5% of all cases of NHL. There are now three distinctly recognized subtypes of ALCL: systemic ALK-1 expressing ALCL, systemic ALK-1 negative ALCL, and primary cutaneous ALCL. ALK-1 positive ALCL is most common in children and young adults. It is characterized by the overexpression of anaplastic lymphoma kinase (ALK-1) protein, which is the result of a chromosomal translocation [t(2;5)] in 40-60% of patients. The majority of patients ALCL present with advanced stage III or IV disease (64% for ALK-1 positive and 58% for ALK-1 negative) frequently associated with systemic symptoms and extra nodal involvement. Systemic ALK-1 positive ALCL predominantly occurs at younger age and has a good prognosis compared to ALK-1 negative ALCL, which occurs in older patients. Five-year overall survival following anthracycline-based therapy was 79% for ALK-positive ALCL compared to 46% for ALK-negative ALCL. Recent survival analysis from the International-T-cell lymphoma project also reported similar outcomes. However, in this report FFS or OS rates were similar in those patients with early stage ALK-positive or ALK-negative ALCL. ALK-negative ALCL patients had a modestly superior outcome compared to those with PTCL-unspecified. Primary cutaneous variant of ALCL is noted for
the absence of ALK-1 protein and indolent course characterized by frequent relapses, generally confined to the skin, and very good long-term survival despite cutaneous relapses.

**Staging and Prognosis**

Staging is similar to that of the other aggressive NHLs. Recently, the Italian Intergroup for lymphoma proposed a new prognostic index for PTCL-NOS (PIT). Risk factors include age older than 60 years, elevated LDH levels, performance status of 2 or more, stage III or higher with bone marrow involvement. Five-year overall survival was only 32.9% for patients with two risk factors and 18.3% for those with three or 4 risk factors. In the NCCN guidelines, patients with stage I-II diseases are stratified into two groups (low intermediate risk and high intermediate risk) based on the age-adjusted prognostic index (aaPI).

In a retrospective GELA study, the prognoses of PTCL (including all subgroups) patients were compared with B-cell lymphoma patients with similar characteristics. The complete response rates were 63% and 54% for patients with B-cell lymphoma and PTCL respectively. Five-year overall survival (OS) rate was also slightly better for patients with B-cell lymphomas (53%) compared to 41% for patients with PTCL. The 5-year EFS rates were 45% and 32% for B-cell and PTCL patients respectively. The difference in 5-year OS rates were more pronounced in patients with 2 or 3 adverse risk factors as determined by IPI (36% and 23% respectively for PTCL; 53% and 35% respectively for B-cell lymphomas). Initial characteristics and prognostic features were analyzed in another retrospective study in 174 patients with PTCL. Most patients were treated with anthracycline-based regimens. The overall complete response rates (69% vs. 45%) and median survival (65 months vs. 20 months) were better for ALCL subgroup compared to PTCL.

**Diagnosis**

Diagnosis of PTCL is similar that described for other lymphomas, requiring adequate immunophenotyping to distinguish PTCL from B-cell neoplasms. The initial paraffin panel for immunohistochemical studies may only include Pan T-cell markers and can be expanded to include antibodies of T-cell lymphoma is suspected. Additionally, PTCL is often associated with clonal rearrangements of the receptor genes that may be seen in non-cancer T-cell diseases. Molecular and cytogenetic analysis can further clarify the T-cell origin of the lymphoma.

PTCL-NOS has variable T-cell associated antigens and lacks B-cell associated antigens. Majority of the nodal cases are CD4+ and CD8-. Systemic ALCL has a strong expression of CD30. Evaluation of ALK-1 status, either based on immunophenotyping or genetic analysis of the t(2;5) or variant chromosomal rearrangements, is extremely important to identify the ALK-1 positive tumors that have a better prognosis. AILT cells express T-cell associated antigens and are usually CD4+. Recently, expression of CXCL13 has been identified as a useful marker in distinguishing AILT from PTCL-NOS. It is also characterized by the presence of Epstein-Barr virus (EBV)-positive B-cells. EBER (EBV-encoded RNA) is positive in about 40% of PTCL and some case series have reported that EBER positive tumors have a worse prognosis. Evaluation of EBV status may also help characterize AILT.

**Workup**

The workup for PTCL is similar to the workup for other lymphoid neoplasms. The workup focuses on determining the stage of the disease, based on routine laboratory studies, physical exam, and imaging studies, as indicated. MUGA scan or echocardiogram is also recommended, since chemotherapy is usually anthracycline based. In selected cases, HIV and HTLV-1 (human T-cell lymphoma virus) may be useful.
Treatment

PTCLs are less responsive to standard chemotherapy regimens and thus carry a poorer prognosis compared to diffuse large B-cell lymphomas. In prospective randomized studies, PTCLs have been included with aggressive B-cell lymphomas. However, it has not been possible to assess the impact of chemotherapy in this subgroup of patients with PTCLs due to small sample size. There have been no randomized studies comparing the chemotherapy regimens exclusively in patients with PTCL. Since there is no standardized treatment for PTCL, clinical trials are the preferred treatment option for all patients with PTCL, and essential to advancing our treatments form these diseases.

CHOP chemotherapy is the most commonly used first-line regimen for patients with PTCL. However, with the exception of ALK+ ALCL, outcomes are disappointing. In the International PTCL clinical and pathologic review project, anthracycline-based chemotherapy was associated with poor outcome in all patients, except for those with one or no risk factors. The inclusion of an anthracycline did not appear to favorably impact survival in this retrospective study. CHOP chemotherapy is frequently curative in only the small number of patients with favorable prognostic features. In a retrospective study conducted by the British Columbia cancer agency, five-year OS rates were higher (64%) in low risk group compared to only 22% in high-risk group, in patients with PTCL treated with CHOP or CHOP-like chemotherapy. ALK-positive ALCL patients had superior outcome compared to ALK- negative ALCL patients (5-year OS: 58% vs. 34% respectively). Chemotherapy regimens that are more intensive than CHOP did not show any significant improvement in the overall survival in patients with PTCL, with the exception of ALCL.

The poor results with conventional chemotherapy have led many to explore the role of HDT/ASCR as a first-line consolidation therapy. Two prospective studies have demonstrated that HDT/ASCR as first-line consolidation improves treatment outcome in patients responding to induction therapy. Both of these studies excluded patients with ALK-positive ALCL. In the prospective study conducted by the Gel-Tamo Study group, 19 out of 26 patients showing CR or PR to induction therapy with MegaCHOP received ASCR. At 2-year post-transplant follow-up, overall survival, progression-free survival and disease-free survival were 84%, 56% and 63% respectively. Nordic lymphoma group evaluated induction therapy with CHOEP followed by ASCR in patients responding to induction therapy. Of the 77 evaluable patients, 58 (75%) patients underwent ASCR. At one-year post-transplant follow-up, 30 of the 39 patients were in complete remission. Longer follow-up is necessary to evaluate the impact of first-line consolidation on time-to-treatment failure and overall survival. In the absence of randomized trials comparing conventional chemotherapy to first-line consolidation with HDT/ASCR, this is a reasonable treatment option only in patients showing good response to induction therapy.

AILT is a very heterogeneous disease and can at times be treated solely with corticosteroids or other immunosuppressive agents. Cyclosporine has been effective in patients with relapsed disease following treatment with steroid or multiagent chemotherapy. The guidelines offer single agent corticosteroids as an initial treatment for AILT. However, given the poor prognosis for the majority, strong consideration should be given to treating these patients with approaches used for other PTCL.

Induction therapy with multiagent chemotherapy is recommended for all patients with PTCL-NOS or ALCL. In addition, patients with stage I-II disease (low-intermediate risk) are often effectively treated by adding adjuvant locoregional radiation therapy to involved region. Suggested
regimens include CHOP, EPOCH or HyperCVAD alternating with methotrexate and cytarabine.

Following initial therapy, all patients undergo interim restaging by repeating all prior positive studies. If a PET scan is positive, rebiopsy is recommended before changing course of treatment. Patients are then divided into three groups according to treatment response (complete response, partial or no response or progressive disease). Subsequent treatment options depend on whether the patient initially presented with Stage I-II or Stage III-IV disease.

**Stage I or II disease (low-intermediate)**

In patients showing complete response after interim restaging, planned radiation therapy is completed. First-line consolidation with HDT/ASCR is recommended for patients showing partial response at interim staging. Clinical trial including allogeneic transplant or radiation therapy is another option for this group of patients. End of treatment restaging is performed after completion of treatment. No further treatment is necessary for those showing complete response. Patients with partial response at end of treatment restaging and those with no response or progressive disease following initial or follow-up therapy are treated as described for relapsed or refractory disease.

**Stage I or II disease (high-intermediate) or stage III-IV**

Patients with a complete response and ALK-1 positive ALCL need no further treatment. Those with ALK-1 negative ALCL, PTCL NOS or AILT with a complete response can be observed or they can be consolidated with HDT/ASCR. Patients with partial or no response or progressive disease after initial therapy are treated similarly to patients with relapsed or refractory disease.

**Relapsed or Refractory Disease**

Several studies have shown that second-line consolidation with HDT/ASCR produces similar outcomes patients with relapsed or refractory PTCL compared to those with B-cell lymphomas. However, these studies are retrospective and in general only evaluated transplanted patients. Recent reports have shown the allogeneic transplantation may be an effective second-line therapy for patients with relapsed or refractory PTCL. In a phase II study, Corradini et al investigated the role reduced intensity conditioning (RIC) followed by allogeneic transplantation in patients with relapsed or refractory PTCL. The estimated 3-year overall and progression-free survival rates were 81% and 64% respectively. Donor lymphocyte infusion induced responses in some patients progressing after allografting. Similar results were reported in a retrospective study from French national survey where majority of the patients were treated with myeloablative regimen. Treatment related mortality was higher (30%) in this study compared to only 6% observed with RIC regimen.

Many new agents such as gemcitabine and denileukin diftitox have shown activity in small number of patients with relapsed or refractory PTCL. Alemtuzumab produced a overall response rate of 36% in patients with relapsed or chemotherapy-refractory PTCLs. But, it was associated with significant hematologic toxicity and infectious complications including deaths from opportunistic infections. Several other studies are evaluating alemtuzumab in combination with CHOP or CHOP-like chemotherapy.

Patients who are candidates for HDT/ASCR may be consolidated with second-line chemotherapy prior to transplant. Those with a complete or partial response can be considered for high dose therapy with allogeneic or autologous stem cell support. Patients who are non-candidates for high-dose therapy are treated with second line regimens for palliative intent only. Suggested treatments include alemtuzumab, bortezomib, gemcitabine and denileukin diftitox. Participation in a clinical trial is strongly preferred for these patients.
Mycosis Fungoides and Sezary Syndrome

Cutaneous T-cell lymphomas (CTCLs) are a group of NHLs primarily developing in the skin and ultimately involve lymph nodes, blood and visceral organs. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of CTCLs. MF accounts for 60% of new cases of CTCL and SS occurs only to an extent of 5%. MF is an extranodal NHL of mature T-cells with primary cutaneous involvement. SS is an erythrodermic, leukemic variant of CTCL and it is characterized by significant blood involvement and lymphadenopathy. In updated EORTC and WHO classification of CTCL, MF is characterized as an indolent neoplasm and SS is characterized as an aggressive neoplasm. However, a transformation to a large T-cell lymphoma has been documented a subgroup of patients and is diagnosed when there are more than 25% of large cells in a biopsy of an MF lesion.

Staging

The TNM staging system developed by the mycosis fungoides cooperative group (MFCG) has been the standard for staging and classification of patients with MF and SS. Recently, ISCL and EORTC recommended revisions to the MFCG staging system are based on the new data available in the area of immunohistochemistry, biology and prognosis of MF and SS since the publication of MFCG. In the revised staging system, all staged patients should have a definitive diagnosis of MF and SS. T1 disease is defined as less than 10% of the skin surface involvement with patches or plaques and T4 disease is erythroderma with at least 80% of the skin surface diffusely involved. The extent of skin involvement is based on the percentage of body surface area (BSA) where the patient’s palm (without digits) is equivalent to 0.5% BSA. Lymph node biopsy for staging is recommended only for clinically abnormal node (1.5 cm or larger in diameter). Visceral disease with the involvement of an organ other than the skin, nodes or blood should be documented using imaging studies.

Blood involvement is classified into three groups: B0 is associated with the absence of significant blood involvement (5% or less of Sezary cells); B1 is defined as having a low tumor burden (more than 5% of Sezary cells but does not meet the criteria for B2); B2 is associated with high tumor burden with more than 1000 Sezary cells/ul. According to the updated staging system, patients with stage III are further divided into two subgroups IIIA and IIIB to differentiate the extent of blood involvement (B0 and B1 respectively).

Prognosis

The most significant prognostic factors of survival include patient’s age at presentation, extent and type of skin involvement, overall stage (T-classification), presence or absence of extracutaneous disease and peripheral blood involvement. Patients diagnosed with limited patch or plaque disease have an excellent prognosis, whereas those who have tumor stage disease or erythrodermic skin involvement have a less favorable prognosis and patients with who present with extracutaneous disease have a very poor prognosis. In a retrospective study involving 525 patients with MF and SS, the 5-year OS was significantly better (80% vs. 56%) for patients less than 57 years of age compared to that of patients 57 years or older. The risk of disease progression, development of extracutaneous disease or death due to MF was correlated with initial stage.

Diagnosis

In the algorithms developed by the International Society for Cutaneous Lymphoma (ISCL), the diagnosis of MF is based on integration of clinical, histopathologic, immunopathologic, and molecular biological characteristics. According to the revised criteria, diagnosis of SS includes one of the following: an absolute Sézary cell count of 1000 cells/mm3 or more; CD4/CD8 ratio of 10 or higher caused by an increase in circulating CD4+ T cells and/or an abnormal immunophenotype including the significant loss of CD7 (>40%) or ...
CD26 (>30%) by flow cytometry with evidence of a T-cell clone in the blood.⁴

Complete skin exam, biopsy of suspicious skin sites and immunohistochemical studies of skin biopsy are essential to confirm the diagnosis. Biopsy of suspicious lymph nodes and assessment of peripheral blood for Sezary cells are recommended in the absence of a definitive skin diagnosis. MF and SS cells are characterized by CD2+, CD3+, CD4+, CD5+, CCR4+, CD45RO+ and they lack certain T-cell markers CD7 and CD26.²²⁶ There are subtypes of MF that are also CD8+. If there is a histological evidence of large cell transformation phenotyping with CD30 is recommended. The T-cells also express cutaneous lymphocyte antigen (CLA) and TH2 cytokines. They are also associated with a loss of TH1 and IL-12 cytokines. T-cell receptor (TCR) gene rearrangement should be interpreted with caution since TCR clonal rearrangements can also be seen in non-malignant conditions. TCR gene rearrangement analysis by polymerase chain reaction (PCR) is a useful technique to support the diagnosis of MF and SS, especially in distinguishing MF from inflammatory dermatoses.²²⁷

**Work Up**

The work-up of patients diagnosed with MF or SS involves complete skin examination to assess the extent of the disease, examination of lymph nodes or other masses for the evaluation of lymphadenopathy or organomegaly. Laboratory studies should include CBC with Sezary screen and Sezary flow cytometry to assess for expanded CD4+ cells with increased CD4:CD8 ratio or with abnormal immunophenotype. Patients with T1 and limited T2 disease without adenopathy, blood involvement, or unfavorable features such as folliculotropic or large-cell transformation do not need any imaging tests other than a chest x-ray, while other patients should additionally undergo either CT or PET/CT scan of the neck/chest/abdomen and pelvis. Integrated PET-CT was found to be more sensitive for the detection of lymph node involvement than CT alone and can help direct biopsies.²²⁸ Bone marrow biopsy is not needed for staging of patients, but may be helpful in those with suspected marrow involvement or in those with an unexplained hematologic abnormality. TCRGR of peripheral blood lymphocytes is recommended if SS is suspected. Biopsy of suspicious lymph nodes is recommended with evaluation for T cell receptor gene rearrangements, especially due to the poor prognosis of patients with clonal rearrangement in lymph nodes.²²⁹

**Treatment alternatives for MF and SS**

Initial treatment in patients with patch/plaque disease consists of skin-directed therapies (localized or generalized), with the addition of systemic biologic therapy for refractory, or progressive disease. Those patients who have unfavorable prognostic features (e.g., folliculotropic or large-cell transformed MF) may have systemic biologic therapies introduced earlier in the treatment algorithm. Patients who do not respond to biologic therapy or those with very aggressive or extracutaneous disease may be treated with chemotherapy.²³⁰,²³¹,²³² Due to the rarity of the condition and the need for an individualized approach, referral to a multidisciplinary academic specialty center is preferred.

**Skin-directed therapies**

Localized skin-directed treatments include topical therapy with corticosteroids, mechlorethamine hydrochloride, carmustine, or topical bexarotene. Generalized skin directed therapies such as phototherapy [UVB or PUVA (psoralen and UVA)] and total skin electronic beam therapy (TSEBT) are indicated in patients with widespread skin involvement.

Topical corticosteroids are effective especially for the treatment of patch-stage MF, producing a CR rate of over 90%.²³³,²³⁴ However, long-term use of topical steroid may lead to skin atrophy or striae
formation and the risk worsens with increased potency of the steroid. High-potency steroid used on large skin surfaces may lead to systemic absorption. Topical chemotherapy with nitrogen mustard or carmustine has been used for the management of MF for many decades. Long term follow-up results in 203 patients have confirmed the safety of topical therapy with nitrogen mustard. The efficacy were similar for aqueous and ointment preparations, however, the ointment was associated with reduced toxicity. Patients with T1 disease had better response rates (93% vs. 72%) and survival outcomes (65% vs. 34%) than those with T2 disease. Freedom from progression (FFP) in T1 disease at 5 and 10 years were 92% and 85% respectively and in T2 disease FFP was 83% at 5 and 10 years. An ongoing multicenter trial is evaluating the efficacy of topical nitrogen mustard in patients with stage I or IIA MF.

Synthetic retinoids such as bexarotene have shown activity in patients with MF and SS. Bexarotene gel is the only FDA approved topical therapy for MF and SS. FDA approval was based on the data from two open-label, historically-controlled clinical studies involving 117 patients with CTCL. In the phase I-II trial involving 67 patients with early stage MF, CR was attained in 21% and PR was observed in 42%. Patients with no prior therapy responded at a higher rate than those who had received prior topical therapies. In the phase III multicenter study of 50 patients with early stage refractory MF, overall response rate was observed in 44% of patients with 8% of patients achieving CR.

MF is extremely radiosensitive and RT is the most effective single agent for early stage MF. TSEBT is effective especially in patients with thick generalized plaque (T2) or tumorous disease (T3). In a retrospective analysis involving 148 patients with T2 and T3 disease, TSEBT alone or in combination with adjuvant topical mechlorethamine hydrochloride yielded significantly higher CR rates for T2 and T3 disease compared to mechlorethamine hydrochloride alone (76% vs. 44% for T2; 44% vs. 8% for T3).

Phototherapy with UVB (including narrow-band) and photochemotherapy (PUVA) are effective alternative treatment options for patients with early stage MF. In long-term follow-up studies, PUVA was associated with prolonged disease-free remissions. In a retrospective analysis, phototherapy with narrow-band UVB and PUVA produced comparable complete remission rate (81% vs. 71%), partial remission rate (19% vs. 29%) and relapse-free survival (24.5 months vs. 22.8 months) in patients with early stage MF. However, cumulative doses of UV are associated with increased risk of UV-associated skin neoplasms. Thus, phototherapy may not be appropriate for patients with the history of squamous or basal cell carcinoma or melanoma. Since narrowband UVB has less skin toxicity than broadband and PUVA, it is preferred to start with narrowband UVB than PUVA in early stage patients with patch or thin plaque disease.

Systemic therapies
Systemic therapies with extracorporeal photopheresis (ECP), interferons, systemic retinoids, denileukin diftitox or vorinostat are preferred over traditional chemotherapy for patients who do not respond to initial skin-directed therapies. Multiagent chemotherapy is reserved only for patients who do not respond to single agent chemotherapy or those with bulky lymph node or solid organ disease. In the absence of other unfavorable prognostic features, it is recommended that systemic therapy be deferred until the patient has failed multiple treatments with local and skin directed therapy.

ECP is an immunomodulatory therapy using psoralen and UVA radiation extracorporeally. It involves the removal of leukocytes by leukopheresis. The leukocytes are treated with 8-methoxypsoralen, exposed to UVA and returned to the patient. ECP is a long standing treatment of MF, and is particularly indicated in patients with or at risk...
of blood involvement (erythrodermic stage III disease or IVA with Sezary Syndrome).  

Interferons and retinoids [all-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid)] have been used for many years for the treatment of CTCL.  

Oral bexarotene has been evaluated for the treatment of refractory or persistent early and advanced stage CTCL in two multicenter clinical trials.  

In early stage CTCL, bexarotene was well tolerated and effective in 54% of patients at doses of 300 mg/m² per day.  

In advanced CTCL, clinical CR and PR were observed in 45% of patients receiving 300 mg/m²/d.  

At more than 300 mg/m²/d, response rate was 55%, including 13% clinical CR. Side effects were reversible and manageable with appropriate medications prior to initiation of treatment. Bexarotene capsules received FDA approval in December, 1999 for the treatment of refractory CTCL. In retrospective comparison, ATRA and bexarotene had similar efficacy in the treatment of patients with relapsed MF and SS.

Denileukin diftitox is a recombinant fusion protein with interleukin-2 (IL-2) and diphtheria toxin, and targets the high-affinity interleukin-2 receptor (CD25) expressed on malignant T-cells and B-cells. In a phase III study, overall response rate was 30% with a median duration of 6.9 months in patients who have received other treatments. Clinically significant improvement in self-rated overall QOL, skin appearance, and pruritus severity was observed in 68% of the patients who had significant pruritus at baseline. However, denileukin diftitox is associated with significant side effects including hypersensitivity reactions and vascular leak syndrome. Myelosuppression is an uncommon side effect. Denileukin diftitox was approved in February, 1999 for the treatment of persistent or recurrent CTCL in patients whose malignant cells express CD25 component of IL-2 receptor.

Histone deacetylase (HDAC) inhibitors are a new class of drugs that are potent inducers of histone acetylation, cell cycle arrest and apoptosis. Activity and safety of vorinostat in patients with refractory CTCL was confirmed in a phase II trial. In a phase IIB study involving 74 patients with persistent, progressive or refractory CTCL, overall response rate and median time to progression were 29.7% and 4.9 months respectively. Median time to progression was greater than 9.8 months for stage IIB or higher responders. The response rates and median response durations were comparable to those obtained with bexarotene capsules and denileukin diftitox. Vorinostat was the first HDAC inhibitor to receive FDA approval in October 2006 for the treatment of patients with progressive, persistent, or recurrent CTCL, on or following two systemic therapies.

Systemic chemotherapy is used as a primary treatment only for advanced disease, or as second-line therapy for early stage disease that is refractory to skin-directed therapies and systemic biological therapies. Low dose methotrexate has been used to treat early stage MF and SS for many years, although there is not extensive literature documenting outcomes. Gemcitabine as a single agent has also been effective in patients with advanced, heavily pretreated CTCL and as front-line therapy in untreated CTCL patients. Pentostatin has shown activity either as a single agent or in combination with interferon alfa in patients with advanced MF or SS. Anecdotal reports suggest activity for temozolomide and bortezomib. Pegylated doxorubicin have also shown significant activity in patients with pretreated, advanced or refractory CTCL.

**Combination therapies**

Combinations of biologic therapies as distinct from combination chemotherapies are used when single agent therapies fail or in advanced, progressive, refractory, or symptomatic disease. Several combination therapies have been studied in clinical trials for CTCL. Most commonly used combinations are phototherapy plus either interferon or systemic retinoid and ECP plus either IFN or systemic...
retinoid or both.\textsuperscript{264-269} PUVA when used in combination with interferon alfa produced an overall response rate of 93\% in patients with stage IB to stage IVB disease.\textsuperscript{264} Median duration of response exceeded 25 months. In another prospective phase III trial, combination of low-dose interferon alfa and PUVA resulted in a CR rate of 84\% in patients with early stage MF.\textsuperscript{265} The addition of PUVA to the combination of ECP, interferon and bexarotene resulted in rapid sustained remission in patients with SS.\textsuperscript{266} In a long-term follow-up study involving patients with advanced CTCL and poor prognostic factors, combined modality therapy (ECP with interferons and/or systemic retinoids) resulted in better response rates (84\%) compared to ECP alone (75\%).\textsuperscript{267} Median survival (74 months vs. 66 months) was better for patients receiving combination therapy. Combination therapy was well tolerated. Combination of bexarotene with PUVA, ECP and/or interferon also resulted in higher response rates in patients with advanced disease.\textsuperscript{268} Systemic retinoids have been studied in combination with other biological response modifiers in patients with advanced disease.\textsuperscript{270,271} The combination of bexarotene and denileukin diftitox is particularly interesting since bexarotene has been shown to increase CD25 expression in CTCL cells and thereby increasing the susceptibility of T-cells to denileukin diftitox.

Treatment based on Clinical Stage

Primary Treatment

Patients with Stage IA have an excellent prognosis using skin directed therapies alone. Stage IA is managed primarily with skin-directed therapies, alone or in combination with other skin-directed therapies including local RT. Treatment options include topical corticosteroids, nitrogen mustard or carmustine, bexarotene, phototherapy with UVB for patch or thin plaques or PUVA for thicker plaques. Patients with Stage IB-IIA disease require generalized skin treatment. Topical retinoids are not recommended for generalized skin involvement since they can cause a lot of irritation. In addition to the other skin-directed therapies used for Stage IA disease, TSEBT is another treatment option for those with severe skin symptoms or generalized thick plaque or tumor. Although TSEBT is highly effective in T1 disease (stage IA), it is reserved for generalized or recalcitrant skin disease due to its toxicities and lack of superior long-term outcome. For patients with sites that are not responsive to generalized treatment, additional treatment may be needed.

Early stage disease (stage IA, stage IB-IIA) with blood involvement (B1) or histological evidence of folliculotropic or large cell transformation, are associated with less favorable outcome, thus, these patients may be best managed with more intense treatments as described for stage IIB limited disease or stage III with B1 involvement, respectively.

Patients with Stage IIB disease can be separated into two categories: limited extent tumor disease with or without patch/plaque disease or generalized tumor disease or limited extent tumor disease with blood involvement (B1) or large cell transformed MF. Patients with limited extent tumors can be managed with local radiation. Skin directed therapies, as described above for stage I-IIIA disease can be used for the residual patch/plaque disease. Alternatively, they can also be treated with systemic therapy (SYST- CAT A) including ECP, systemic retinoids (bexarotene, ATRA or isotretinoin [13-cis-retinoic acid]), interferons, vorinostat, denileukin diftitox or low-dose methotrexate.

Patients with generalized tumor disease or limited extent tumor disease with blood involvement (B1) or large cell transformed MF are treated with TSEBT or systemic therapies, with or without adjuvant skin directed therapy. Suggested systemic therapy options include ECP, systemic retinoids (bexarotene, ATRA or isotretinoin [13-cis-retinoic acid]), interferons, vorinostat or denileukin diftitox, chemotherapy agents such as methotrexate, liposomal doxorubicin, gemcitabine (first-line therapy) and chlorambucil, pentostatin, etoposide, cyclophosphamide, temozolomide (second-line therapy).
Management of patients with stage III disease depends on the extent of blood involvement: no significant blood involvement (B0) or some blood involvement (B1), which is less than that observed for SS. Patients with no significant blood involvement are treated with generalized skin-directed therapies (similar to those recommended for stage IB-IIB) with or without systemic therapy (ECP, low dose methotrexate and other biological agents recommended for stage IIB disease). Safety data on the use of vorinostat in combination with phototherapy or RT is currently lacking. Generalized skin-directed therapies other than topical steroids may not be well tolerated for patients with stage III disease. Patients with stage III disease with significant blood involvement are treated mainly with ECP, low dose methotrexate or systemic biologic therapies as recommended above for those with no blood involvement.

Mid-potency steroids should be used in combination with systemic therapy to reduce skin symptoms. Antibiotic therapy should be considered for this group of patients since they are at increased risk of developing secondary infections.

Stage IV disease includes SS (with or without lymph node involvement) and bulky lymph node or visceral (solid organ disease). SS patients are treated with single agent systemic biologic therapy (ECP, systemic retinoids, interferons, vorinostat, denileukin diftitox or low dose methotrexate) or combination therapies. Suggested regimens for combination therapies are listed in MFSS-A. Bulky lymph node or solid organ disease is frequently managed with chemotherapy (SYST-CAT B) with or without RT and skin-directed therapy. SYST-CAT B agents in general have more rapid onset of responses and are more often used. In certain clinical circumstances SYST-CAT A agents or even RT alone may be used. Adjuvant biologic therapy may be considered following chemotherapy to improve response duration.

All patients (stage IA through stage IV) showing response should be considered for maintenance or tapering therapy to optimize response duration. Patients with a PR or disease relapse following primary treatment should be treated with the other options included in the primary treatment to improve response before starting treatment for refractory disease. In addition, patients with disease relapse or persistent disease may be considered for clinical trials. Patients with stage IV disease should be considered for clinical trials.

**Refractory or Progressive Disease**

Autologous stem cell transplantation (SCT) has been used infrequently for patients with CTCL. In general, the durations of response have been short thus limiting its usefulness. The use of allogeneic SCT in patients with advanced MF and SS has been reported only in case reports and small series. Data on allogeneic SCT, particularly using non-myeloablative conditioning, suggest the existence of graft versus T-cell lymphoma effect and success with long term durable remissions has been reported in highly selected patients. Alemtuzumab, anti-CD52 antibody has shown promising activity in patients with advanced MF and SS. However, it is also associated with significant toxicity.

**Systemic therapy (SYST-CAT A)**, single agent or combination therapy is recommended for patients with stage IA, IB-IIB disease that is progressive or refractory to primary skin-directed therapies. Skin-directed therapy can be used as adjuvant treatment to reduce skin symptoms. Patients who do not respond to treatment with SYST-CAT A agents are treated with single agent systemic chemotherapy (SYST-CAT B). Suggested agents are listed in MFSS-A. Allogeneic SCT may be considered for patients with stage IIB-Iv disease that is progressive or refractory to multiple primary treatment options. Appropriate patients (stage IIIB or greater MF who have failed multiple systemic therapies and adequate trial of skin-directed therapy or whose disease is not amenable to skin-directed therapy), may be referred for a transplant consultation. Ideal time for allogeneic SCT is when their disease is well controlled with induction therapy and before their
disease has progressed to a state where the chance of response or survival with allogeneic SCT is low. Patients should have failed biologic options and single agent chemotherapy prior to allogeneic SCT. When appropriate, TSEBT may be considered as cytoreductive therapy before transplant. Alemtuzumab may be considered for patients with stage III-IV (specifically, SS) disease that is refractory to previous treatments.

Currently there is no definitive treatment for advanced disease that can produce reliable durable remissions or curative results, other than possibly, allogeneic SCT. The guidelines recommend participation in a clinical trial as a treatment option for all patients with relapsed or progressive disease.
References


67. Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 2004;104:3064-3071.

68. McLaughlin P, Hagemeister FB, Rodriguez MA et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with


120. Kahl B, Longo W, Eickhoff J, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free


139. Miller TP, Unger JM, Spier C, et al. Effect of Adding Rituximab to Three Cycles of CHOP Plus Involved-Field Radiotherapy for


146. Pfleuderschuh M, Truemper L, Kloess M et al. Two-weekly or 3-weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Elderly Patients with Aggressive Lymphoma: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641.


155. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and


175. Hoelzer D, Baur K, Giagounidis A et al. Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, Mature B-ALL and other high-grade B-NHL. Blood 2003;102(11)[abstract 236].


